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Abstract 
I investigated stem cell dynamics in normal human colon by detecting somatic variants 
affecting X-linked and autosomal genes using immunohistochemistry. Applying neutral clonal 
marks to a large cohort of patients to interpret age-related trends in clone frequencies has 
established the baseline stem cell dynamics of the tissue.  
Analysis of a number of new clonal marks showing biased behaviours suggests that different 
gene-specific mutations can subvert constraints resulting from the tissue architecture in 
different ways. In respect of intra-gland competition of stem cell derived clones, a disadvantage 
is observed for the histone modifier HDAC6, while at the other end of the spectrum, loss of the 
cohesin member STAG2 strongly advantages affected stem cells. 
Subsequent clonal expansion beyond the boundary of a single crypt is recognised by clones 
occupying multi-crypt patches. Quantification of such events allows the rate of lateral 
expansion for different mutations to be measured. Moderate effects were found for PTEN, p53 
and STAG2, while mutations in the histone demethylase KDM6A generate very large areas of 
mutant epithelium in aged humans. Further, targeted sequencing revealed dramatic expansion 
of KRAS-mutant clones in histologically normal colon.  
Patches may arise from crypt fission and fusion events. Using a clonal mark based on mild 
periodic acid-Schiff staining, the neutral crypt fission and fusion rates were quantified. Against 
this baseline, it was found that KDM6A-mutant clones expand mainly by fission, while fusion 
remains at homeostatic levels. 
The emerging picture is that of the aged human colon consisting of a mosaic of different 
mutations. The work presented in this thesis offers detailed insights into the rates at which 
different gene-specific mutations arising in colonic stem cells can become fixed within 
individual crypts and undergo subsequent lateral expansion through crypt fission and fusion 
events. This defines the timeframe taken for cancer drivers to achieve high mutant allele burden 
within the tissue, which can serve as a basis for cancer prevention strategies. 
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 Chapter 1 Introduction 
1.1 What is a stem cell? 
New mammalian life starts with a fertilised egg, the zygote, which is a totipotent stem cell, 
meaning it is capable of giving rise to any cell type of a complete embryo. Following 
fertilisation, the zygote undergoes a number of rounds of cell division until it develops into the 
blastocyst, which consists of the inner cell mass, a ball of cells that will form the embryo proper, 
and the surrounding trophoblast, which will form the supporting structures (Gilbert, 2000). 
Cells can be collected from the inner cell mass and grown in vitro as embryonic stem cells 
(Evans & Kaufman, 1981; Martin, 1981). 
As the embryo develops further, cells become increasingly specified as they are segregated into 
different groups that contribute to the growth of individual tissues and organs. These fate 
choices are governed by precisely timed action of specific transcription factor networks 
(Gilbert, 2000; Pantazis & Bollenbach, 2012).  
From this brief description of early mammalian development, the two main characteristics of 
stem cells can be extracted. The first is potency, which is the ability to differentiate into 
specialised cell types. Importantly, different types of stem cells can harbour different degrees 
of potency. Cells found in the inner cell mass can differentiate into all cell types, except for 
trophoblast cells, and are thus called pluripotent. Later during development, pools of more 
restricted, multipotent, stem cells are specified. The second universal characteristic of stem cells 
is self-renewal, defined as the ability to generate progeny indefinitely (Weissman, 2000). 
Traditionally, research has tried to classify different types of stem cells according to their gene 
expression profile. Such grouping relied on specific genes acting as markers for stem cells. It 
is important to note, however, that the two fundamental features of stem cells are both 
functional in nature. Therefore, the true ‘stemness’ of a cell can only be defined retrospectively. 
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A cell that performs the functions attributed to stem cells is a functional stem cell, irrespective 
of the markers it expresses. A simple analogy can help to illustrate this point (Figure 1.1). 
Therefore, while markers can be very useful for elucidating the capabilities of certain stem cells 
as well as the underlying molecular pathways, their use will likely not reveal the full complexity 
present in a given stem cell-based biological system. This requires the study of functional stem 
cells, which has been a focus of the Winton laboratory over the past decade and will act as a 
recurring theme throughout this introduction. 
 
Figure 1.1 Baking analogy to illustrate the concept of functional stem cells. 
(A) A kitchen (representative of a tissue) contains a table with baking ingredients, an oven and 
two groups of people, which represent cells: Professional bakers are identified by their hats, 
which represent putative stem cell markers. Amateurs represent cells that do not express 
putative stem cell markers, illustrated by the absence of a baker’s hat. The assignment is to 
bake a birthday cake, which here is representative of stem cell function. 
(B) One of the amateurs, meaning a cell that does not express the marker, takes on the task. 
(C) The result is a beautiful cake. The amateur was thus able to bake a cake, or in other words, 
the cell that did not express the putative stem cell marker performed the stem cell function. This 
illustrates that marker expression is not necessarily indicative of stem cell function. 
Furthermore, it demonstrates that stem cell identity can only truly be verified retrospectively, 
after a stem cell function has been observed. 
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1.2 Adult tissue stem cells 
The presence of stem cells is not limited to the developing embryo. Mammalian young are born 
with a set of spatially defined tissue pools of so-called adult stem cells that support growth into 
the adult as well as maintain homeostasis throughout life. A special case is the female breast, 
in which the mammary stem cell population undergoes drastic expansion as the organism enters 
puberty (Gjorevski & Nelson, 2011).  
Adult stem cell pools function in ways that reflect the needs of their resident tissues. A major 
distinction can be made between renewing and non-renewing tissues. A key example for the 
latter is the brain. While there are neuronal stem cells, which can divide to generate new neurons 
in an adult mammal, there is, apart from the olfactory bulb in certain species (Kornack & Rakic, 
2001; Winner et al., 2002), no constant turnover of the tissue. Therefore, the stem cells in the 
brain are found in restricted areas where they can generate new neurons as part of specific 
processes such as learning (Bergmann, Spalding & Frisén, 2015; Yau, Li & So, 2015).  
Quite different are the demands on the stem cell pools of renewing mammalian tissues such as 
the haematopoietic system, skin and intestine. They need to continuously supply new cells to 
fuel tissue turnover. Historically, such tissues were described as exhibiting a hierarchical 
organisation. Stem cells with (seemingly) unlimited self-renewing capacity produce shorter-
lived, more differentiated progeny that, after additional replication, ultimately differentiate into 
the mature cell types of the tissue. Such organisation was first demonstrated in the blood, which 
lends itself to experimentation due to its easy accessibility. It was thus possible to isolate cells 
from mouse blood and transplant them into recipient mice whose bone marrow had been 
removed by irradiation. This identified the cells able to long-term regenerate the entire 
hematopoietic system as hematopoietic stem cells. Similarly, progenitors were defined as cells 
that could achieve regeneration, but only for certain lineages (Weissman & Shizuru, 2008).  The 
hematopoietic system was thus defined as a branching hierarchy of stem, progenitor and mature 
blood cells. Similar hierarchical architecture was found in the skin (Blanpain & Fuchs, 2006), 
olfactory system (Lander et al., 2009), and epithelium of the intestine (Potten & Loeffler, 1990). 
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Tiered organisation allows for advantageous features. It enables segregation of stem cells into 
niches, thereby physically protecting them from hostile environments and providing them with 
the signalling cues required for their maintenance. In addition, definition of a specific ‘master’ 
stem cell population allows for tight regulation of tissue growth, homeostasis and repair by 
modulation of symmetric and asymmetric divisions. 
In the past two decades however, a more plastic picture has emerged. In the skin, cells attributed 
to the progenitor pool have been shown to act functionally as stem cells in stress conditions 
(Jaks, Kasper & Toftgård, 2010). Lineage plasticity, the ability of progenitors of one lineage to 
differentiate into functional cells of another, has been demonstrated for a variety of 
hematopoietic cells (Graf, 2002). From these examples it transpires that while the stem cell 
pools in renewing adult tissues follow hierarchical organisation, there is a substantial degree of 
plasticity. This relates back to the functional definition of stem cells discussed earlier. It seems 
that which cells act functionally as stem cells in adult tissues can be context-dependent and is 
not necessarily restricted to the cells originally defined to sit at the apex of the hierarchy.  
1.2.1 Experimental methods to study adult stem cells 
Adult tissue stem cells can be studied both in vivo or in vitro. The former enables investigation 
of cells in their physiological context but is more complex, time-consuming, costly and ethically 
challenging. The latter allows for more high-throughput experimentation that is cheaper and 
ethically more accepted, however, to what extent results obtained this way are physiologically 
relevant has to be evaluated on a case-by-case basis. 
1.2.1.1 In vivo methods 
1.2.1.1.1 Experimental organisms 
Historically, studies on adult tissue stem cells relied on lineage tracing, whereby cells are 
labelled followed by identification and quantification of progeny. This type of experiment thus 
retrospectively defines the cells that gave rise to progeny as stem cells. Since the early 1990s, 
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genetic recombination has been widely used for such studies in mice. The method is based on 
expression of site-specific recombination systems such as the Cre-loxP system adapted from 
bacteriophage P1 (Sternberg & Hamilton, 1981). In a typical experiment Cre recombinase is 
expressed under control of a tissue or cell-specific promoter. In addition, experimental animals 
also harbour a reporter gene such as GFP or tdTomato flanked by a loxP-STOP-loxP sequence. 
This combination results in reporter gene expression in cells in which the promoter is active, as 
well as in their progeny. As an example, this method was used to demonstrate that Sox9-
expressing cells can give rise to all lineages in the hair follicle (Nowak et al., 2008). A more 
advanced version of this system are inducible CreERT-lines, in which Cre recombinase is fused 
to a mutated version of the human oestrogen receptor (ER), which results in cytoplasmic 
retention until a ligand such as tamoxifen leads to activation (Littlewood et al., 1995; Metzger 
et al., 1995; Feil et al., 1996). This system allows for temporal regulation of Cre expression, 
enabling selective activation in adult animals. For example, by crossing Lgr6-CreERT mice to a 
reporter strain, Lgr6-expressing cells were identified as stem cells giving rise to all lineages of 
the adult skin (Snippert, Haegebarth, et al., 2010). Importantly, such experiments require a 
priori knowledge, as a promoter has to be chosen to drive Cre expression. An unbiased 
alternative is to express CreER from a promoter active in all cells in the tissue and titrate down 
the dose of tamoxifen such that only very few cells are marked in a stochastic manner. If 
progeny is produced long term, the labelled cell was a stem cell. Together with its progeny it 
forms a clone, the size of which can be used to quantify stem cell behaviour. This approach 
therefore identifies stem cells in a marker-free, purely functional way. It has been used to 
describe stem cell behaviour in the mouse mammary gland during embryonic development, 
puberty and reproductive age (Lloyd-Lewis et al., 2018). 
Not all stem cells in a tissue may necessarily proliferate continuously. Any slowly cycling stem 
cells may be missed by the lineage tracing methods described above. Nucleotide analogues such 
as BrdU or EdU can be used instead. Following a pulse of such a label, it is rapidly diluted in 
actively proliferating cells, but is retained much longer in cells that divide more slowly. Due to 
this phenomenon, pools of slowly cycling stem cells are commonly referred to as label-retaining 
cells. 
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Two additional methods to investigate adult stem cell lineages in model organisms are 
transplantation and direct observation. Using transplantation into damaged organs, the degree 
of potency of different (stem) cell populations can be defined as the degree to which short- or 
long-term regeneration is achieved. Direct observation is currently limited to two-photon 
microscopy, which is restricted to near-body surface imaging, or intravital microscopy, 
whereby inner organs are observed through a surgically applied window. Combined with 
fluorescent labelling, these methods enable observation of stem cell divisions in real time, thus 
removing the need of any inference. A caveat of this method is the limited time window of 
observation, which may overlook stem cells that remained inactive and may complicate 
discrimination between different degrees of potency. 
1.2.1.1.2 Non-experimental organisms 
In tissues from non-experimental organisms, where labelling and genetic modification are not 
feasible, experiments rely on post-mortem detection of marks that are naturally acquired 
through life. One such label is alterations in microsatellites, which are small repetitive regions 
of the genome that are prone to replication errors. From different degrees of similarity between 
the patterns of alterations in specific microsatellites, the lineage tree of cells in a tissue can be 
deduced (Frumkin et al., 2005). DNA methylation patterns can be used in the same way (Kim 
& Shibata, 2002, 2004). Another naturally occurring label is 14C. As the levels of this carbon 
isotope fluctuate in the earth’s atmosphere, and this is reflected in the biomass of the planet, the 
age of a cell can be inferred from its 14C content. Importantly, human nuclear weapon testing 
lead to a significant rise in 14C contents in the 1950s and early 60s. Applied to brains of 
individuals born in that period, the method dated neurons to be much younger than the 
individual they belonged to, providing evidence for adult neurogenesis (Spalding et al., 2005).  
1.2.1.2 Organoids 
A method to study adult stem cells in vitro is by derivation of organoids. These are miniaturised 
and simplified versions of organs that retain some of the micro-anatomy of the organ of origin 
but are comprised solely of epithelial cells. Organoid growth requires media supplemented with 
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modulators of the signalling pathways controlling stem cell activity in the tissue of origin. 
Importantly, organoids can be disaggregated, with the consequence of each piece growing into 
a new mini-organ. Such ability to repeatedly generate organoids is commonly used to measure 
the ‘stemness’ of cells of interest. Furthermore, this platform lends itself to the use of 
CRISPR/Cas9 technology or inhibitors to study specific signalling pathways. Finally, in vitro 
culture quickly generates large amounts of material for molecular analysis. However, organoids 
lack physiological context such as stromal and inflammatory cells. In addition, the anatomy of 
the organ of origin is only partially retained. This limits the scope of biological questions that 
can be answered with this experimental system. 
1.3 Mammalian intestinal stem cell biology 
One of the best studied model systems for adult mammalian stem cell biology is the intestine, 
the site of nutrient absorption. It is, similarly to the skin, in contact with the exterior and 
therefore provides a barrier against damaging chemicals and infectious agents. A consequence 
of this ongoing exposure to harmful extrinsic factors is the continuous renewal of the intestinal 
epithelium, which is fuelled by a population of adult stem cells. The next sections will delve 
deeper into our current understanding of the biology of this tissue and its resident stem cells. 
1.3.1 Structure of the mammalian intestinal epithelium 
The mammalian intestine is lined by an epithelium consisting of a single layer of cells. In the 
small intestine, this is arranged into invaginations called crypts of Lieberkühn and finger-like 
protrusions known as villi (Figure 1.2). It is a very rapidly renewing tissue, which in mice is 
replaced approximately every 5 days. This remarkable turnover is fuelled by the division of 
intestinal stem cells (ISCs) residing at the bottom of the crypts. The daughter cells produced by 
stem cell divisions are fed into a so-called transit-amplifying compartment. There, cells undergo 
approximately 4-5 rounds of rapid cell division, after which point they terminally differentiate 
into nutrient-absorbing enterocytes or one of the secretory cell types, which are Paneth cells, 
goblet cells, tuft cells and enteroendocrine cells (Cheng & Leblond, 1974a, 1974b; Bjerknes & 
Cheng, 1999; Gerbe et al., 2011). Around 5 days after genesis the cells reach the villus tip and 
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are subsequently shed into the gut lumen. Paneth cells migrate downward to reach their final 
destination at the base of the crypt, intermingled between the stem cells. They have a relatively 
long lifespan of 6-8 weeks (Ireland et al., 2005) and act as niche cells, providing short-range 
Wnt, Notch and EGF signals to support the stem cells (Sato et al., 2011; Farin et al., 2016). The 
architecture of the colon is very similar to the small intestine. The two main differences are 
firstly the flat luminal surface lacking villi and secondly that Paneth cells are nearly absent and 
substituted by deep secretory cells (Altmann, 1983; Rothenberg et al., 2012; Sasaki et al., 2016) 
(Figure 1.2). 
1.3.2 The intestinal stem cell niche 
Stem cell niches are defined as the microenvironment necessary to maintain stem cell self-
renewal, pluripotency and proliferation as well as direct positioning of differentiating progeny. 
In the intestine this consists of the extracellular matrix, soluble factors as well as cellular 
components. The latter comprises epithelial Paneth (small intestine) or deep secretory cells 
(colon, see above) as well as a plethora of subepithelial mesenchymal cells that line the basal 
lamina. These are also called stromal cells and include fibroblasts, myofibroblasts, pericytes, 
endothelial cells and smooth muscle cells (Meran, Baulies & Li, 2017). In addition, the 
epithelium contains intraepithelial lymphocytes interspersed between epithelial cells as well as 
populations of other immune cells such as dendritic cells and macrophages that can be found 
throughout the lamina propria (Van Kaer & Olivares-Villagómez, 2018). These are key to 
mediating mucosal immunity (Allaire et al., 2018) 
Subepithelial stromal cells provide signalling molecules to maintain ISCs. Key among these are 
Wnts which are the major driver of ISC proliferation. Recently, subepithelial telocytes as well 
as Gli1-expressing mesenchymal cells have been identified as major sources of Wnt proteins in 
the intestine (Degirmenci et al., 2018; Shoshkes-Carmel et al., 2018). Subepithelial cells also 
produce R-spondins, potent Wnt agonists, as well as BMP antagonists such as Noggin and 
Gremlin, that prevent BMP-mediated differentiation (He et al., 2004; Clevers, Loh & Nusse, 
2014; Meran, Baulies & Li, 2017). In contrast, BMP expression increases along the crypt-villus 
axis, thereby promoting differentiation of cells upon upwards movement (He et al., 2004; Spit, 
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Koo & Maurice, 2018). ISCs and their daughter cells are thus exposed to and directed by a 
complex array of signals which influences the gradient of stemness and differentiation that 
exists along the crypt-villus axis. 
 
Figure 1.2 Architecture of the mammalian intestinal epithelium.  
The small intestine is folded into crypts and villi while the latter are absent in the colon. Stem 
cells are located at the bottom of crypts. Their division generates progenitors that, as they 
shift upwards, differentiate into the mature cell types.  
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1.3.3 Mouse studies on intestinal stem cells 
A lot of our current knowledge about ISCs originates from studies using transgenic mouse 
models. In particular, lineage tracing from specifically marked populations has been used to 
identify the cells giving rise to long-lived clonal progeny as true stem cells. 
1.3.3.1 Intestinal stem cell markers 
The first marker that could reliably be used for such experiments was Lgr5, which is the 
receptor for the Wnt signalling agonist R-spondin (Glinka et al., 2011), identified by the Clevers 
group in 2007 (Barker et al., 2007). Based on its expression, it was estimated that each mouse 
small intestinal crypt contains around 16 stem cells. Lgr5-expressing cells at the bottom of 
intestinal crypts were found to be positive for the proliferation marker Ki67 and were shown to 
incorporate the nucleotide analogue 5-bromodeoxyuridine, which indicates active cycling 
(Barker et al., 2007). However, it had been known since the late 1970s that intestinal crypts 
also contain quiescent or slowly cycling stem cells, as indicated by nucleotide analogue 
retention over periods of around 4 weeks in cells located in a supra-Paneth cell (+4) position 
within crypts (Potten et al., 1978; Potten, Owen & Booth, 2002). Expression of Bmi1 (Sangiorgi 
& Capecchi, 2008), mTert (Montgomery et al., 2011) and Hopx (Takeda et al., 2011) were all 
proposed as markers for slowly-cycling intestinal stem cells. Their functional relevance was 
studied using lineage tracing as well as ablation and injury models. Lineage tracing using LacZ 
or fluorescent reporters revealed infrequent contribution of these quiescent stem cell 
populations to intestinal homeostasis (Sangiorgi & Capecchi, 2008; Montgomery et al., 2011). 
However, upon selective ablation of Lgr5+ cells using diphtheria toxin administration in mice 
expressing the diphtheria toxin receptor in Lgr5+ cells, crypt architecture was maintained. This 
suggested a role for slowly-cycling stem cells as ‘reserve stem cells’. Intriguingly, removal of 
Bmi1+ cells with the same system resulted in crypt attrition, suggesting a requirement of Bmi1+ 
cells for crypt maintenance (Sangiorgi & Capecchi, 2008; Tian et al., 2011). Further, Lgr5+ 
cells could be eliminated by irradiation and crypt regeneration achieved by proliferation of 
radiation-resistant reserve stem cell populations (Montgomery et al., 2011; Yan et al., 2012). 
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Taken together these studies suggested the coexistence of two distinct intestinal stem cell 
populations: One of actively cycling Lgr5-expressing cells and one composed of overlapping 
subgroups expressing markers such as Bmi1, mTert and Hopx.  
However, this model has recently been refined. Using an unbiased split Cre recombinase 
approach label retaining cells were shown to act as stem cells in an injury setting but normally 
be fated towards the secretory lineage (Buczacki et al., 2013). The same was found for Bmi1+ 
cells (Jadhav et al., 2017; Yan et al., 2017). In addition to active and quiescent ISCs, markers 
have also been proposed for various cell lineages, such as Dll1 (van Es et al., 2012) and Atoh1 
for secretory progenitors and Ngn3 (Jenny et al., 2002) for enteroendocrine cells. Interestingly, 
it has been shown that at least two of the proposed stem cell populations are able to interconvert 
(Takeda et al., 2011). Moreover, there is evidence that Dll1- and Ngn3-expressing cells, which 
are predominantly lineage restricted, can also give rise to long-lived multi-lineage clones of 
cells during homeostasis and post-irradiation (Schonhoff, Giel-Moloney & Leiter, 2004; van 
Es et al., 2012). Plasticity has also been demonstrated for Paneth cells, which have been shown 
to contribute to intestinal regeneration in injury or inflammation settings (Schmitt et al., 2018; 
Yu et al., 2018). The picture is further complicated by the fact that many of the proposed marker 
genes are expressed by overlapping populations of cells (Muñoz et al., 2012). 
Two themes emerge from the above discussion: Firstly, the data obtained from marker-based 
studies indicate that the stem cell pool exhibits dynamic phenotypic variability. Context seems 
to determine which cells can and do act as stem cells in the intestine, with a considerable degree 
of plasticity. Therefore, a more fluid description that takes context (homeostasis, injury, disease, 
ageing) into account is thus required. Secondly and related to this point is that a marker-free 
approach is required for capturing of the true functional output of the system. This is in line 
with findings from other tissues discussed earlier and fits in with the baking analogy from 
section 1.1. Therefore, intestinal stem cells will from now on be discussed in a marker-free, 
purely functional way. 
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1.3.3.2 Mouse intestinal stem cell dynamics 
In addition to defining different populations of stem cells, a number of studies in the past decade 
have addressed the question of how stem cells populate the crypt. It had been known since the 
late 1980s that mouse crypts become monoclonal by the time the animals are 2 weeks old and 
that adult intestinal crypts undergo continuous monoclonal conversion such that all cells within 
a crypt are derived from a single stem cell (Schmidt, Winton & Ponder, 1988; Winton, Blount 
& Ponder, 1988). However, the precise dynamics of this process remained unquantified for over 
20 years. The prevailing model for many years suggested that the number of stem cells in a 
crypt remained constant through asymmetric stem cell divisions. This assumption was mainly 
based on a number of studies in Drosophila, where asymmetric divisions are important for 
specifying cell fates during brain development (Betschinger & Knoblich, 2004; Knoblich, 2008; 
Fürthauer & González-Gaitán, 2009).  
This model changed with two landmark studies in 2010, which employed short and long-term 
pulse-chase lineage tracing experiments in both Lgr5- as well as unbiased CreER mouse lines. 
This revealed that monoclonality is achieved through stochastic, unbiased competition between 
stem cells - a process termed neutral drift (Lopez-Garcia et al., 2010; Snippert, van der Flier, et 
al., 2010). In this model, the stem cells at the crypt base form an equipotent population of cells 
that continuously replace each other. Stem cell divisions are balanced by differentiation and 
loss, such that the overall size of the stem cell pool remains the same. Importantly, while 
describing the process by which stem cells populate the crypt, these studies did not define the 
key parameters associated with it, namely the number of functional stem cells and their 
replacement rate. 
This was achieved in a subsequent study by Kozar and colleagues, which confirmed the 
dynamics of neutral drift as well as precisely quantified both the number of functional stem 
cells (known as Ncrypt) and their rate of replacement (λcrypt) in the mouse intestine (Kozar et al., 
2013). The study was based on the (CA)30 mouse model, in which microsatellite mutation 
activates reporter gene expression. This leads to continuous appearance of labelled cells 
throughout the animal’s life. When intestinal stem cells are labelled, they can, due to neutral 
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drift, populate the entire crypt or disappear when non-labelled cells outcompete them. 
Therefore, the number of crypts fully populated by mutant cells (wholly populated crypts, 
WPC) increases linearly with age, while the number of crypts partially populated by mutant 
cells (partially populated crypts, PPC) stays constant as wild type cells readily replace mutant 
cells (Figure 1.3). The slope of WPC accumulation is hereafter referred to as ΔCfix and the 
constant frequency of PPC as Cpart. The age-related behaviour of WPC and PPC was predicted 
from the neutral drift model, from which it could also be derived that ΔCfix depends on the 
mutation rate and the stem cell replacement rate λcrypt, while Cpart also depends on the mutation 
rate as well as the number of functional stem cells per crypt, Ncrypt.  
 
Figure 1.3 Continuous labelling data.  
Scatter plot showing numbers of PPC and WPC in the mouse colon. Orange lines indicate 
predictions from modelling. ΔCfix and Cpart are indicated with blue arrows. Adapted from Kozar 
et al., 2013.  
 
The mutation rate was calculated from the frequency of single cell clones in the transit 
amplifying (TA) compartment, which were indicative of de novo mutation events, as opposed 
to belonging to a stem-cell derived clone. Combined with the experimentally derived values for 
ΔCfix and Cpart this enabled inference of stem cell dynamics parameters in the mouse colon. The 
values obtained were: functional stem cells per crypt, Ncrypt = 7 (95% confidence interval, CI: 
± 0.3) and replacement rate, λcrypt = 0.3 (95% CI: ± 0.04) per crypt per day. With a stem cell 
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division rate of around once per day, this suggests that the majority of stem cell divisions in the 
mouse intestine are symmetric (Kozar et al., 2013).  
A further layer of complexity was added by a recent study elegantly combining Lgr5 genetic 
labelling with intravital imaging. The technique enabled a detailed description of individual 
clone lineages and their position along the z-axis of the crypt. This demonstrated that Lgr5+ 
cells positioned towards the base of the crypt experience a bias towards renewal while the cells 
near the border are, due to their location, more prone to removal from the niche, resulting in 
differentiation and loss. However, stem cells can be rearranged at the base of the crypt, which 
can reassign the fate bias to whichever cells are most central (Ritsma et al., 2014).  
In summary, in homeostasis in the mouse intestine, a heterogeneous population of cells near 
the bottom of the crypt with varying and changing degrees of stem cell potential functions long-
term as a smaller population of effective equipotent stem cells (7 in the colon) with dynamics 
described by neutral drift. Therefore, the output of the neutral drift model quantitatively 
captures the more complex biological system. Such thorough understanding of homeostatic 
stem cell dynamics formed the basis for investigations into the effects of perturbations, such as 
genetic mutations. 
1.3.3.3 Mutations impacting on neutral drift dynamics 
Using mice harbouring inducible alleles for KrasG12D mutation or Apc inactivation as models 
for intestinal tumour initiation, Vermeulen and co-workers demonstrated by lineage-tracing that 
these mutations confer a marked competitive advantage to intestinal stem cells. A KrasG12D 
mutation or the loss of Apc increases the likelihood of a clone becoming fixed. However, the 
presence of either mutation is not deterministic. Rather, the dynamics governing this process 
are still stochastic as mutated stem cells are still readily replaced by wild-type stem cells. 
Interestingly, mutations in the tumour suppressor gene Tp53 seem to only confer an advantage 
in an inflammation setting (Vermeulen et al., 2013).  
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1.4 Defining human intestinal stem cell dynamics 
Studies in genetically modified mice have provided invaluable insights into the homeostatic 
behaviour of stem cells in the intestinal crypt. Investigating the same processes in human tissue 
has traditionally been more challenging, as transgenic lineage tracing approaches are clearly 
not feasible in this setting. 
1.4.1 Early studies on hereditary conditions 
Early observations in humans were based on data from rare hereditary genetic changes. Indeed, 
the serendipitous finding of an XO/XY mosaic patient who also had Familial Adenomatous 
Polyposis (FAP, this is a colorectal cancer-predisposing syndrome, meaning that a resection 
sample was available, the concurrence of these two genetic defects is estimated to occur at a 
frequency of 1 in 100 million births) showed that human crypts are also monoclonal, as crypts 
were either Y-positive or -negative, but never mixed. This means that each crypt originates 
from a stem cell that is either XO (hence Y-negative) or a stem cell that is XY. (Novelli et al., 
1996). Novelli and colleagues also studied a cohort of Sardinian women heterozygous for the 
X-linked glucose-6-phosphate dehydrogenase (G6PD) gene. Due to X-inactivation, cells in 
these individuals appeared either positive or negative for G6PD activity following 
histochemical staining. Assessment of intestinal tissue confirmed that human crypts are 
monoclonal, as individual crypts stained either entirely positively or negatively for G6PD 
activity (Novelli et al., 2003). Importantly, all these studies were based on germline 
polymorphisms and clonal evolution that occurs very early in mammalian development. 
Therefore, they did not provide information about the dynamics and functional stem cell 
numbers in the adult.  
1.4.2 Human lineage tracing 
In recent years, new methods to conduct lineage tracing in adult human tissue samples have 
become available. Importantly, they all rely on observation of progeny from mutant stem cells, 
without specifically identifying the stem cells with markers. Human studies therefore quantify 
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the output of functional stem cells, without the use of any stem cell markers, in an analogous 
manner to the continuous labelling approach used by Kozar and colleagues (Kozar et al., 2013). 
1.4.2.1 Using mitochondrial DNA mutations 
A number of studies have utilized mitochondrial DNA (mtDNA) mutations as a marker of 
clonal expansion of human intestinal stem cells. Mitochondria are the main cellular generators 
of adenosine triphosphate, the energy currency of the cell. They replicate independently from 
the host cell and contain their own genomes. Mitochondrial DNA (mtDNA) is more susceptible 
to mutations than genomic DNA owing to poor repair mechanisms, lack of protective histones 
and location in a highly oxidative environment (Taylor & Turnbull, 2005). Stochastic somatic 
mutations within mtDNA can lead to a loss of cytochrome c oxidase (CCO, also known as 
complex IV) enzyme activity, which can be detected by histochemistry. Somatic mtDNA 
mutations occur randomly and their incidence increases with age (Michikawa et al., 1999; 
Taylor et al., 2003). In addition, CCO mutations do not seem to confer any positive or negative 
selective pressure onto affected cells (Nooteboom et al., 2010; Greaves et al., 2012). Applying 
this system to ten patient samples ranging in age from 45 to 74 years, Gutierrez-Gonzalez and 
co-workers observed small intestinal crypts that were composed entirely of CCO- or CCO+ cells 
as well as crypts containing a mixed population of cells. This supports the notion that human 
crypts are monoclonal and represents strong evidence for the existence of at least two functional 
stem cells within the crypt undergoing some form of competition (Gutierrez-Gonzalez et al., 
2009). Analogous experiments also demonstrated monoclonal conversion for human colonic 
crypts (Taylor et al., 2003). 
The same methodology was taken a step further by Baker and colleagues who cleverly exploited 
the characteristic architecture of the crypt to perform measurements on stacks of sections. The 
group examined changes in cell streams resulting from stem cell replacement events on the 
walls of colonic crypts and came to the conclusion that human intestinal stem cells conform to 
neutral drift dynamics with a functional stem cell number of five to six (Baker et al., 2014). 
However, the use of mtDNA mutations is not without limitations. Each cell contains multiple 
mitochondria and it is not clear what fraction is mutated when a phenotype is observed. It is 
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also not clear in what way this mixed population of mitochondria is represented in the next 
generation of cells upon cell division. Modelling of stem cell dynamics with CCO should 
include a model of mitochondrial dynamics, which is not currently available. Hence, nuclear 
DNA mutations would represent more reliable markers. 
1.4.2.2 Using somatic clonal marks  
Instead of mtDNA mutations, the Winton laboratory has recently developed a method based on 
so-called somatic clonal marks. These are nuclear DNA mutations that can be detected in 
human colonic tissue sections by (immuno)histochemistry. The method assumes that permanent 
genetic changes result in altered protein structures or abundance, causing a different staining 
pattern when specific antibodies or staining methods are used. Somatic clonal marks can be 
used for continuous labelling studies analogous to those performed by Kozar and colleagues. 
The following paragraphs describe this work which was recently published (Nicholson et al., 
2018). 
1.4.2.2.1 mPAS 
Mild periodic acid Schiff (mPAS) staining is a well-established clonal mark. This histochemical 
method distinguishes O-acetylated (stain negative) from non-O-acetylated sialoglycoproteins 
(stain positive) (Veh et al., 1982). In the human colonic mucosa, individuals exhibit one of three 
phenotypes: uniformly mPAS positive, uniformly mPAS negative or negative with rare 
dispersed positive crypts. The scattered pattern was never observed in children, which suggests 
that this phenotype arises due to spontaneous somatic mutations in a single gene in intestinal 
stem cells of heterozygous individuals (Fuller et al., 1990). Monogenic inheritance was 
confirmed by examination of the distribution of the three staining patterns among different 
racial groups (Campbell et al., 1994). The genetic cause of the phenotype is still unknown. 
Based on its role in O-acetylation of sialic acids, CASD1 has emerged as a candidate gene 
(Arming et al., 2011).  
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1.4.2.2.2 Inference of human colonic stem cell dynamics using mPAS 
Analogous to the continuous labelling approach used in the mouse, inference of human colonic 
stem cell dynamics using mPAS was based on scoring of frequencies of WPC and PPC in 
histologically normal colonic epithelial samples from individuals of a wide range of ages. 
(Figure 1.4A) This revealed an age-related increase in WPC with a slope, ΔCfix, of 5.85 × 10-6 
crypts per year (95% CI: 3.87 × 10-6–9.26 × 10-6) (Figure 1.4B top panel). As expected, the 
frequency of PPC (Cpart) remained constant (Figure 1.4B bottom panel). The rate of conversion 
of PPC to maintain ΔCfix indicated that monoclonal conversion of human crypts takes several 
years (median 6.3). The de novo mutation rate was calculated from single cell clones in the TA 
compartment and, combined with the experimentally derived values of ΔCfix and Cpart, enabled 
inference of stem cell dynamics parameters. For the number of stem cells per human colonic 
crypt, Ncrypt, we found 7 (95% CI: 5-10). The replacement rate λcrypt, was calculated as 1.3 stem 
cell replacements/crypt/year (95% CI: 0.65-2.7) (Figure 1.4C). This is nearly 100-fold slower 
than the mouse (Kozar et al., 2013). 
1.4.2.2.3 Validation using the mark MAOA 
The rate of accumulation WPC will vary for different clonal marks because different loci will 
harbour different somatic mutation rates. For neutral marks, neutral drift will act on the PPC 
generated by somatic mutations, independently of the rate at which they appear. Hence, as the 
emergence of PPC is balanced by loss or expansion into WPC to maintain ΔCfix, the ratio of 
ΔCfix/Cpart normalises for mutation rate. It can be used as a metric to describe the intra-crypt 
dynamics that lead to monoclonal conversion. For the neutral mark mPAS, we found ΔCfix/Cpart 
to be 0.056 (95% CI: 0.034–0.095). To validate that this mark is indeed neutral, the staining 
and scoring was repeated for the mark monoamine oxidase A (MAOA Figure 1.4D). This 
mitochondrial enzyme is involved in catalysing the oxidative deamination of amines, such as 
dopamine, noradrenaline and serotonin (Bortolato, Chen & Shih, 2008). It is expressed in many 
tissues, including the intestine (Grimsby et al., 1991) and is not involved in DNA repair or pro-
oncogenic processes. Reassuringly, the ratio of ΔCfix/Cpart for MAOA was calculated as 0.072 
1.4 Defining human intestinal stem cell dynamics 19 
 
(95% CI: 0.054–0.099), incredibly similar to that of mPAS. This validated the stem cell 
dynamics derived using mPAS (Figure 1.4E).  
 
Figure 1.4 Inference of human stem cell dynamics using clonal marks. 
(A) En face tissue section with single mPAS-positive (i) WPC and (ii) PPC. 
(B)Top: Regression analysis showing ΔCfix plotted in red with 95% margin of error in grey 
Bottom: Frequency of mPAS+ PPC plotted against patient age. 
(C) Heatmap representing probabilities for the indicated combination of stem cell number 
and replacement rate with blue indicating high likelihood. 
(D) En face tissue section with single MAOA-negative (i) WPC and (ii) PPC. 
(E) Boxplot showing similar ratio of ΔCfix/Cpart for mPAS and MAOA. Error bars = 95% CI. 
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Interestingly, the replacement rate calculated by our method is about 100-fold slower than that 
derived by Baker and colleagues. A possible explanation may be that the ‘plumes’ of clones 
observed in their study were heavily enlarged by TA compartment proliferation, which may 
have caused dramatic overestimation of the stem cell replacement rate. 
Derivation of the baseline behaviour of human colonic stem cells paves the way for 
investigations into non-homeostatic scenarios. A key question is, whether mutations can alter 
intestinal stem cell dynamics to promote tumour initiation, as has been shown in mice 
(Vermeulen et al., 2013). 
1.5 Mutations, stem cells and cancer in renewing tissues 
A textbook definition of cancer is that it is a disease of deregulated growth caused by somatic 
mutations. The generally accepted view is that cancer initiation occurs as a process of sequential 
accumulation of genetic alterations (Nowell, 1976). The origin of these mutations has recently 
been the focus of intense debate. One camp argues that cancer incidence can be explained by 
the number of stem cell divisions, suggesting that mutations occur mostly as a consequence of 
aberrant DNA replication (such notions are often referred to as the ‘bad luck’ hypothesis) 
(Tomasetti & Vogelstein, 2015). This is contradicted by a study demonstrating that cancer risk 
is heavily influenced by environmental and lifestyle factors (Wu et al., 2016). 
1.5.1 Mutation accumulation and colorectal cancer (CRC) 
Bowel cancer is the 4th most common cancer in the UK, accounting for 12% of all cases in 
females and males combined. There are currently over 40,000 new diagnoses per year as well 
as over 16,000 deaths (Cancer Research UK, 2015).  
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1.5.1.1 Hereditary colorectal cancer syndromes 
About 10% of CRC cases are caused by hereditary cancer syndromes, most frequently Lynch 
syndrome (previously known as Hereditary Non-Polyposis Colorectal Cancer) and Familial 
Adenomatous Polyposis (FAP).  
Lynch syndrome is caused by inherited mutations in one of the four mismatch repair genes 
MLH1, MSH2, MSH6 and PMS2 or mutations in the end of the EPCAM gene (Snyder & 
Hampel, 2019). This predisposes affected individuals for colorectal and endometrial cancer and 
increases their risk for a number of other cancers including ovarian, gastric, urothelial and 
hepatobiliary cancer (Staffa et al., 2015; Yurgelun & Hampel, 2018; Snyder & Hampel, 2019).  
FAP is caused by inherited mutations in APC, a negative regulator of Wnt-signalling, which 
controls stem cell homeostasis in the intestine (Fevr et al., 2007). The syndrome is characterised 
by the formation of hundreds to thousands of intestinal polyps with an onset age of about 16 
years. A diagnosis of colorectal cancer is essentially inevitable, with a mean age at diagnosis 
of 39 years. Therefore, patients are recommended to undergo regular colonoscopies from age 
10-12 years onwards (Bussey, 1975; Snyder & Hampel, 2019) with total colectomy usually 
performed once adult (Campos, 2014).  
1.5.1.2 CRC subtypes  
Over the past decade, molecular analysis has revealed the broad spectrum of alterations in CRC. 
Analysis of genomic sequence, methylome and proteome from tumour samples from over 4,000 
patients enabled the CRC subtyping consortium to define four consensus molecular subtypes 
(CMS1-4) of CRC (Guinney et al., 2015). Strikingly, no single variable is sufficient to subtype 
a given tumour. This sets CRC apart from most other cancer types, in which classification is 
achieved by specific characteristics such as overexpression of particular genes. A prime 
example is breast cancer, whereby expression of the oestrogen receptor, progesterone receptor 
and human epidermal growth factor receptor 2 define the cancer subtype, which then guides 
treatment (Dai et al., 2015). 
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A key criterium used by the CRC subtyping consortium is microsatellite instability (MSI), 
which can be detected in about 15% of CRC (Guinney et al., 2015). Microsatellites, also known 
as short tandem repeats, are 1-6 bp long repeating stretches of DNA which, due to their 
repetitive nature, are prone to high error rate (Ellegren, 2004). Alterations in DNA mismatch 
repair genes (as they occur in Lynch syndrome described above) result in error-prone DNA 
replication, which manifests as unstable (length-changeable) microsatellites (Kim & Kang, 
2014). It follows that MSI tumours, compared to their microsatellite stable (MSS) counterparts, 
harbour more and different somatic mutations. As they represent the majority, the following 
sections will focus on MSS disease. 
1.5.1.3 The mutational landscape of CRC 
The majority of CRC occurs as a consequence of spontaneous somatic mutations. When the 
current list of frequencies of somatic mutations found in MSS CRC is plotted, a striking 
distribution emerges: Apart from a handful of frequently mutated genes, which have been 
referred to as ‘mutational mountains’ (Wood et al., 2007), there are a number of mutations in 
the 5-20% mutation frequency range (‘hills’) as well as a remarkably long tail of drivers with 
low mutation frequencies (Figure 1.5 and Table 1.1) (data from Giannakis et al., 2016 via 
cBioPortal). This indicates that a broad range of mechanisms may to varying degrees contribute 
to the transformation of colorectal tissue.  
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Figure 1.5 Long tail of frequently mutated genes in MSS colorectal cancer.  
Data obtained from Giannakis et al., (2016) and replotted using R.  
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Crucially, the mutational landscape of a tumour is merely a representation of the end stage of 
an evolutionary process occurring on the level of a cellular population. Therefore, these data do 
not provide insights into the roles and timing of different mutations during transformation. Such 
information has historically been gained from studying samples of intermediate stages from 
normal human tissue to malignant tumour. 
Table 1.1 CRC driver genes with mutation frequency over 5%. 
Data from Giannakis et al., (2016) 
 
Gene 
Mutation frequency 
(%) 
APC 61.9 
TP53 56.8 
KRAS 31.1 
PIK3CA 17.8 
MUC17 15.4 
SMAD4 11.5 
BRAF 10.9 
FBXW7 10.9 
SOX9 8.2 
CHD4 6.8 
ZFP36L2 5.7 
PTEN 5.7 
ARID1A 5.3 
TCF7L2 5.1 
 
1.5.2 The Vogelstein model of colorectal cancer progression 
In the 1980s and 90s, cancer progression was studied by examination of key genetic alterations 
in early, intermediate and advanced human colorectal lesions (Fearon & Vogelstein, 1990). 
This generated a number of fundamental observations: Firstly, tumours seemed to be 
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monoclonal. Secondly, RAS mutations were only present in adenomas exceeding 1 cm3. Finally, 
carcinomas exhibited more genetic alterations than early adenomas. Combining these findings 
led Fearon and Vogelstein to propose a step-wise model, in which CRC progression from 
benign adenomatous polyps to more advanced and finally invasive cancer and metastasis is 
driven by sequential accumulation of mutations in specific genes, which perturbs specific 
signalling pathways. According to this model at each step during progression, the newly 
acquired mutation generates a subclone with a competitive advantage, enabling it to outcompete 
its neighbours in a so-called clonal sweep. Due to the frequency of mutations found in human 
samples APC loss was defined as an initiating event, followed by mutations in KRAS and then 
TP53 (Figure 1.6). Interestingly, their landmark paper also contains the speculation that RAS, 
rather than APC, mutations may act as the initiating event in certain tumours. It also proposes 
the notion that the number of mutations may be more important than their order (Fearon & 
Vogelstein, 1990). Importantly, a key aspect of the sequential model is that the growth of 
tumours requires substantial amounts of time, easily decades, which was validated by the 
association of colorectal cancer and age (Muto, Bussey & Morson, 1975). 
 
 
Figure 1.6 The Vogelstein model of CRC progression.  
Loss of APC in normal epithelium drives a hyperplastic phenotype. Subsequent activating 
mutation of KRAS causes growth of an adenoma. This is transformed into a carcinoma by 
acquisition of mutations in TP53. 
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1.5.3 The Big Bang model of CRC initiation 
The Vogelstein model has recently been called into question, as numerous studies in both 
human tissue and mouse models have generated results that cannot be accommodated by the 
sequential model. In particular, the aspects of time, tumour heterogeneity and mutation order 
have exposed the necessity for refinement. From the sequential model with its predetermined 
sequence of mutations, relatively uniform speed of growth would be predicted for human 
tumours. However, serial endoscopies showed that different polyps grow at substantially 
different rates (Pickhardt et al., 2013). Furthermore, synchronous polyps and adenocarcinomas 
were shown to be clonally related, also demonstrating that progression can occur at very 
different speeds despite similar genomic changes (Yang et al., 2015). Stronger evidence against 
the sequential model comes from description of intratumour heterogeneity, which to a large 
extent has been enabled by advances in genomic sequencing technologies. Therefore, the clonal 
nature of tumours described in the 1990s is most likely related to the sequencing method. 
Regional sampling within individual adenomas and adenocarcinomas has revealed substantial 
intratumour heterogeneity, with subclones found throughout the tumours. This contradicts the 
notion of clonal sweeps (Sottoriva et al., 2015) and is further supported by sequencing of 
adenomas and small polyps (Siegmund et al., 2009; Sievers et al., 2017). A final aspect of the 
sequential model is mutation order, whereby in- or hyperactivation of specific pathways is 
thought to be required at specific timepoints during cancer progression. Several mouse studies 
have challenged this view, whereby PIK3CA mutation lead to rapid development of invasive 
adenocarcinomas, circumventing the adenoma stage (Leystra et al., 2012). Equally, 
simultaneous mutation of APC, KRAS and PIK3CA in mice still resulted in adenoma-carcinoma 
sequence, demonstrating that the order of mutation acquisition may not be key (Hadac et al., 
2015). 
These and other findings have led Sottoriva and colleagues to propose the Big Bang model, 
whereby colorectal cancers arise as a single expansion event when a combination of factors 
reaches a critical threshold (Sottoriva et al., 2015) (Figure 1.7). In this model, initiation occurs 
as step-wise mutation accumulation in absence of any phenotype. When a threshold is reached, 
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meaning transformation has occurred, colorectal cancer grows as a single expansion. During 
this growth further mutations are acquired, which can be detected as subclones. Of note the 
initiating mutations seem to determine the tumour phenotype, whereby certain tumours can be 
‘born to be bad’, which can include early metastasis (Hu et al., 2019). 
 
Figure 1.7 Two models for CRC initiation.  
(A) In the Vogelstein model, sequential clonal sweeps populate the tissue. 
(B) According to the Big Bang model, a tumour arises as a single growth when a threshold of 
factors is exceeded. 
 
1.5.4 Mutation acquisition and spread in renewing tissues 
Both the sequential as well as the Big Bang model rely on the acquisition of mutations. To 
persist within renewing tissues such as the intestine, mutations must occur in functional stem 
cells. Or, to avoid semantic discussions: to expand into a tumour, the cells carrying the initiating 
mutations must continuously self-renew as well as produce progeny. Thus, at the moment of 
initiation, these cells act functionally as stem cells. In line with this notion, stem cells are seen 
as the cell of origin in cancer of the intestine (Barker et al., 2008; Schwitalla et al., 2013). 
The acquisition of secondary (and subsequent) mutations, which will drive cancer progression, 
is favoured by expansion of stem cell-derived clones within the tissue, as this increases the pool 
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of cells available for additional mutation. This effect is further exacerbated by the spread of 
alterations that predispose for mutation accumulation. Figure 1.8 illustrates this process for the 
colonic epithelium. The idea of such expansion of mutations, termed ‘field cancerisation’ dates 
back two decades, when it was found that a proportion of individuals with oral cancer had 
multifocal tumours, suggestive of an underlying mutated ‘field’ (Garcia et al., 1999). Equally, 
in the colon, tumours as well as their surrounding tissue were found to harbour the same KRAS 
mutations (Zhu et al., 1997). Similar evidence for field cancerisation has in the meantime also 
been found in the bladder and prostate (Curtius, Wright & Graham, 2017). 
The models of mutation accumulation and field cancerisation predict the presence of mutant 
clones in non-transformed aged tissues. Indeed, mathematical modelling indicated that at least 
half of the mutations in cancers of self-renewing tissues originate prior to tumour initiation 
(Tomasetti, Vogelstein & Parmigiani, 2013). Due to its easy accessibility, patterns of mutant 
clonal expansion were first documented in the hematopoietic system of aged humans (Welch et 
al., 2012; Genovese et al., 2014; Xie et al., 2014). More recently, sequencing of microbiopsies 
of skin and oesophagus from aged individuals have found these tissues to be a mosaic of somatic 
mutations (Martincorena et al., 2015, 2018). These findings were confirmed by analysis of 
mutant allele fractions in RNA-sequencing data from a range of normal tissues, which found 
macroscopic clonal expansions in 95% of samples tested (Yizhak et al., 2019).  
Importantly, the size of clonal expansions can fall below the sensitivity of such bulk approaches. 
Analysis of single cells or organoids from in vitro expanded single cells can generate a more 
comprehensive overview over the mutational landscape of normal adult tissue (Behjati et al., 
2014; Blokzijl et al., 2016; Jager et al., 2017; Lodato et al., 2018). Sequencing of organoids 
derived from single human small intestinal and colonic cells suggests that mutations accumulate 
in this tissue at a rate of around 40 mutations per year (Blokzijl et al., 2016). However, only a 
very small number of cells were analysed, therefore rarer mutations as well as the extent of 
clonal expansions were not quantified. The same holds true for a recent study employing laser 
capture microdissection and whole exome sequencing to describe the mutational landscape of 
just over 2,000 normal human colonic crypts. The authors found a large number of somatic 
mutations, mostly associated with the ageing signature. However, only a handful of mutations 
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in the cancer most common CRC drivers and no large-scale clonal expansions were detected 
(Lee-Six et al., 2018). Again, this most likely relates to the low number of crypts probed. To 
gain more thorough insights into the accumulation of mutations in normal colon, larger areas 
need to be examined. 
 
Figure 1.8 Scenarios for second mutation acquisition. 
(A) Left: The first mutation (pink) hits a number of crypts at random.  
Right: The second mutation (blue) hits a number of crypts at random. By chance, one crypt 
ends up with both mutations (purple). 
(B) Left: The first mutation (pink) hits a crypt and subsequently expands into a field. 
Right: The second mutation hits a number of crypts at random. Due to the underlying field, 
several crypts end up with both mutations (purple). 
(C) Left: The first mutation (pink) hits a crypt and subsequently expands into a field. This 
mutation predisposes towards accumulation of subsequent mutations.  
Right: The mutation-promoting field results in an increased number of crypts carrying two 
mutations compared to situation (B). 
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1.6 Summary and aims 
Stem cells can be defined functionally through their ability to self-renew and differentiate. In 
adult mammals, key populations of stem cells fuel the turnover of renewing tissues such as the 
intestine. The functional unit of the intestinal epithelium is the crypt, which contains an 
equipotent population of functional stem cells that replace each other stochastically through 
neutral drift. In the mouse, mutations can lead to biases in this process, whereby affected stem 
cells have an increased probability of fixation within a crypt. CRC is thought to arise from 
intestinal stem cells that have acquired somatic mutations. According to the current Big Bang 
model, CRC is initiated when a critical threshold of pro-oncogenic factors is exceeded. In such 
a scenario, mutations that set cells onto a path towards cancer would originally arise in intestinal 
stem cells at the bottom of crypts, where they would ride the wave of neutral drift or even 
subvert it to increase their probability of fixation. Subsequent clonal expansion would occur by 
crypt division. Eventually, a tumour would be initiated when several driver mutations coincide.  
Crucially, both mutation fixation in the crypt and expansion beyond determine the size of the 
pool of cells that can acquire further hits. Therefore, understanding these processes in normal 
tissue is key to understanding the earliest events during cancer evolution. 
Within this framework the overarching goal of this project was to investigate the means by 
which mutations populate the normal human colon with age. This encapsulated the following 
aims: 
1.  To expand on the tools available for investigating human intestinal stem cell dynamics. 
 
2. To determine the effect of gene-specific mutations on variant fixation within colonic 
crypts. 
 
3. To investigate the rates and mechanisms of lateral expansion of mutant clones in the 
human colon. 
 Chapter 2 Materials and methods         
2.1 Human tissue 
Normal colon tissue samples were obtained from both Addenbrooke’s Hospital Cambridge and 
Norfolk and Norwich University Hospital under full local research ethical committee approval 
(Approval document IDs 15/WA/0131 & 17/EE/0265 as well as 06/Q0108/307 & 
08/H0304/85, respectively) according to UK Home Office regulations. A total of 351 
individuals were included in the study with an age range of 8–93 years (Appendix A). 
Colectomy specimens were fixed in 10% neutral buffered formalin. From areas of tissue 
without macroscopically visible disease mucosal sheets were removed from the specimens and 
embedded en face in paraffin blocks. For standard stainings, sections were cut from each sample 
at 5 μm thickness and mounted onto charged glass slides. 
2.2 mPAS staining 
Sections were de-waxed and rehydrated on a Leica Multistainer ST5020 before washing in 0.1 
M Acetate buffer pH 5.5 at 4 ºC for 5 minutes. This was followed by oxidation in 1 mM sodium 
periodate buffer at 4 ºC for 10 minutes before washing in 1% glycerol for 5 minutes. Then, 
three washes were performed in ultra-pure water for 5 minutes in total, followed by staining in 
Schiff’s reagent for 15 minutes. Sections were then washed again in ultra-pure water and 
counter-stained in Mayer’s Haematoxylin for 40 seconds. After another wash in ultra-pure 
water and brief blueing in tap water a final rinse in ultra-pure water was performed. This was 
followed by dehydration, clearing and mounting in DPX on the same Leica Multistainer. 
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2.3 Immunohistochemistry  
2.3.1 Standard protocol 
Sections were de-waxed and re-hydrated on a Leica Multistainer ST5020. This was followed 
by heat-induced epitope-retrieval in citrate buffer (10 mM sodium citrate, pH6) in a medical 
pressure cooker and washing in PBS. All subsequent washes were 3 x 5 min in PBS-T (PBS 
with 0.05% Tween-20). After a 15 min incubation with 3% H2O2 in methanol and a wash, slides 
were incubated with blocking buffer (PBS-T with 10% Donkey Serum, Dako) for 30 min. This 
and all following incubations were performed at room temperature in a humidified slide box. 
Slides were then incubated with the primary antibody (Table 2.1) for one hour at room 
temperature or overnight at 4 ºC. After a wash, slides were incubated with the secondary 
antibody (biotin-SP-conjugated AffiniPure donkey anti-mouse, anti-rabbit or anti-goat, Jackson 
ImmunoResearch, all 1:500 in PBS-T) for 40 min. Following a wash, slides were incubated 
with Vectastain® Elite® ABC reagent (Vector Laboratories) for 40 min. This was followed by 
a final wash and immunoperoxidase detection using a liquid DAB + substrate chromogen 
system (Dako). Finally, sections were counterstained with Mayer’s Haematoxylin, dehydrated 
and mounted in DPX on the Leica Multistainer.  
 
2.3.2 Adaptations for laser capture microdissection 
For staining of sections for laser capture microdissection the protocol was largely identical apart 
from the following changes: Tissue was cut at 10 μm thickness onto UV-irradiated PEN 
membrane slides (ZEISS). Heat-induced epitope retrieval was performed in citrate buffer in a 
water bath at 76 ºC for 16 hours. Counterstaining with Mayer’s Haematoxylin was performed 
manually for 15 seconds followed by blueing in tap water for 1 minute and drying at room 
temperature. Slides were stored at room temperature (short-term) or -20 ºC (long-term). 
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Table 2.1 Primary antibodies tested for IHC.  
N/A denotes that no suitable titre was found for staining of human colonic FFPE sections. 
Antigen Antibody Supplier Titre 
ADGRG4 HPA017372 HPA 1:50 
ATRX HPA001906 HPA 1:500 
BRAFV600E E19290 Spring Bioscience 1:200 
DDX3X HPA059585 HPA N/A 
DUSP6 ab76310 Abcam 1:100 
H3K27me3 ab6002 Abcam 1:1000 
HDAC6 HPA003714 HPA 1:200 
HDAC6 #7558 CST 1:600 
HTATSF1 HPA000504 HPA 1:200 
HUWE1 HPA002548 HPA 1:300 
HUWE1 ab70161 Abcam 1:400 
HUWE1 OALA01854 Aviva 1:300 
IDH3G HPA000425 HPA N/A 
KDM6A HPA002111 HPA 1:100 
KDM6A #33510 CST 1:200 
KRASG12D #14429 CST 1:250 
MAOA SC-271123 Santa Cruz 1:200 
NONO HPA054559 HPA 1:500 
NONO HPA054094 HPA 1:2000 
p-4EBP1 #2855 CST 1:600 
p53 ab1101 Abcam 1:1000 
PDHA1 HPA063053 HPA 1:700 
PTEN #9559 CST 1:300 
PTEN 6H2.1 Sigma-Aldrich 1:200 
RBMX HPA057707 HPA 1:100 
RPS6KA HPA003221 HPA 1:1000 
RPS6KA A302-460A Bethyl 1:2000 
SH3KBP1 HPA003351 HPA 1:500 
SLC25A5 HPA071684 HPA N/A 
SMAD4 ab217267 Abcam 1:400 
SMC1A HPA063884 HPA 1:300 
SMC1A ab133643 Abcam 1:400 
SMC1A orb94671 Biorbyt 1:200 
STAG2 HPA002857 HPA 1:100 
STAG2 LS-B11284 LSBio 1:1000 
STARD8 HPA060788 HPA N/A 
XIAP HPA042428 HPA 1:1000 
ZMYM3 HPA003211 HPA 1:500 
ZNF75D HPA004705 HPA 1:50 
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2.4 Clonal marks data acquisition and analysis 
2.4.1 Clone and crypt counting 
WPC and PPC numbers as well as multicrypt patch sizes were manually scored in stained tissue 
sections using a standard brightfield microscope. Sections were scanned at 20X using a Leica 
Aperio AT2 scanner and stored as .svs files on a CRUK Cambridge Institute server. Scans were 
examined online using the Aperio eSlide Manager (Leica) or downloaded and annotated using 
QuPath (Bankhead et al., 2017). To count the total number of crypts on each section, .svs files 
were analysed with the DeCryptICS neural network developed by Dr Edward Morrissey and 
Dr Doran Khamis (https://github.com/MorrisseyLab/DeCryptICS, manuscript in preparation). 
2.4.2 Scoring fusion 
To score crypt fusion, the term ‘fufi’ was invented to agnostically refer to structures that could 
represent a crypt undergoing fusion or fission in en face human colonic tissue sections. A fufi 
was defined as two crypts joined together without any visible gap but with two clearly 
distinguishable lumina. For stained sections, fufis can consist of two wild type crypts (WT fufi), 
two mutant crypts (mut fufi) or a WT and a mut crypt (WT-mut fufi). To count the total number 
of fufis on each section, .svs files were analysed with DeCryptICS followed by manual 
annotation in QuPath to classify fufis as WT, mut or WT-mut. 
2.4.3 Clone and fufi data analysis 
Data was analysed and plotted using R. 
2.4.4 Patch size frequencies 
For all marks, the total numbers of patches consisting of 2-14 crypts as well as ≧ 15 crypts were 
determined and frequencies calculated from division by total clone numbers (whereby a patch 
is a clone). 
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2.4.4.1 All other clonal marks data analyses 
The age-related behaviour of WPC and PPC for HDAC6, KDM6A, MAOA, mPAS, NONO, 
p53, PTEN and STAG2 was used to infer intra-crypt behaviour as well as crypt fission rates 
associated with gene-specific mutations. This was performed by Dr Edward Morrissey and is 
outlined in detail in Appendix C.  
The frequencies of WT-mut as well as mut fufis combined with the patch sizes for mPAS and 
KDM6A were used by Dr Doran Khamis to infer the crypt fusion rates associated with these 
two clonal marks. KDM6A fufi data was further used to infer the duration of crypt fusion. 
Details of mathematical models used can be found in Appendix E. 
2.5 Laser capture microdissection and sequencing 
2.5.1 Laser capture microdissection and sample lysis 
On stained FFPE human colonic tissue sections (see 2.3.2), crypts of interest were harvested 
into lids of 0.2 mm radius PCR tubes using a Leica LMD7000 Laser Microdissection System. 
10 μl of Proteinase K solution from the Arcturus® PicoPure® DNA Extraction Kit 
(ThermoFisher) were added and tubes centrifuged in a mini-centrifuge for PCR tubes. 
Following lysis for 3h at 65 ºC in a standard PCR block the enzyme was inactivated by 
incubation at 95 ºC for 10 min. Samples were kept at 4 ºC until PCR. 
2.5.2 Assessment of FFPE DNA quality  
2.5.2.1 By quantitative PCR 
DNA was extracted from laser capture microdissected crypt sections as described above as well 
as from FFPE sections using the QIAmp DNA FFPE Tissue Kit (QIAGEN) according to the 
manufacturer’s instructions. Human female genomic DNA (Promega) was used as a control. 
Quantitative PCR analysis was performed using a TaqManTM probe for Atoh1, which generates 
an 83-bp amplicon (Assay ID: Hs00944192_s1, ThermoFisher) using the supplier’s reagents 
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and protocol in a QuantStudioTM 6 Flex Real-Time PCR system. Each 20 μl reaction contained 
10 μl TaqManTM Universal PCR Mastermix, 1 μl nuclease-free water, 1 μl TaqManTM probe 
and 8 μl sample at the relevant DNA concentration. 
2.5.2.2 By PCR with varying amplicon size 
For assessment of optimal amplicon size, DNA extracted from FFPE sections as described 
above was diluted to equivalents of 5, 20 and 100 crypts and used for PCR reactions containing 
primers at 1 μM concentration (Appendix B: Table B.1), 0.5 mM dNTPs (New England 
BioLabs), 5 μl 5X Phusion® HF Reaction Buffer (New England BioLabs), 1 U of Phusion® 
High-Fidelity DNA Polymerase (New England BioLabs) and nuclease-free H2O (Ambion) to 
make up a volume of 25 μl. PCR cycling was performed at 95 ºC for 2 min for one cycle, 
followed by 35 cycles at 95 ºC for 10 s, 60 ºC for 10 s and 72 ºC for 15 s. The final cycle was 
followed by a 5 min extension at 72ºC. 
2.5.3 Sequencing library preparation 
2.5.3.1 Pre-amplification 
Due to low quantities of input DNA a pre-amplification PCR was performed. All primers were 
designed using Primer3 (Rozen & Skaletsky, 2000). They included Fluidigm CS1 and CS2 tags 
and were ordered from Sigma (Appendix B: Tables B.2 and B.3). Reactions were performed in 
multiplex primer groups with primers each at 1 μM concentration. For MAOA, two primer 
groups (odd and even numbered primers) were used. For KDM6A, three groups were used 
(group 1: primers 1,4,7…group 2: 2,5,8… group3: 3,6,9…). The LCM DNA sample was diluted 
such that each PCR reaction contained 10 μl DNA sample. In addition, each reaction contained 
0.5 mM dNTPs (New England BioLabs), 5 μl 5X Phusion® HF Reaction Buffer (New England 
BioLabs), 1 U of Phusion® High-Fidelity DNA Polymerase (New England BioLabs) and 
nuclease-free H2O (Ambion) to make up a volume of 25 μl. PCR cycling was performed at 95 
ºC for 2 min for one cycle, followed by 35 cycles at 95 ºC for 10 s, 60 ºC for 10 s and 72 ºC for 
15 s. The final cycle was followed by a 5 min extension at 72ºC. Samples were then treated 
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with ExoSAP-IT enzyme (2 μl of enzyme for 5 μl of sample, ThermoFisher) at 37 ºC for 15 
min followed by a 15 min inactivation at 80 ºC. Samples were then diluted 1:10 in DNA 
Suspension Buffer (Teknova) and stored at 4 ºC until further processing.  
2.5.3.2 Individual amplification 
To obtain adequate amounts of DNA for sequencing, the pre-amplified products were further 
amplified using the Fluidigm Access Array™ according to the supplier’s protocol. Primers with 
Fluidigm CS1 and CS2 tags used in the chip were ordered from Sigma (Appendix B: Tables 
B.2 & B.3). 
2.5.3.3 Barcoding 
A unique Fluidigm barcode was added to each sample by PCR in 10 μl reactions using the Fast 
Start High Fidelity PCR System (Roche) containing: 400 nM barcoding primers, 1 μl diluted 
PCR product, 1X Fast Start HF buffer without MgCl2 , 4.5 mM MgCl2, 5% DMSO, 0.2 mM 
dNTPs each, 0.05 U/μl High fidelity enzyme mix and nuclease-free H2O (Ambion) to make up 
a reaction volume of 10 μl. PCR cycling was performed using the protocol: 95ºC for 10 min 
followed by 15 cycles at 95 ºC for 15 s, 60 ºC for 30 s and 72 ºC for 60 s. The final cycle was 
followed by a 3 min extension at 72 ºC.  
2.5.3.4 Purification and size selection 
Samples were then pooled, purified using a Clean & Concentrator Kit (Zymo Research) and 
primer dimers eliminated by broad range (200-400 bp) size selection using a PippinBlue (Sage 
Science). Samples were kept at 4 ºC until submission for sequencing. 
2.5.4 Next-generation sequencing 
Samples were submitted to the in-house genomics core facility for sequencing on the Illumina 
MiSeq platform. Samples from one Fluidigm Access Array™ were sequenced on one lane using 
150 bp paired-end sequencing with 10% PhiX. 
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2.5.5 Sequencing data analysis 
Fastq files were converted to .BAM files and analysed using a PERL script (available upon 
request) by Dr Richard Kemp. Briefly, from the bulk of reads the script first identifies reads 
corresponding to the amplicons of interest by pulling out reads starting and finishing with the 
expected sequence as well as containing an expected stretch of sequence in the middle. For 
these reads, at every nucleotide position outside of the primer sequence, the number of reads 
corresponding to the reference genome as well as the number of reads containing a base change 
at that position are recorded. This enables calculation of the noise at every position. Candidate 
mutations were identified when the mutant allele frequency was either >4x the mean of the 
noise at that position or >3.29 x the standard deviation at that position (p≦ 0.001). True 
mutations were called if they were present in all samples originating from the same patch in 
serial sections but absent in all wild-type samples from the same sections. To complement this 
analysis and identify insertions and deletions the script was modified to a version that scans the 
reads using pairs of four nucleotides corresponding to the reference genome. If a match is found, 
the base in between is recorded (Figure 2.1). Importantly, if there is a mismatch between one 
of the quadruplets of nucleotides and the read, the script will not record the base in between. 
Thus, for a single nucleotide variation, the script will record 4 positions with no reads, followed 
by a position with reads and then again 4 positions without (Figure 2.1A). For a 1 base deletion, 
there will be a continuous mismatch for 9 positions (Figure 2.1B). Following this analysis 
SNPs, SNVs and deletions are easily identified by plotting the total reads against nucleotide 
position. Dips with a peak represent a SNV or a SNP, dips lacking a peak appear due to a 
deletion or insertion (Figure 2.1). Again, mutations were considered real if they appeared in all 
samples corresponding to the same patch in serial sections but were absent in surrounding wild 
type crypt samples. 
This analysis was complemented by manual inspection of reads using the Integrative Genomics 
Viewer by the Broad Institute (Robinson et al., 2011). 
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Figure 2.1 Illustration of PERL script used for analysis of mutations in LCM DNA. 
Schematics outlining the scanning of reads (Seq) in pairs of four nucleotides corresponding to 
the reference genome (Ref) with recording of the base in between. Red indicates a mismatch. 
(A) Schematic outlining the analysis of a read containing an SNV or SNP (blue). 
(B) Schematic outlining analysis of a read containing a deletion. 
 
2.6 Targeted KRAS sequencing 
2.6.1 FFPE DNA sample preparation 
Sections were cut from FFPE colonic tissue blocks at 10 μm thickness as scrolls into standard 
Eppendorf tubes. From these, DNA was extracted using the QIAmp DNA FFPE Tissue Kit 
(QIAGEN) according to the supplier’s protocol. DNA was eluted in 20 μl of TE and stored at -
20 ºC or -80 ºC (short- or long-term, respectively). 
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2.6.2 Library preparation 
2.6.2.1 PCR amplification 
Primer pairs (Appendix B: Table B.4 ) flanking KRAS codons 12 and 13 as well as the mimic 
area in the mimic gene PITPNM2 were designed using Primer3 (Rozen & Skaletsky, 2000). 
Fluidigm CS1 and CS2 tags were added to all primers. For amplification, two methods were 
used. Initially, 188 samples were amplified in two independent PCR reactions using KRAS_2 
primers at 1 μM concentration as well as 1 μ1 DNA sample, 0.5 mM dNTPs (New England 
BioLabs), 5 μl 5X Phusion® HF Reaction Buffer (New England BioLabs), 0.5 U of Phusion® 
High-Fidelity DNA Polymerase (New England BioLabs) and nuclease-free H2O (Ambion) to 
make up a volume of 25 μl. 
For subsequent experiments, the mimic amplicon method as outlined in section 5.3 was used, 
which required amplification of each DNA sample in two independent duplex PCR reactions 
containing the KRAS_1 and corresponding MIMIC_1 primers or KRAS_2 and corresponding 
MIMIC_2 primers, respectively. To balance the PCR reactions, KRAS and MIMIC primers 
were present at concentrations of 1.2 μM and 0.8 μM, respectively. Reactions also contained 1 
μ1 DNA sample, 0.5 mM dNTPs (New England BioLabs), 5 μl 5X Phusion® HF Reaction 
Buffer (New England BioLabs), 0.5 U of Phusion® High-Fidelity DNA Polymerase (New 
England BioLabs) and nuclease-free H2O (Ambion) to make up a volume of 25 μl.  
For both methods, PCR cycling was performed as: 95 ºC for 2 min for one cycle, followed by 
35 cycles at 95 ºC for 10 s, 60 ºC for 10 s and 72 ºC for 15 s. The final cycle was followed by 
a 5 min extension at 72 ºC. 
2.6.2.2 Barcoding and next-generation sequencing 
Prior to barcoding, PCR products were diluted 1:15 in DNA suspension buffer (Teknova). 
Barcoding to add a unique identifier was then performed as described in section 2.5.3.3. 
Libraries consisting of barcoded PCR products from 192 samples were then cleaned up using a 
Clean & Concentrator Kit (Zymo Research), primer dimers eliminated by broad range (200-
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400 bp) size selection using a PippinBlue (Sage Science) and then submitted for 150 bp paired-
end sequencing with addition of 15% PhiX on the Illumina MiSeq platform in the in-house 
genomics facility.  
2.6.3 Targeted KRAS sequencing data analysis 
Corresponding forward and reverse reads were combined into a single consensus sequence 
using PANDAseq 2.11 with default options (Masella et al. 2012). Artefactual sequences were 
removed on the basis of not beginning and ending with the forward and reverse gene specific 
primer sequence and incorrect overall length (+/- 3bp tolerance).   
2.6.3.1 Mutation calling in single amplicon method 
This method was used for analysis of the first 188 samples, which were included in our recent 
publication (Nicholson et al., 2018). Only samples with read number ≥1000 were considered. 
The frequency of all nucleotides at all amplicon positions was calculated using a custom PERL 
script written by Dr Richard Kemp (available on request). A minimum of 10 variant reads was 
required to estimate mutant allele frequency (MAF) for any given nucleotide position. The 
mean allele frequency and standard deviation were calculated for all samples on a sequencing 
run for each particular amplicon position and nucleotide. Mutations were called in a sample if 
the estimated MAF exceeded either 4 × the mean allele frequency or the mean allele frequency 
+ 3.209 standard deviations of the mean allele frequency in both KRAS replicates, 
corresponding to a p-value of < 0.001. The actual MAF for a particular mutation was calculated 
by subtracting the mean allele frequency (corresponding to noise) from the estimated MAF. 
2.6.3.2 Mutation calling in mimic amplicon method 
This method was applied to all subsequent samples. Mutation calling focused on codons 12 and 
13 of the KRAS gene and used a custom PERL script written by Dr Richard Kemp. For each 
DNA sample, reads containing the sequences corresponding to wild type (GGTGGC) as well 
as all possible mutations of codons 12 and 13 were extracted (Table 2.2). This yielded a MAF 
for every possible mutation in all four amplicons for every DNA sample and thus also revealed 
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the noise at every position. KRAS mutations were called if 1) >1000 reads were obtained for 
both KRAS amplicons and at least one mimic amplicon and 2) the MAF in both KRAS amplicons 
was > 0.1% (corresponding to at least 10 mutant reads) but found at background levels in the 
mimic amplicons. These criteria correspond to ≧ 1.96 standard deviations or a p-value of < 
0.025 for the noisiest nucleotide position (KRASG12D). The actual MAF for a particular 
mutation was calculated by subtracting the mean allele frequency (corresponding to noise) from 
the estimated MAF. 
 
Table 2.2 Sequence context used to extract mutant reads from sequencing data. 
For each variant, the frequency was calculated by dividing by the total read number. 
Context Nucleotide change Amino acid change 
GAGCTGGTGGCGTA WT WT 
GAGCTGATGGCGTA G>A G12D 
GAGCTGCTGGCGTA G>C G12A 
GAGCTGTTGGCGTA G>T G12V 
GAGCTAGTGGCGTA G>A G12S 
GAGCTCGTGGCGTA G>C G12R 
GAGCTTGTGGCGTA G>T G12C 
GAGCTGGTGACGTA G>A G13D 
GAGCTGGTGCCGTA G>C G13A 
GAGCTGGTGTCGTA G>T G13V 
GAGCTGGTAGCGTA G>A G13S 
GAGCTGGTCGCGTA G>C G13R 
GAGCTGGTTGCGTA G>T G13C 
GAGCTGGAGGCGTA T>A WT 
GAGCTGGCGGCGTA T>C WT 
GAGCTGGGGGCGTA T>G WT 
GAGCTGGTGGAGTA G>T WT 
GAGCTGGTGGGGTA G>C WT 
GAGCTGGTGGTGTA T>C WT 
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2.6.3.3 Mathematical modelling of KRAS clone behaviour 
The MAFs obtained by analysis of targeted sequencing data described in 2.6.3.1 and 2.6.3.2 
were used by Dr Edward Morrissey to model the behaviour of KRAS-mutant clones. The 
mathematical methods used are described in Appendix D.  
   
 Chapter 3 Clonal marks discovery 
3.1 Introduction 
Lineage tracing experiments undertaken in transgenic mice have informed our current 
understanding of intestinal stem cell dynamics. For human studies however, such approaches 
are not feasible. Therefore, insights are largely gained by visualisation of spontaneous 
mutations in samples from cohorts of individuals from a wide range of ages. Conceptually, this 
type of study is analogous to the continuous labelling approach taken by Kozar and colleagues, 
which defined the number and replacement rate of effective stem cells in the mouse intestine 
(Kozar et al., 2013). In our laboratory we use visualisation of genetic alterations in nuclear 
DNA as a tool for human lineage tracing. We refer to such visualisable events as clonal marks. 
3.1.1 The concept behind human clonal marks 
Human clonal marks rely on visualisation of somatic mutations. The method is predicated on 
genetic changes resulting in a different staining pattern when specific antibodies or 
histochemical methods are used. Somatic mutations can cause translation of a structurally 
altered or truncated protein, which abrogates binding of specific antibodies. Mutations may also 
occur in regulatory elements, leading to up- or downregulation of gene expression. Changes in 
protein abundance may further be caused by heritable epigenetic events. For most of our marks 
we use IHC, whereby immunodetection is carried out via horseradish peroxidase-catalysed 
oxidation of 3,3’-Diaminobenzidine (DAB), resulting in a brown precipitate. Mayer’s 
Haematoxylin is used as a counterstain, which yields blue nuclear staining. An exception is the 
clonal mark mPAS, which is detected by a different histochemical method (see 2.2) and which 
we previously used to infer human intestinal stem cell dynamics (Nicholson et al., 2018). 
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Clonal marks can be positive or negative. In the latter case, genetic alterations cause reduction 
or loss of immunoreactivity, resulting in mutant clones appearing blue on a brown background. 
For positive marks, genetic alterations lead to upregulation or stabilisation of a protein that is 
normally absent or rapidly turned over. Mutations may also introduce very specific amino acid 
changes that can only be detected by antibodies against that particular mutant form. In both 
cases, rare dark brown clones are visualised on a pale background. For both types of clonal 
mark, the same set of technical and biological requirements apply. 
3.1.2 Requirements for clonal marks 
This section formalises, in increasing order of stringency, the requirements candidate clonal 
marks need to fulfil in order to be applied. 
3.1.2.1 Uniform staining pattern 
The most basic requirement for a candidate clonal mark is that all intestinal epithelial cells stain 
evenly. Failure to meet this criterion precludes distinction of real negative or positive cells from 
artefacts caused by the plane of sectioning. Figure 3.1A illustrates this point. Variability of 
protein expression along the crypt axis can, when the epithelium is not perfectly horizontally 
aligned within the paraffin block, lead to a variegated staining pattern in which identification 
of true positives or negatives is not possible. A further exclusion criterium is cell-state or cell-
type specific protein expression, as demonstrated in Figure 3.1B. Rare positive or negative cells 
could in such a case be falsely identified as crypts partially populated by mutant clones, 
corrupting the data.  
Related to uniformity of staining is saturation. For negative marks, strong saturated staining is 
necessary for unequivocal detection of negative clones. Equally, for positive marks, dark clones 
are required for identification against the background. Antibody titres are optimised to achieve 
these saturated outcomes. However, depending on the price of a specific antibody, the required 
titre may result in a cost per section that exceeds the budget of the project (> £5 per section). 
Such antibodies are not pursued further.  
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Figure 3.1 Clonal marks scenarios.  
A-D are not suitable as clonal marks. 
A) Protein expression variability along the crypt axis can result in a variegate pattern on 
transverse sections when the plane of sectioning is not orthogonal to the crypt axis. 
B) Expression in specific cell types is indistinguishable from partially populated crypts in 
transverse sections. 
C) Non-confined clones with stromal immuno-reactivity are challenging to interpret. 
D) Weak immunoreactivity complicates clone identification. 
E) Useable clonal marks yield confined clones that are easily identified within the uniformly 
different background. 
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3.1.2.2 Confined clones 
Mutations detected as clonal marks are assumed to occur in stem cells at the bottom of the crypt 
and become fixed by the process of neutral drift. Clones may thus manifest as crypts partially 
populated by mutant cells or crypts that are entirely mutant. The ability to identify the former 
provides strong support for the genetic origin of a clonal mark, because it demonstrates the 
ability to define cellular boundaries separating the clone from wild type epithelium where 
juxtaposed within a single crypt. Importantly, the biology of the intestinal epithelium precludes 
spread of a genetic event occurring in intestinal stem cells to non-epithelial cells. Therefore, 
areas containing epithelial as well as stromal reactivity could be indicative of local insults 
including infection or damage or could be an artefact relating to tissue fixation or sectioning 
thickness. A telling characteristic of such artefacts is altered staining that is not confined to 
cellular boundaries. As these staining patterns are generally indicative of non-genetic events, 
such marks are abandoned. Of note, stromal reactivity could be a direct reaction to the presence 
of a mutant crypt, in which case the clonal mark may be useable. However, distinguishing such 
an effect from artefacts would require mechanistic insights, which exceeds the scope of the 
project. Therefore, any marks displaying local areas of stromal and epithelial reactivity are not 
pursued further (Figure 3.1C). 
3.1.2.3 Distinctive clones 
The use of clonal marks relies on staining of hundreds of samples followed by manual scoring 
of clones. Their easy identification is a prerequisite for time-efficient data acquisition. It is 
conceivable that certain mutations, for example of the missense type, will only moderately 
change the protein structure and thus also immunoreactivity, resulting in clones that are only 
marginally different from the surrounding wild-type crypts (Figure 3.1D). This may 
significantly increase the time required for scoring to a point where it is impractical. Further, 
faint clones may lead to uncertainties in slightly thicker/thinner areas of a section. Therefore, 
alternative antibodies from different suppliers must be tested to improve on the staining pattern 
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(Figure 3.1E) (see 3.1.2.4). If this fails to yield more distinctive clones, the protein is not 
pursued further.  
3.1.2.4 Independent antibody validation 
Screening of large area sections may identify weakly or strongly immuno-reactive epithelium 
present as confined clones. In both cases, this is indicative of mutations leading to changes in 
the protein in question. However, in absence of positive or negative controls the specificity of 
the antibody needs to be validated. Thus, even when screening identifies distinctive clones for 
a particular candidate mark, serial sections are stained with an independent antibody 
recognising a different epitope within the protein. If this identifies the same crypts as clones, 
the mark is validated. Further, when the recognised epitope is conserved across different 
species, staining of tissues from genetically engineered knock-out animals can provide an 
additional layer of validation. 
3.1.2.5 Validation by sequencing 
In addition to using an independent antibody, clonal marks could in theory also be validated 
by targeted sequencing, which would require isolation of clones followed by DNA extraction. 
However, to date no suitable protocol was available in the Winton laboratory. 
3.1.2.6 Clone frequency 
In practical terms, whether a validated clonal mark is useable or not heavily relies on the 
frequency at which clones are detected. For the previously used marks MAOA and mPAS, 
clones occur at frequencies of approximately 1 in 10,000 and 1 in 5,000 crypts, respectively 
(Nicholson et al., 2018). This range of rates is sufficient for inference of stem cell behaviours, 
and empirically sets the bar for new marks. Thus, when screening sections for clones, 10 large 
area sections with > 10,000 crypts each are evaluated. The probability of not finding a clone in 
100,000 crypts when they occur at a frequency of 1/10,000 is: 
 
(
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑛−𝑐𝑙𝑜𝑛𝑒𝑠 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑟𝑦𝑝𝑡𝑠 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑟𝑦𝑝𝑡𝑠 𝑠𝑐𝑟𝑒𝑒𝑛𝑒𝑑 
≈ 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑛𝑜 𝑐𝑙𝑜𝑛𝑒 𝑓𝑜𝑢𝑛𝑑  
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Which, if the numbers used here are inserted gives: 
 
9,999
10,000
100,000
≈ 0.00005 
This means that for every 100,000 antibodies trialled by screening 100,000 crypts each, only 5 
marks occurring at a frequency of 1/10,000 would be missed. Or in other words, if no clones 
are found in 100,000 crypts, it is very likely that they occur at a frequency below 1/10,000, 
which, when compared to the known MAOA, would require an impractical amount of sections 
to be scored for data to be used quantitatively. 
3.1.3 Aims 
We have recently used the clonal marks mPAS and MAOA to define the homeostatic stem cell 
dynamics in the human colon (Nicholson et al., 2018). To begin to define a repertoire of 
behaviours associated with gene-specific mutations, more clonal marks were required. The 
specific aims for this part of the study were thus: 
 To identify novel X-linked clonal marks. 
 To identify new marks related to frequent mutations in colorectal cancer.  
 To develop a method for validation of IHC results by sequencing. 
3.1.4 Published work 
STAG2, the validation of which I performed and describe in this chapter, was included in our 
recent publication (Nicholson et al., 2018), on which I am second author. 
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3.2 Identification of novel X-linked clonal marks 
X-linked genes lend themselves as clonal marks, as X-inactivation in females and hemizygosity 
in males results in both genders presenting as effectively heterozygous for the loci in question. 
This means that in principle only one ‘hit’ is required for a change in protein levels or structure. 
Identification of novel X-linked clonal marks followed a sequential filtering process as outlined 
in Figure 3.2. Importantly, the screen focused on potential negative marks, relating to the left-
hand side of Figure 3.1. 
3.2.1 Selection of X-linked genes 
The human X chromosome contains approximately 156 megabases of sequence and is 
estimated by the Consensus Coding Sequence Project to contain just over 800 protein-encoding 
genes (Pruitt et al., 2009). This would make testing each and every protein encoded by this 
chromosome by IHC a very laborious and expensive process. Therefore, a pre-selection had to 
be performed. Assuming that somatic mutations hit the genome at random, it follows that gene 
length should correlate with amount of somatic mutations. Based on this hypothesis, genes 
could initially be filtered according to length. However, not all mutations will have the same 
impact on protein structure. It is plausible that exonic mutations are more impactful than 
intronic alterations. Therefore, a high exon-intron ration may be favourable. Moreover, it is 
hard to predict the impact of single amino acid changes on antibody binding. It is conceivable 
that mutations affecting areas hidden within large proteins may not affect antibody binding as 
much as this could happen in smaller proteins (encoded by smaller genes). Therefore, small 
proteins should not be excluded from initial screening. As a consequence of these 
considerations, a variety of genes with different characteristics (long absolute length, high exon-
intron ratio, long coding sequence) were selected for an initial screen. In theory, the results of 
this screen would define selection criteria for future studies. The preliminary list was cross-
referenced with the Human Protein Atlas (HPA), where staining intensity has been assessed 
with IHC on a tissue-by-tissue basis. Only genes with detectable expression in colonic tissue 
were taken further. The final selection criterion was antibody availability. Importantly, for this 
project a collaboration was set up with Dr Cecilia Lindskog Bergström at the HPA. 
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Figure 3.2 Workflow/decision tree for identification of new X-linked clonal marks. 
Rectangular encapsulation represents input of work, rounded boxes are evaluation points, 
ellipses are outputs. 
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From the filtered list of X-linked genes she was able to provide samples of development-stage 
antibodies against 21 X-linked proteins. Table 3.1 lists the selected genes and the characteristics 
discussed above. The balance between the different characteristics among the genes chosen is 
illustrated in figure 3.3, which shows the sum of ranking by total gene length, coding sequence 
length and exon-intron ratio. The figure includes MAOA as a comparison as well as STAG2 
which is discussed in 3.2.4.1. As there are 23 genes on the list, an average ranking (position 12) 
for all three categories would score 36. There is a fairly even spread of genes around this 
number, showing that for the genes chosen, high ranks in one category are often balanced by 
low scores in another. For example, the gene HDAC8 is the third largest, however, this is mainly 
due to introns, as it has the lowest exon-intron ratio. Combined with the low ranks for the exons, 
a total score of 47 results. Conversely, SLC25A5 is the smallest gene but with a very high exon-
intron ratio. The combined ranks also add up to 47, despite very different gene characteristics.  
 
Figure 3.3 Schematic representation of spread of gene characteristics.  
For each gene, a rank from 1-23 was assigned for total gene length, length of exons combined 
and exon-intron ratio. In each of the three categories, rank 1 corresponds to the largest value 
among the 23 genes and 23 to the smallest value in that particular category. The three ranks 
obtained for each of the 21 candidate marks, the previously used mark MAOA and the 
previously identified STAG2 were then combined to give the final scores. These are plotted in 
alphabetical order. Blue line = 36, the value obtained for median ranking (12) in all three 
categories. 
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3.2.2 Antibody testing 
For each of the 21 antibodies provided by the HPA, IHC was performed on en face human 
colonic FFPE sections using both ends of the recommended titre range. As this screen was 
aimed at detecting negative marks, uniformly strong staining was required for an antibody to 
pass this stage. In four cases, for DDX3X, IDH3G, SLC25A5 and STARD8, this was not 
achieved (Figure 3.4).  
Table 3.1 Intron, exon and total gene length data for candidate marks. 
Gene Introns (bp) Exons (bp) Intron/exon ratio Total length (bp) 
ADGRG4 102216 9820 0.096 112036 
ATRX 270172 11167 0.041 281339 
DDX3X 11478 6907 0.602 18385 
EIF1AX 12900 4414 0.342 17314 
HDAC6 18792 4196 0.223 22988 
HDAC8 241574 1754 0.007 243328 
HTATSF1 12245 3019 0.247 15264 
HUWE1 139893 14731 0.105 154624 
IDH3G 7273 1335 0.184 8608 
KDM6A 233654 5438 0.023 239092 
MAOA 86588 4015 0.046 90603 
NONO 14873 2661 0.179 17534 
PDHA1 14329 3484 0.243 17813 
RBMX 5253 2012 0.383 7265 
RPS6KA3 109012 8111 0.074 117123 
SH3KBP1 348896 4728 0.014 353624 
SLC25A5 1646 1307 0.794 2953 
SMC1A 38796 9784 0.252 48580 
STAG2 135762 5218 0.038 140980 
STARD8 73228 4841 0.066 78069 
XIAP 45362 8591 0.189 53953 
ZMYM3 8981 5536 0.616 14517 
ZNF75D 52708 5611 0.106 58319 
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Figure 3.4 Antibody screen for novel X-linked clonal marks.  
Representative images for staining of human FFPE colonic tissue sections. 
56 Clonal marks discovery 
 
 
For SH3KBP1, IHC on en face tissue sections revealed a variegated staining pattern. Inspection 
of longitudinal sections revealed a gradient of protein expression along the crypt axis, with 
highest levels at the top of the crypt (Figure 3.5A). The protein was thus rejected as a clonal 
mark. However, it may find future applications when orientation along the crypt axis is 
required. For the remaining 16 antibodies a suitable titre was found, enabling progression to the 
next stage, which was screening for negatively staining crypts.  
 
Figure 3.5 Candidate marks abandoned at validation stage. 
(A) Representative images of SH3KBP1 staining showing (i) variegated pattern in transverse 
section and (ii) crypt-axis gradient in longitudinal section. 
(B) IHC with antibody against HUWE1, crypt with weak immunoreactivity highlighted. 
(C) IHC with antibody against SMC1A, three crypts with weak immunoreactivity highlighted. 
(D) RPS6KA3-negative crypts confirmed in serial sections stained with antibodies from (i) HPA 
and (ii) Bethyl. 
3.2 Identification of novel X-linked clonal marks 57 
 
3.2.3 Pre-screening for clonal marks 
For each of the 16 antibodies taken further, at least 10 large (>10,000 crypts) area sections were 
screened for the presence of confined clones with reduced immuno-reactivity. As discussed in 
3.1.2.6. this number was deemed sufficient to identify candidate marks with a sufficiently high 
event rate. For 10 out of the 16 antibodies screened no weaker staining crypts were found. 
Several reasons may account for this result. Mutations may alter a protein structure in a way 
that does not affect the epitopes for the antibodies used here. Mutations may not be tolerated in 
human colonic epithelium or the antibody used may not harbour the specificity stated. 
In six cases, for the antibodies against HDAC6, HUWE1, KDM6A, NONO, RPS6KA3 and 
SMC1A faintly or entirely negatively staining crypts were identified (Figures 3.5 & 3.6) These 
were indicative of stable reduction of protein expression in epithelial cells. These antibodies 
were thus taken further for optimisation and or validation. 
3.2.4 Validation and optimisation  
For each of the six potential marks one or more alternative antibodies were tested (Table 3.2). 
For HUWE1 and SMC1A none of these validated the fainter staining crypts in serial sections. 
For RPS6KA3 the weaker staining crypts were confirmed with an alternative antibody used on 
serial sections but with substantial residual immunoreactivity (Figure 3.5). Hence, these 
candidate marks were not pursued further. 
For KDM6A and HDAC6 alternative antibodies by Cell Signalling Technology (CST) were 
tested. Both improved the staining quality and lead to clean negatives confirming the HPA 
antibody result in serial sections (Figure 3.6). For NONO staining with the HPA antibody 
resulted in very clean negative crypts. These could be confirmed by staining of serial sections 
with an alternative antibody also provided by the HPA (Figure 3.6). 
To summarise, all X-linked genes were filtered to generate a list of genes of interest. The HPA 
provided development-stage antibodies which were evaluated as potential clonal marks. 
Ultimately, screening of 21 antibodies yielded three new X-linked clonal marks: HDAC6, 
KDM6A and NONO.  
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Table 3.2 Antibodies tested for validation of candidate clonal marks. 
Antigen Supplier Antibody Result 
HDAC6 CST #7558 validated as clonal mark 
HUWE1 Abcam ab70161 not validated 
HUWE1 Aviva OALA01854 not validated 
NONO HPA HPA054559 validated as clonal mark 
KDM6A CST #33510 validated as clonal mark 
RPS6KA3 Bethyl A302-460A weakly validated 
SMC1A Abcam ab133643 not validated 
SMC1A Biorbyt orb94671 not validated 
STAG2 LSB LS-B11284 validated as clonal mark 
 
3.2.4.1 Validation of the clonal mark STAG2 
Before the screen described above was carried out, Dr Anna Nicholson in the lab performed a 
smaller scale screen of HPA antibodies. This identified the candidate X-linked mark STAG2, 
for which weakly negative crypts had been found. Staining of serial sections with an alternative 
antibody by LifeSpan BioSciences Inc. (LSB, Table 3.2) resulted in cleaner negative crypts, 
validating STAG2 as a clonal mark (Figure 3.6). 
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Figure 3.6 Validation of new X-linked clonal marks.  
IHC on serial sections with different antibodies. Negative crypts highlighted and enlarged. 
(A) HDAC6 (i) HPA antibody (ii) CST antibody 
(B) KDM6A (i) HPA antibody (ii) CST antibody 
(C) NONO (i) HPA antibody (ii) CST antibody 
(D) STAG2 (i) HPA antibody (ii) LSB antibody 
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3.3 Identification of cancer-associated clonal marks 
X-linked marks represent an invaluable tool to study stem cell dynamics in the crypt. As such 
they enable detailed description of homeostatic stem cell turnover as well as investigation of 
behaviours associated with different gene-specific mutations. Extension of the method to genes 
commonly associated with colorectal cancer may enable deeper understanding of the specific 
mechanisms promoting the earliest stages of the disease. Unfortunately, none of the most 
common driver genes of colorectal cancer are located on the X chromosome. However, this 
may not preclude detection of certain specific alterations. This screen was conceptually 
different from the process that identified new X-linked clonal marks. The latter was aimed at 
detection of any heritable genetic event that reduced protein abundance in affected cells. Here, 
the genetic alterations to be identified are well defined, but their detection may not be trivial. 
Driver mutations in CRC were discussed in section 1.5.1.3. Table 3.3 summarises the antibodies 
that were screened for cancer-associated clonal marks. An overview of their relationships in 
oncogenic signalling is presented in Figure 3.7. Importantly, the two commonly used categories 
of genes mutated in cancer, oncogenes and tumour suppressors, harbour different challenges 
for IHC-based detection. For this reason they are discussed separately. 
Table 3.3 Antibodies screened for colorectal cancer-associated clonal marks. 
TSG = tumour suppressor gene 
Antigen Type Antibody Supplier Result 
BRAFV600E oncogene E19290 Spring Bioscience no clones detected 
DUSP6 surrogate ab76310 Abcam no clones detected 
KRASG12D oncogene #14429 CST no clones detected 
p-4E-BP1 surrogate #2855 CST no clones detected 
p53 TSG ab1101 Abcam positive clones  
PTEN TSG #9559 CST negative clones  
PTEN TSG 04-035 Sigma-Aldrich validation 
SMAD4 TSG ab217267 Abcam no clones detected 
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Figure 3.7 Overview of relationships between selected cancer-associated proteins. 
KRAS activated by mutation engages the mitogen-activated protein kinase pathway via BRAF-
MEK-ERK. A negative feedback loop around ERK exists via DUSP6. The pathway can also be 
activated by mutation of BRAF. Activated KRAS can further signal through the PI3K-PDK1-
AKT pathway. PTEN acts as a tumour suppressor, opposing the activity of PI3K. 4-EBP1 is an 
inhibitor of translation and is inhibited by phosphorylation. SMAD4 is an effector of TGFβ 
signalling, inhibiting gene expression. Proteins screened for are highlighted in colour. 
Magenta = activated oncogene, pink = surrogate marker, blue = tumour suppressor, TF = 
transcription factor, yellow = signal relay molecule. 
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3.3.1 Detection of oncogene activation  
Oncogenes are usually activated by single nucleotide variants (SNVs) leading to very specific 
amino acid changes. According to TCGA sequencing data from 2,644 human samples, the four 
most common specific SNVs in human colon adenomas and adenocarcinomas occur in KRAS 
and BRAF (KRASG12D, KRASG12V, KRASG13D and BRAFV600E). Antibodies advertised as 
detecting KRASG12D and BRAFV600E are commercially available. However, detection of 
such specific amino acid changes by IHC remains challenging. In addition, it may be possible 
to detect oncogenic activation by a surrogate marker, meaning a downstream protein the levels 
of which should increase or decrease as a consequence of the oncogenic signalling. For 
example, the levels of DUSP6 and phosphorylated 4E-BP1 (p-4E-BP1) should rise upon 
oncogenic activation of BRAF or KRAS (Figure 3.7) (Rojo et al., 2007; Ekerot et al., 2008; 
Buffet et al., 2017; Silva et al., 2017; Ahmad et al., 2018; Unni et al., 2018). Of note, activated 
oncogenes as well as their surrogates would all present as positive clonal marks, the challenges 
of which are discussed in the introduction and illustrated on the right side of Figure 3.1. 
Four antibodies (two for direct detection, two for surrogates) were initially tested in human 
FFPE colonic tumour sections to optimise titres (Figure 3.8A). This was followed by IHC on 
normal human FFPE colon sections (Figure 3.8). The antibodies against KRASG12D and 
BRAFV600E yielded patchy staining. This result is suggestive of at least partially non-specific 
immunoreactivity. For DUSP6 and p-4E-BP1 relatively strong staining was obtained, even at 
increased titres (Figure 3.8B). Screening of large area normal tissue sections did not identify 
any confined significantly stronger positive clones, which would have validated the use of the 
antibodies despite background immunoreactivity. Hence, the four antibodies were not pursued 
further. 
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Figure 3.8 Antibody screen for oncogene-associated clonal marks. 
(A) IHC on human colonic tumour sections using antibodies against the activated oncogenes 
KRASG12D and BRAFV600E as well as the surrogates DUSP6 and p-4E-BP1. 
(B) IHC on normal human colonic tissue sections with the same antibodies as in (A). 
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3.3.2 Detection of tumour suppressor loss or gain-of-function 
Tumour suppressors are usually mutated in a way that abrogates their function. Such loss-of-
function mutations should in principle be detectable in the same way as negative X-linked 
clonal marks. However, as the genes in question are autosomal, both copies may need to be 
affected for a change to be visualisable by IHC. This implies that the clone frequency may be 
significantly lower than that observed for X-linked marks. Alternatively, single copy loss may 
present as weaker but not completely negative clones, which would preclude use as a clonal 
mark.  
A special case for detection of a tumour suppressor is p53. The levels of this protein are low in 
normal cells, due to turnover via ubiquitination and proteasomal degradation (Lahav et al., 
2004). Two types of p53 alterations occur in cancer: Mutations that abrogate its function as 
well as SNVs that confer oncogenic functions by means of a dominant gain-of-function (GOF) 
mechanism. GOF mutant p53 can stabilise and accumulate in the nucleus where it may activate 
transcription factors to promote tumourigenesis (Brosh & Rotter, 2009; Nakayama & Oshima, 
2018). As such, p53 may be detected as a positive mark.  
For the three tumour suppressors p53, PTEN and SMAD4, mutations occur in 51.7%, 8.2% and 
11.6% of colorectal cancers, respectively (Giannakis et al,. 2016, via cBioPortal).  
IHC with antibodies against these three proteins (Table 3.3) was performed on normal human 
FFPE colon sections. Uniformly strong staining was achieved for PTEN and SMAD4. As 
expected staining was absent for p53, due to low levels of this protein reported in normal cells 
(Figure 3.9). Screening of at least 10 large area sections (>10,000 crypts each) revealed 
individual negative crypts for PTEN, indicative of loss-of-function mutations. These were 
validated by staining of serial sections with an alternative antibody (Figure 3.9A). For p53, rare 
individual positive crypts were identified, suggestive of stabilisation of the protein (Figure 
3.9B). For SMAD4, no negative crypts were identified (Figure 3.9C).  
In summary, seven antibodies to visualise common CRC mutations in normal colonic 
epithelium were tested. Four related to detection of oncogene activation did not yield 
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satisfactory outcomes. Out of three antibodies aimed at detecting alterations in tumour 
suppressors, two yielded new clonal marks: p53 and PTEN. 
 
Figure 3.9 Antibody screen for tumour suppressor-associated clonal marks. 
(A) IHC for PTEN on serial sections with antibodies from (i) Sigma-Aldrich (ii) CST. 
Negative crypt highlighted. 
(B) IHC with antibody against p53. Crypt with stabilised p53 highlighted.  
(C) IHC with antibody against SMAD4. 
 
 
3.4 A method for next-generation sequencing of laser captured 
FFPE crypt samples 
IHC-based detection of mutant clones builds on the assumption that the observed staining 
pattern is caused by a genetic event which changes the abundance or structure of a protein. 
Validation using alternative antibodies in serial tissue sections provides compelling support for 
this hypothesis. However, sequencing of DNA from specific crypts harbours the potential to 
identify the causal mutations in the gene, therefore unequivocally demonstrating the genetic 
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origin of a clone. Laser capture microdissection (LCM) is a technique enabling precise isolation 
of specific cells in a tissue section (Emmert-Buck et al., 1996). High power IR or UV lasers 
activate a polymer film that expands and surrounds the area of interest while preserving cell 
morphology, DNA, RNA and protein composition (Espina et al., 2006). Specific cells can thus 
be isolated from a tissue sample, DNA extracted and subjected to sequencing. A protocol for 
LCM and sequencing of human FFPE colonic crypt sections was thus devised. 
3.4.1 Optimisation of antigen retrieval for LCM 
The standard protocol used for IHC in the Winton laboratory requires heat-induced antigen 
retrieval (AR) with citrate buffer at high temperature (126°C) and pressure. However, current 
laser microdissection systems require special polyethylene naphthalate (PEN) membrane slides, 
which are not resistant to high temperatures. Hence, three alternative types of AR for IHC of 
FFPE tissue sections on membrane slides were tested: Pepsin, Tris buffer and citrate buffer. All 
three have been published for LCM (Eberle et al., 2010).  
The first AR method tested was Pepsin at 37 °C for 5-20 minutes. Short incubation times 
resulted in absence of staining, whereas longer treatment seemed to cause unspecific staining, 
possibly due to tissue digestion. Subsequently, AR with Tris buffer (pH9) at 60–75 °C for 16 h 
was attempted. This yielded satisfactory staining (Figure 3.10A middle). However, this method 
resulted in frequent detachment of the tissue sections from the slides, which may be attributable 
to the relatively harsh pH conditions. This was prevented by use of the gentler citrate buffer 
(pH6). Optimal results were obtained with AR with citrate buffer at 75 °C for 16 h (Figure 
3.10A right). The method was successfully applied to MAOA, STAG2 and KDM6A. 
Occasionally, bleb formation underneath the membrane was observed. However, this did not 
affect the quality of the IHC or subsequent LCM. 
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Figure 3.10 Optimisation of IHC and PCR on FFPE tissue sections and extracted DNA. 
(A) Representative images of optimised IHC for STAG2 on serial sections on membrane slides 
compared to the standard protocol with a normal slide. 
(B) Results from qPCR for ATOH1 using diluted commercially available DNA (Promega), 
diluted DNA bulk extracted from FFPE tissue sections (FFPE) and laser capture micro-
dissected crypts (LCM). 
(C) Products generated by PCR amplification of parts of MAOA, STAG2, CASD1 and 
LOC107985193 using FFPE DNA diluted to equivalents of 5, 20 and 100 crypts. 
(D) Products from individual PCR reactions with one MAOA primer pair each, each using the 
product of a multiplex PCR (with 12 MAOA primer pairs) on DNA extracted from 10 or 20 
laser captured FFPE crypts as a template. Note that one tube evaporated in the panel on the 
right. 
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3.4.2 Optimisation of protocol for PCR on FFPE DNA from crypt sections 
With a reliable method for IHC on membrane slides in place, the next step was to develop a 
protocol for obtaining DNA for sequencing from clonal mark-negative crypts. Two challenges 
were identified: Firstly, the very low amounts of input of DNA available. Secondly, 
fragmentation of DNA due to formalin fixation. It has been demonstrated that amplicons greater 
than 500 bp are only very inefficiently amplified from such material (Dietrich et al., 2013). 
In a first step, the quality of DNA extracted from the available FFPE tissue was assessed. 
Varying numbers of transverse crypt sections of 10 μm thickness were laser capture 
microdissected from stained human FFPE sections and DNA extracted. One crypt section 
contains an average of 43 cells. One human genome equates to approximately 6 pg of DNA 
(Gillooly, Hein & Damiani, 2015). Hence one crypt section can be estimated to contain a 
maximum of 0.258 ng of DNA. For qPCR work-up DNA samples originating from bulk 
extractions from large area sections with known crypt numbers as well as commercially 
available human DNA were used. Both were diluted down to a concentration estimated to be 
similar to the laser capture microdissected crypt sections (using the estimation from above).  
Analysis by qPCR revealed that bulk or small sample extracted DNA from FFPE tissue is 
equally amplifiable. However, even though used at the same concentration as determined by 
spectrophotometry, both these samples exhibited much higher Ct values than the purchased 
DNA at equivalent concentrations (Figure 3.10B). This suggests that when working with FFPE 
DNA, the concentration does not inform the amplifiability (or bioavailability) of the DNA in 
PCR based assays. To gain further insight into the quality of the material, PCR on DNA bulk 
extracted from FFPE sections, diluted to concentrations ranging from that expected from 100 
down to 5 crypt sections per reaction, was performed. Primers were designed for a set of 
amplicons ranging from 150–350 bp across 6 different genomic loci including the exons of 
MAOA, STAG2 and CASD1. Primers available to generate amplicons of desired length from a 
locus encoding a non-coding RNA (LOC107985193) were also used. This experiment 
demonstrated that for the template material used here, exceeding 150 bp in amplicon size leads 
to a marked reduction in PCR product yield (Figure 3.10C).  
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Next, a test was performed on MAOA, as this gene has a relatively short combined cDNA 
sequence of 1484 bp. A set of 24 primer pairs to tile the exons of MAOA in amplicons of 
approximately 150 bp was designed. A library for sequencing was generated in a two-step 
process: An initial round of two multiplexed PCR reactions (due to overlap of the amplicons) 
followed by 24 individual reactions using the first product as a template. Of note, PCR products 
reach a size of approximately 200 bp due to addition of adapters for next-generation sequencing 
to the primers. Amplicons were reliably obtained from DNA extracted from 10 FFPE crypt 
sections (Figure 3.10D). 
In summary, a method to generate a library for sequencing of DNA extracted from laser capture 
microdissected FFPE crypt samples was developed. This included optimisation of IHC on 
membrane slides and design of a protocol for PCR amplification of 24 small (approx. 150 bp) 
amplicons from DNA extracted from a sample of 10 laser capture microdissected transverse 
crypt sections.  
3.5 Validation of MAOA and KDM6A by sequencing 
With a suitable protocol in place, LCM followed by next generation sequencing was performed 
on MAOA- and KDM6A-negative crypts (Figure 3.11). This was aimed at unequivocally 
demonstrating that clones originate from somatic mutations and are not epigenetic events. 
Analysis focused on patches of epithelium consisting of several adjacent mutant crypts. Such 
patches were hypothesised to arise from expansions of single clones via crypt division, which 
is discussed in detail in chapter 5. 
3.5.1 Identification of mutations in MAOA- patches 
Serial colonic FFPE tissue sections with previously identified MAOA-negative patches of 
crypts from 11 tissue blocks were stained for MAOA and mutant patches as well as wild type 
control crypts laser capture microdissected. Of note, preliminary experiments defined a 
minimum requirement of 10 crypts for reliable DNA extraction and PCR amplification (Section 
3.4). However, MAOA-negative patches mostly consisted of fewer than 10 crypts. Therefore, 
patches smaller than 10 were complemented with wild-type crypts (Figure 3.11). This would 
70 Clonal marks discovery 
 
 
be reflected in the mutant allele frequency in that the proportion of mutant reads in each sample 
would be proportional to the fraction of mutant crypts that were captured. DNA was extracted 
and amplified in 24 amplicons across the coding sequence of MAOA by two consecutive PCR 
reactions and sequenced.  
 
Figure 3.11 Laser capture microdissection and sequencing of multicrypt patches. 
(A) Illustration of general workflow. 
(B) Example of MAOA- patch before and after LCM. 
 
The resulting reads varied in quantity and quality between different samples as well as between 
the 24 amplicons within each sample. In the majority of cases, >3500 reads per amplicon were 
obtained (Figure 3.12A). Using the Integrative Genomics Viewer (IGV, Robinson et al. 2011) 
three common germline single nucleotide polymorphisms (SNPs), rs6323, rs2186 235and 
rs1137070 in MAOA were identified in the samples (Figure 3.12B & C). None of the identified 
SNPs result in amino acid changes. Of note, due to the X-linked nature of MAOA, male patients 
always appear as homozygous for either the reference sequence or the SNP.  
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To find mutations in MAOA, analysis with IGV was complemented by a PERL script written 
by Richard Kemp in our laboratory. Using the reference human genome, it scans each read with 
pairs of four nucleotides and records the base in between (Figure 3.13A). Importantly, if there 
is a mismatch between one of the quadruplets of nucleotides and the read, the script will not 
record anything. (Figure 3.13A, second to the left). Thus, for a single nucleotide variant (SNV), 
the script will record 4 positions with no reads, followed by a position with reads (Figure 3.13A 
SNV) and then again 4 positions without. For a 1 base deletion, there will be a continuous 
mismatch for 9 positions (Figure 3.13A rightmost). Following this analysis SNVs and deletions 
are easily identified by plotting the total reads against nucleotide position. Dips with a peak 
represent a SNV, dips lacking a peak appear due to a deletion (Figure 3.13B & C). Of note, the 
script also identifies SNPs, but these were more rapidly detected using IGV. When analysing 
the data, it was key to bear in mind that MAOA is an X-linked gene. Therefore, in samples from 
a female patient, even if they consisted of only MAOA-negative crypts, the expected allele 
frequency would be 50%, as the second copy of the X-chromosome would lack the mutation. 
Further, the expected allele frequency would drop for patches smaller than 10 due to added 
wild-type crypts. Finally, wild-type stromal cells between mutant crypts would add wild-type 
reads. Therefore, for mutations, even male samples are not expected to yield 100% mutant 
reads, as the stroma surrounding MAOA-negative crypts is wild-type. This was not the case for 
SNPs, which are germline variants and therefore present in both epithelial and stromal cells. 
Using the methods described above mutations were found in 5 out of 11 laser capture 
microdissected MAOA-negative patches. 4 different candidate mutations were identified, 
located in exons 8 and 13 of the gene. These appeared in the same MAOA-negative patch in 
serial sections but were absent in corresponding wild-type crypt samples (Figure 3.13D). The 
data is summarised in Table 3.4. Notably, the exact same deletion in exon 13 was found in two 
independent (different individuals) samples.  
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Figure 3.12 Identification of germline SNPs in MAOA. 
(A) Graph showing read numbers for each of the 24 amplicons covering the exons of MAOA. 
Error bars = standard deviation. 
(B) IGV snapshots of (i) heterozygous SNPs and (ii) homozygous SNPs identified. 
(C) Graphical representation of MAOA gene structure with location of identified SNPs 
highlighted. 
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Figure 3.13 Identification of mutations in MAOA- patches. 
(A) Illustration of method used to identify SNVs and deletions. Pairs of four nucleotides from 
the reference genome are compared to reads. If there is a match, the middle nucleotide is 
recorded. For more detailed schematic see Figure 2.1 
(B) Graph showing data for SNV identified in samples 2A-C and corresponding WT sample. 
(C) Graph showing data for deletion identified in samples 4A-C and corresponding WT sample. 
(D) Graphical representation of MAOA gene structure with location of identified mutations. 
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Table 3.4 Summary of mutations found in MAOA- multicrypt patches. 
Ref = nucleotide in reference genome, freq = frequency, Alt = alternative nucleotide -> this is 
the mutation, Change = predicted consequence of the mutation. Frequencies derived from 
frequency of mutant reads in samples. 
 
Gender Patch Sample Exon Ref Alt 
Alt 
freq 
Expected    
alt freq 
Change 
female 1 + 8 WT 1A 8 C T 5.8 5.6 Q>STOP 
female 1 + 8 WT 1B 8 C T 2.8 5.6 Q>STOP 
female 1 + 8 WT 1C 8 C T 4.8 5.6 Q>STOP 
female 1 + 8 WT 1D 8 C T 3.4 5.6 Q>STOP 
male 7 2A 8 A T 64.2 0 K>M 
male 7 2B 8 A T 74.5 0 K>M 
male 7 2C 8 A T 48.4 0 K>M 
female 3 + 5 WT 3A 13 C T 8.3 18.75 A>V 
female 3 + 7 WT 3B 13 C T 14.3 15 A>V 
male 5 + 5 WT 4A 13 T del 31.4 50 frameshift 
male 5 + 5 WT 4B 13 T del 53.6 50 frameshift 
male 4 + 5 WT 4C 13 T del 43.6 44.4 frameshift 
female 5 + 5 WT 5A 13 T del 25 6.3 frameshift 
female 5 + 5 WT 5B 13 T del 25 11.6 frameshift 
 
3.5.2 Identification of mutations in KDM6A- patches 
The workflow described for MAOA was largely followed for KDM6A, with two alterations: 
Firstly, much larger patches of KDM6A-negative crypts could be found, eliminating the 
necessity of adding wild-type crypts to samples. Secondly, the coding sequence of KDM6A is 
a lot longer than that of MAOA (cDNA lengths of 4206 bp and 1484 bp, respectively). This 
meant that all exons of KDM6A could not be covered with 24 amplicons of 150 bp size. 
Amplicons were thus designed to cover loci where mutations had been identified in cancers, as 
listed in the COSMIC database as well as TCGA. An amplicon covering a mutation 
communicated by H. Lee-Six from the Sanger Institute was also added (Figure 3.14A).  
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Figure 3.14 Identification of mutations in KDM6A- patches. 
(A) Overview of KDM6A cDNA with annotation of selected mutations from databases. Orange 
= area covered by amplicons. The domains important for KDM6A function, the 
tetratricoprotein repeat (TPR) for protein-protein interaction and the JmjC domain for 
demethylase activity (JmjC) are indicated. 
(B) Graph showing read numbers for each of the 24 amplicons covering the exons of KDM6A. 
Error bars = standard deviation. Logarithmic scale on y-axis. 
(C) Graphical representation of KDM6A gene structure with location of identified mutations. 
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11 KDM6A-negative patches as well as wild-type control samples from the same blocks were 
laser capture microdissected, DNA extracted, amplified and sequenced. The resulting reads 
varied in quality across amplicons and samples: >1000 reads were obtained for 40% of samples. 
Two amplicons did not yield any reads (Figure 3.14B). Two further amplicons yielded very few 
reads (Figure 3.14B).  
To find mutations in KDM6A, an adapted version of the script written for MAOA by Richard 
Kemp was applied. This identified mutations in 4 out of the 11 analysed patches. In three cases 
these were present the same KDM6A-negative patch in serial sections but absent in 
corresponding wild type samples. The fourth mutation was found at nearly 50% mutant allele 
frequency in one patch sample but was absent in the serial section as well as corresponding wild 
type samples. As the staining quality on this block was poor, it is possible that wild type, instead 
of KDM6A-negative, crypts were laser captured in one case. The mutation calls for the 
experiment are summarised in Figure 3.14C and Table 3.5. Of note, the mutation found in intron 
18 was present in two independent patches. Furthermore, the mutations S1154* and W1193* 
have previously been found in cancer samples (COSMIC database).  
 
Table 3.5 Summary of mutations identified in KDM6A- patches. 
Ref = nucleotide in reference genome, freq = frequency, Alt = alternative nucleotide -> this is 
the mutation, Change = predicted consequence of the mutation. Frequencies derived from 
frequency of mutant reads in samples. 
 
Gender Sample Exon Ref Alt Alt freq 
Expected   
alt freq 
Change 
male 1A intron 18 A G 85.8 100 intronic 
male 1B intron 18 A G 72.9 100 intronic 
male 2A intron 18 A G 82.9 100 intronic 
male 2B intron 18 A G 85.3 100 intronic 
male 3A 24 C A 51 100 S>STOP 
male 3B 24 C A 0 100 N/A 
female 4A 25 G A 15.8 50 W>STOP 
female 4B 25 G A 10.4 50 W>STOP 
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3.6 Summary and Discussion 
3.6.1 Identification of four novel X-linked clonal marks 
The first aim of this part of the study was to develop novel clonal marks for investigation of 
human intestinal stem cell dynamics. As transgenic approaches are not feasible in humans, 
lineage tracing experiments rely on the detection of spontaneous somatic mutations. X-linked 
clonal marks were previously used to define the baseline stem cell dynamics in the human colon 
(Nicholson et al., 2018). Here, the toolbox of such marks was expanded by means of an 
antibody screen. Out of 21 antibodies tested, three yielded new clonal marks: HDAC6, KDM6A 
and NONO. In addition, the previously identified STAG2 was validated.  
As described in the introduction to this chapter, identification of novel X-linked clonal marks 
occurs in a sequential filtering process. It contains a number of decision points at which certain 
requirements need to be met for a candidate mark to proceed to the next stage.  The first criterion 
is, as these were all candidate negative marks, uniform and strong staining. For four of the 
antibodies, against DDX3X, IDH3G, SLC25A5 and STARD8 this was not achieved. According 
to HPA tissue protein expression data, these proteins should be expressed at sufficient levels to 
be detected by IHC. As the antibodies used were still at development stage, this was likely due 
to absence of immunoreactivity. For most of the other antibodies tested, uniformly positive 
staining was achieved but no negative crypts were identified. This may have technical reasons 
such as lack of appropriate specificity of the antibody or failure of the antibody to detect specific 
mutations. These hypotheses could be tested by western blotting in wild-type and CRISPR-
modified isogenic cell lines. Equally, this might provide biological insights. Potentially, 
mutations in these genes or their regulatory regions are exceedingly rare. They may confer a 
strong negative bias to affected stem cells, such that they are rapidly outcompeted by 
surrounding wild-type cells. Or mutations in these genes may not be tolerated in the colonic 
epithelium. In two cases, for SMC1A and HUWE1, weakly negative crypts were identified with 
HPA antibodies but this could not be validated. As the epitopes differ for the antibodies used, 
it is plausible that very specific mutations are not detected by most of them. Alternatively, the 
weaker staining seen using the HPA antibodies could have been an artefact. 
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When selecting X-linked candidates for the antibody screen, genes with a range of different 
characteristics (total gene length, combined exonic length, exon-intron ratio) were chosen 
(Table 3.1 and Figure 3.3). Analysis of the genes that yielded new marks reveals no unifying 
feature. In terms of total length, KDM6A and STAG2 rank near the top, while HDAC6 and 
NONO are considerably shorter. Coding sequence length proved no more indicative, with 
NONO being considerably shorter than the other four genes. Finally, the exon-intron ratios vary 
10-fold between the highest (HDAC6) and the lowest (KDM6A). An approach not considered 
initially was analysis of RNA-Seq data for human colonic epithelium. This was retrospectively 
obtained from our collaborator Dr Matthias Zilbauer. Read counts were normalised for exonic 
sequence length, to account for the fact that longer genes are covered by more reads. This 
analysis revealed no correlation between normalised read counts and outcome of IHC as 
reported here (Table 3.6). This is exemplified by the failed marks as well as ADGRG4 
(highlighted in red): For DDX3X, IDH3G and SLC25A5 reads are present but protein is not 
detected while IHC for ADGRG4 yielded strong signal despite no apparent RNA expression. 
These results may relate to fast RNA or protein turnover or lack of antibody specificity. The 
identified clonal marks exhibit a range of values for normalised reads. For future studies, a cut-
off around 0.1 reads per bp could be considered. However, this will not eliminate negative 
results stemming from lack of antibody specificity, as illustrated by the high values displayed 
by four marks that were not detected. 
Taken together, these results validate a very broad almost trial-and-error approach to screening 
for novel X-linked clonal marks. Importantly, only a very small number of genes were 
considered here. Therefore, a practical cut-off may be useful for larger scale studies.  
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Table 3.6 Normalised human colonic RNA expression for candidate marks. 
For completeness MAOA and STAG2 are included. 
Gene Exons (bp) Mean reads Reads per bp 
SLC25A5 1307 5117 3.915 
MAOA 4015 5041 1.256 
RBMX 2012 1560 0.775 
DDX3X 6907 4441 0.643 
NONO 2661 1648 0.619 
PDHA1 3484 1160 0.333 
IDH3G 1335 442 0.331 
STAG2 5218 1541 0.295 
RPS6KA3 8111 2053 0.253 
EIF1AX 4414 934 0.212 
SH3KBP1 4728 909 0.192 
HUWE1 14731 2760 0.187 
HTATSF1 3019 522 0.173 
SMC1A 9784 1269 0.130 
KDM6A 5438 635 0.117 
XIAP 8591 995 0.116 
HDAC6 4196 440 0.105 
ATRX 11167 840 0.075 
HDAC8 1754 104 0.059 
ZMYM3 5536 175 0.032 
ZNF75D 5611 148 0.026 
STARD8 4841 38 0.008 
ADGRG4 9820 <1 <0.001 
 
3.6.2 Identification of two CRC-associated clonal marks 
X-linked clonal marks enable investigation of stem cell behaviours in human colonic 
epithelium. However, IHC detection of CRC-associated mutations could provide more specific 
insights into mechanisms of CRC initiation. Initially, detection of oncogenes and their 
surrogates was attempted. The antibodies were first tested in tumour tissue, where 
immunoreactivity was confirmed. This was followed up by IHC on normal colonic tissue. For 
antibodies aimed at detecting the common activating mutations KRASG12D and BRAFV600E 
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the patchy staining pattern obtained in normal colonic tissue sections indicated 
immunoreactivity with the wild-type protein. Equally, IHC for the surrogate markers DUSP6 
and pE4-BP1 yielded strong immunoreactivity. In principle however, background 
immunoreactivity should not preclude detection of clones with significantly increased or mutant 
protein, as these would be expected to stand out. However, upon screening of 10 large area 
(>10,000) sections, no significantly darker crypts were identified. This may indicate non-
specificity of the antibody or rarity of the pro-oncogenic genetic alterations in normal human 
colon. Sequencing-based methods may represent a more high-throughput and technically 
straightforward way of detecting such specific mutations.  
Antibodies were also tested for detection of alterations in the CRC-associated tumour 
suppressors p53, PTEN and SMAD4. Negative clones were identified for PTEN, indicating 
genetic events causing protein loss or truncation. The PTEN gene is located on the autosomal 
chromosome 10. Hence the remaining wild-type copy of the gene would be expected to 
compensate for mutations of one allele. Alternatively, heterozygous mutations could manifest 
as weakly immunoreactive clones. The observed clones show very low levels of remaining 
immunoreactivity. As such they may be caused by homozygous mutations. In normal tissue 
such spontaneous homozygous mutations should occur very infrequently. Their presence may 
be indicative of positive selection pressure promoting loss of the second copy of the gene. 
Equally, promoter hypermethylation of PTEN has been reported as a frequent mechanism of 
gene expression reduction (Goel et al., 2004). Bisulfite sequencing has recently been optimised 
for FFPE DNA (Ludgate et al., 2017). It may be possible to adapt this technique to DNA from 
laser captured material. Combining it with sequencing this may identify the mechanism of 
PTEN protein reduction in PTEN-negative crypts. 
A special case of detection of an altered tumour suppressor was p53, for which rare positive 
crypts were identified. Also known as ‘guardian of the genome’, p53 plays a crucial role in the 
cellular response to genotoxic stress (Lane, 1992). Levels of the protein are usually low due to 
ubiquitination and degradation (Lahav et al., 2004). However, upon detection of a stress signal 
such as DNA damage, oncogene activation or hypoxia, p53 is stabilised via post-translational 
modification. It then exerts its tumour suppressive role by inducing a variety of mechanisms 
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including cell cycle arrest, apoptosis and senescence (Vogelstein, Lane & Levine, 2000; 
Vousden & Prives, 2009). Hence, when stabilised p53 is detected, this could be evidence of 
various stress signals, cancer-promoting mutations such as oncogene activation or loss of 
MDM2 as well as mutations in the TP53 gene itself. Importantly, p53 stabilisation was observed 
in confined clones that look histologically normal. This is suggestive of a genetic event, as 
opposed to more widespread stress or insults such as infection.  
Finally, IHC for SMAD4, which is more commonly mutated in human adenocarcinomas than 
PTEN, did not identify any negative crypts. As for X-linked marks, several reasons may account 
for this result. There may be a technical explanation, whereby the epitope recognised by the 
antibody is unaffected by the most frequent mutations in SMAD4. The antibody used here 
recognises a C-terminal epitope around amino acid residue 500 of the protein. According to the 
COSMIC database, the most common mutation in SMAD4 in CRC is R361H, which may not 
affect antibody binding. In addition, SMAD4 mutations in normal colon may be mostly 
heterozygous and therefore hard to detect by IHC. Homozygous mutations may be exceedingly 
rare, not be tolerated in normal human colon or rapidly convert to pathology.  
3.6.3 LCM and sequencing of MAOA- and KDM6A- crypt sections 
To complement and validate the IHC-based work, a protocol for sequencing of DNA from laser 
capture microdissected FFPE colonic epithelial sections was devised. Formalin fixation causes 
DNA fragmentation, so evaluation of the quality of DNA obtained from the FFPE tissue 
available was paramount. qPCR demonstrated that DNA can be extracted from laser capture 
microdissection of samples as small as 10 FFPE crypt sections and can be used as a template 
for PCR. However, for reliable amplification, amplicon size should not exceed 150 bp. This 
lays the groundwork for further validation of clonal marks by sequencing as well as targeted 
sequencing approaches where IHC was unsuccessful for mutation detection. 
Laser capture microdissection and next-generation sequencing of multicrypt patches revealed 
that the absence of staining correlates with mutations in MAOA and KDM6A. Patches contained 
single mutations that were absent in surrounding crypts, validating the hypothesis that patches 
arise from crypt division (For a detailed discussion see chapter 5). The fractions of mutant reads 
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obtained largely corresponded to the expected values. In some cases, a substantially lower 
frequency was found. This discordance has two likely causes: Firstly, the poor DNA quality 
may have caused allele dropout leading to an overrepresentation of wild-type DNA molecules 
in the sample. Also, wild type stroma was microdissected alongside mutant crypts, further 
lowering the mutant allele frequency in the sample. For MAOA, mutations were identified in 5 
out of 11 patches. From this small sample size, it appears that exons 8 and 13 may represent 
mutational “hotspots”. Interestingly, a deletion in exon 13 was present in two independent 
samples. Sequencing of a larger number of mutant patches could confirm whether this is a 
particularly common mutation. Further informative experiments would be introduction of the 
mutations into cell lines by CRISPR or computational modelling of MAOA structure to fully 
confirm that the mutations are causative of the loss of staining. The antibody used in this study 
binds to the amino acid residues encoded by exons 13-15. This may explain the mutations found 
in exon 13. However, it is plausible that a mutation in exon 8 causes an overall change in the 
MAOA protein structure, hence abolishing antibody binding. In addition, as the entire coding 
sequence of MAOA was analysed, the lack of mutation identification in 6 out of 11 patches is 
indicative of alternative mechanisms causing the loss of staining. For example, intronic 
mutations could generate truncated forms of MAOA via altered splicing. This is supported by 
the finding of an intronic mutation in a KDM6A-negative patch and could be tested by 
sequencing of introns in MAOA-negative patches. Equally, mutations may affect regulatory 
elements or genes involved in the regulation of MAOA transcription or translation. For example, 
the transcription factor GATA2 has been implicated in regulating MAOA expression (Gupta et 
al., 2015). To test the involvement of transcription factors, IHC could be used, while regulatory 
sequences could be explored by sequencing. Finally, epigenetic changes could cause the loss 
of MAOA expression. Potential changes in DNA methylation could be investigated by bisulfite 
or methylation sequencing. 
For KDM6A, only partial coverage of the coding sequence was achieved, it thus is not surprising 
that mutations were only identified in 4 out of 11 sequenced patches. For two of these mutations, 
W1193* and S1154*, entries can be found in the COSMIC database. Intriguingly, both these 
mutations are located in the JmjC domain of the protein, which is the catalytic domain 
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responsible for demethylation of histones. A third mutation, located in intron 18, was found in 
two separate KDM6A-negative patches. It is conceivable that this would impair splicing and 
therefore generate mutant forms of KDM6A protein. Interestingly, the antibody used for 
detection of KDM6A binds near the amino acid 490 of the protein, N-terminally to the 
mutations observed here. However, it is plausible that they cause large-scale changes in the 3D 
structure of the protein, therefore impeding antibody binding. All these hypotheses could be 
tested using CRISPR/Cas9 in cell lines followed by IHC or Western blotting as well as 
computational modelling of KDM6A protein structure. Importantly, no mutations were found 
in 7 out of 11 KDM6A-negative patches. As only parts of the coding sequence were analysed, 
the experiments presented here should be followed up by sequencing of the remaining exonic 
sequence. In addition, the same mechanisms discussed for MAOA may also regulate KDM6A 
expression and could be investigated in an analogous manner.  
 
 
  
 
 Chapter 4 Inference of intra-crypt behaviours 
4.1 Introduction 
According to the Big Bang model, colorectal cancer is initiated when a number of factors 
reaches a critical threshold (Sottoriva et al., 2015). One important such factor are mutations, 
which, to initiate cancer, must accumulate in normal tissues. To persist within renewing tissues 
such as the intestine, mutations must occur in stem cells. However, each colonic crypt contains 
a number of effective stem cells that replace each other in a process of neutral drift (Lopez-
Garcia et al., 2010; Snippert, van der Flier, et al., 2010; Baker et al., 2014; Nicholson et al., 
2018). Therefore, the fate of neutral mutations within the crypt is stochastic and the probability 
of fixation is proportional to the number of stem cells. Mouse studies have shown that this 
balance can shift in the presence of pro-oncogenic mutations such as Kras activation and loss 
of Apc, whereby affected stem cells are more likely to achieve fixation within a crypt. 
Importantly, the process remains stochastic (Vermeulen et al., 2013). This mechanism can 
enable cancer drivers to achieve significantly higher mutant allele frequencies within the 
intestinal epithelium than would be possible from mutation alone. 
In human colon, clonal marks allow for investigation of stem cell dynamics. Using a large set 
of colonic samples from individuals of a wide range of ages enabled identification of age-related 
trends in clone accumulation for the neutral marks mPAS and MAOA, which allowed for 
inference of the number (Ncrypt) and replacement rate (λcrypt) of functional stem cells in the 
human colon (Nicholson et al., 2018). From this result the next key question was whether 
mutations could, as had been seen in the mouse, subvert the dynamics in the crypt to achieve 
higher probability of fixation and therefore higher mutant allele burden in the epithelium.  
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4.1.1 Aim 
The screens described in chapter 3 identified and validated six novel clonal marks: HDAC6, 
KDM6A, NONO, TP53, PTEN and STAG2. Here, the aim was to use these marks to determine 
whether different gene-specific mutations could alter the dynamics within human colonic crypts 
to achieve altered probability of fixation. 
4.1.2 Published work 
The data I obtained for STAG2 was included in our recent publication (Nicholson et al., 
2018), on which I am second author. 
4.2 General workflow 
To infer the stem cell behaviours associated with the new clonal marks, the same method that 
enabled calculation of Ncrypt and λcrypt for the human colon using mPAS and MAOA was applied 
(Figure 4.1). 
4.2.1 Scoring of WPC and PPC frequencies 
For each of the clonal marks identified in chapter 3, IHC was performed on FFPE colonic tissue 
sections from at least 50 individuals from a range of ages and numbers of WPC and PPC 
manually scored (Figure 4.1). An exception was PTEN, which was developed most recently 
and for which therefore only 36 individuals are included here. 
The total number of crypts on each section was determined by means of a neural network-driven 
image analysis software package, Deep Crypt Image Classification Segmentation 
(DeCryptICS), developed by Dr Edward Morrissey and Dr Doran Khamis 
(https://github.com/MorrisseyLab/DeCryptICS, manuscript in preparation) to enable 
calculation of WPC and PPC frequencies. Plots revealed age-related accumulation of WPC and 
constant background frequencies of PPC for all new clonal marks. Regression analysis was then 
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performed on the data to obtain the slope of WPC accumulation, ΔCfix, and the frequency of 
PPC, Cpart, from the data (see Appendix C for the mathematical methods used) (Figure 4.1). 
 
Figure 4.1 Workflow for inference of stem cell behaviours.  
Normal FFPE colon sections from at least 50 individuals are stained and manually scored. 
Crypt counts are obtained by means of DeCryptICS. Regression analysis is then performed on 
clone frequencies to obtain ΔCfix and Cpart, which are used for inference of stem cell behaviour. 
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4.2.2 A note on sampling and noise  
For all marks, the WPC data showed a large spread. This may lead a critical mind to question 
the linear regression performed to derive ΔCfix. Human data is, due to a large number of genetic 
as well as environmental factors, notoriously noisy. In addition, when sampling events with a 
low frequency, such as the clones detected here, the sample size will heavily influence 
fluctuations in the data. This relationship between sampling and calculated clone frequency is 
illustrated in Figure 4.2A. Simulations performed by Dr Edward Morrissey show accurate 
regression fitting despite the noise (Figure 4.2B). Importantly, the Bayesian inference used here 
to obtain ΔCfix takes account of variable estimates in clone frequencies arising from sampling 
noise. 
4.2.3 Inferring intra-crypt bias from ΔCfix/Cpart 
The ratio of ΔCfix/Cpart enables inference of biases in stem cell behaviour. This is because ΔCfix 
and Cpart are dependent on the rate of stem cell replacement and number of effective stem cells 
per crypt, respectively, but are also both dependent on the mutation rate. Therefore, the ratio of 
ΔCfix/Cpart is a metric that describes the dynamics of monoclonal conversion independently of 
mutation rate. For advantageous mutations an upwards shift as compared to neutral marks will 
be observed, as PPC are underrepresented due to increased rate of fixation into WPC. 
Conversely, disadvantageous mutations will decrease ΔCfix/Cpart as decreased probability of 
clone fixation will lead to WPC underrepresentation. 
Additionally, the probability of replacement (PR) associated with a particular mark can be 
estimated from a full equation containing ΔCfix/Cpart, Ncrypt and λcrypt (see Appendix C for full 
mathematical model). For neutral marks, this is 0.5, as every stem cell has a 50% chance of 
replacing its neighbour and a 50% chance of being replaced by the neighbour.  
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Figure 4.2 Sampling and noise in human clonal marks data.  
(A) Schematic illustration of how sample size influences the measured clone frequency. Top: 
Dashed circles represent samples of increasing size. Bottom: Coloured dots represent the clone 
frequency obtained by the corresponding sample. Dashed line represents the actual clone 
frequency. Larger samples result in measured clone frequencies approaching the real value.  
(B) Simulation of clonal marks data. Top: Scoring of 100 million (left) or 100 thousand 
(right) crypts per patient. Bottom: Independent simulations of scoring crypt numbers typically 
used here. Red line: Cfix. 
90 Inference of intra-crypt behaviours 
 
 
4.3 Behaviours associated with X-linked marks 
4.3.1 NONO confirms neutral stem cell dynamics 
The 471 amino acid protein NONO (Non-POU domain-containing octamer binding protein) is 
a member of the Drosophila behaviour/human splicing (DBHS) protein family. The protein is 
modular in structure, possessing domains for protein as well as nucleic acid binding. This 
translates into association with a broad spectrum of transcription factors to regulate a variety of 
aspects of gene expression such as transcriptional activation, repression, initiation, elongation 
and termination (Knott, Bond & Fox, 2016). NONO has also been found to be involved in the 
formation of paraspeckles, which are ribonucleoprotein bodies localised in the nucleus of 
mammalian cells (Fox et al., 2002; Bond & Fox, 2009; Passon et al., 2012). Most recently, 
NONO was reported to be regulating telomere stability (Petti et al., 2019). Germline mutations 
in NONO have been associated with X-linked mental retardation (Carlston et al., 2019). 
To look at the intra-crypt effect of NONO mutations, IHC was performed on FFPE colon 
sections from 78 patients aged 20–93 years. WPC and PPC were then scored (Figure 4.3A) and 
plotted, revealing an age-related increase of WPC with a ΔCfix of 1.44 × 10-6 (95% CI: 1.04 × 
10-6–2.04 × 10-6) (Figure 4.3B) and a constant Cpart (Figure 4.3C). The value obtained for 
ΔCfix/Cpart was 0.082 (95% CI: 0.048–0.141), remarkably similar to both mPAS and MAOA 
(Figure 4.3D). In addition, PR was calculated to be 0.546 (95% CI: 0.454–0.678). This indicated 
that mutations affecting NONO protein levels are probably neutral, meaning they do not alter 
the competition between stem cells in the crypt.  
4.3 Behaviours associated with X-linked marks 91 
 
 
 Figure 4.3 Inference of stem cell behaviour associated with NONO mutation. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for NONO. 
(B) Regression analysis showing ΔCfix for NONO (1.44 × 10-6 per year) with 95% margin of 
error (ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for NONO- clones. Bottom panel shows 
PPC frequencies alone on condensed y-axis. 
(D) Plot showing similar ratio for ΔCfix/Cpart for mPAS, MAOA and NONO. Error bars = 95% 
CI. 
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4.3.2 HDAC6 loss confers disadvantage 
Histone deacetylase 6 (HDAC6) is a 1215 amino acid protein with a counterintuitive name. It 
is a unique member of the type II HDACs in that due to its nuclear export sequence (NES) as 
well as cytoplasmic retention motif (SE14) it is actually located in the cytoplasm (Verdel et al., 
2000; Bertos et al., 2004). Therefore, contrary to its name, HDAC6 does not deacetylate 
histones to regulate gene activity in the nucleus but works to maintain the acetylation balance 
of various non-histone substrates. This includes the cytoskeletal proteins α-tubulin (the building 
blocks of microtubules) and cortactin, which means that HDAC6 plays an important role in cell 
motility (Hubbert et al., 2002; Zhang et al., 2007; Deakin & Turner, 2014). An additional target 
of HDAC6 is the chaperone HSP90 (Aoyagi & Archer, 2005), which assists protein folding. 
IHC for HDAC6 was performed on colonic FFPE samples from 66 individuals of the age range 
8-89 years, WPC and PPC scored (Figure 4.4A) and plotted. This revealed an age-related 
increase in WPC (Figure 4.4B) with a ΔCfix of 3.19 × 10-6 (95% CI: 2.31 × 10-6-4.65 × 10-6) and 
a constant frequency of PPC (Figure 4.4C). Following regression analysis, the ratio of 
ΔCfix/Cpart revealed a value of 0.027 (95% CI: 0.017–0.042) for HDAC6. This is significantly 
(p-value = 0.0004) lower than the values obtained for the neutral marks mPAS and MAOA 
(Figure 4.4D), implying a disadvantage. In line with this finding, a PR of 0.432 (95% CI: 0.359–
0.494) was calculated.  
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Figure 4.4 Inference of stem cell behaviour associated with HDAC6 mutation. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for HDAC6. 
(B) Regression analysis showing ΔCfix for NONO (3.19 × 10-6 per year) with 95% margin of 
error (ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for NONO- clones. Bottom panel shows 
PPC frequencies alone on condensed y-axis. 
(D) Plot showing lower ratio for ΔCfix/Cpart for HDAC6 as compared to mPAS and MAOA. 
Error bars = 95% CI. 
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4.3.3 KDM6A loss confers advantage 
KDM6A (lysine-specific demethylase 6A), also known as UTX (ubiquitously transcribed 
tetratricopeptide repeat X chromosome) is a 1401 amino acid protein with two paralogs in 
humans, KDM6B and UTY. All three contain a JmjC-domain which catalyses the 
demethylation of tri- or dimethylated histone H3. Interestingly, the catalytic activity of UTY is 
negligible (Walport et al., 2014). KDM6A acts as part of the MLL2/3 or ‘COMPASS’ protein 
complex (also described as MLL3/4 or ASCOM complex) which transcriptionally activates 
genes mainly via H3K4 methylation and H3K27me2/me3 demethylation (Cho et al., 2007). It 
thus antagonises the action the polycomb repressor complex 2 (PRC2), which catalyses H3K27 
tri- and dimethylation (Margueron & Reinberg, 2011). The COMPASS complex has also been 
shown to be involved in chromatin remodelling via the SWI/SNF complex, a function that does 
not seem to require demethylase activity of KDM6A (Miller, Mohn & Weinmann, 2010). 
Germline KDM6A mutations cause the hereditary Kabuki syndrome, a condition characterised 
by a broad spectrum of symptoms including distinctive facial features, skeletal abnormalities 
and mild to moderate intellectual disabilities (Niikawa et al., 1981). 
For determination of intra-crypt dynamics, colonic FFPE sections from 120 patients aged 21–
93 years were stained, WPC and PPC (Figure 4.5A) scored and plotted, revealing an age-related 
increase in WPC (Figure 4.5B) with a ΔCfix of 6.04 × 10-6 (95% CI: 4.69 × 10-6–7.80 × 10-6) 
(Figure 1.5B) and constant Cpart (Figure 4.5C). The value obtained for ΔCfix/Cpart was 0.234 
(95% CI: 0.164–0.339) around 4.5-fold higher than that for neutral marks, indicating a 
competitive advantage (Figure 4.5D). PR was calculated to be 0.760 (95% CI: 0.605–0.999) 
implying that KDM6A-deficient stem cells have a significantly increased probability of 
populating the crypt. 
4.3.3.1 Loss of KDM6A does not alter H3K27me3 levels in human 
colon 
As KDM6A functions in demethylation of H3K27me3, loss of this protein could in theory lead 
to an increase in this histone modification. To test whether loss of KDM6A resulted in greater 
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abundance of H3K27me3 in human colonic epithelium, IHC for H3K27me3 was performed on 
serial sections. This did not show any increase in H3K27me3 in KDM6A-negative patches 
(Figure 4.6) (n = 5). 
 
Figure 4.5 Inference of stem cell behaviour associated with KDM6A mutation. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for KDM6A. 
(B) Regression analysis showing ΔCfix for KDM6A (6.53 × 10-6 per year) with 95% margin of 
error (ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for KDM6- clones. Bottom panel shows 
PPC frequencies alone on expanded y-axis. 
(D) Plot showing 4.5-fold higher ratio for ΔCfix/Cpart for KDM6A as compared to mPAS and 
MAOA. Error bars = 95% CI. 
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Figure 4.6 Loss of KDM6A does not increase H3K27me3 in human colon. 
Representative images of IHC for KDM6A and H3K27me3 on serial human colonic FFPE 
sections. The same two KDM6A- crypts are highlighted in both images. 
 
4.3.3.2 KDM6A may not escape X-inactivation in human colon 
Choosing X-linked genes for clonal marks is advantageous as X-inactivation in females 
effectively leaves their cells haploid for these genes, which due to the XY karyotype is always 
the case for males. Therefore, in both sexes, one ‘hit’ should be sufficient for loss of staining, 
enabling higher clone frequencies and therefore more robust data than would be obtained from 
autosomal genes. However, it has been known since the 1990s that some X-linked genes escape 
X-inactivation in somatic cells (Carrel et al., 1999). Recently, analysis of both whole exome 
sequencing as well as data from the GETx project found that tumour suppressor genes that 
escape from X-inactivation (EXITS genes) may contribute to the male bias for certain cancers. 
Importantly, the list of candidate EXITS genes included KDM6A (Dunford et al., 2017). In 
addition, a recent analysis of RNA-seq data from 29 tissues including the colon found KDM6A 
expression to be higher in females than males, suggestive of incomplete X-inactivation 
(Tukiainen et al., 2017). Escape from X-inactivation should manifest in our samples as 
markedly reduced clone frequency in females. However, this is not the case, as there is no 
marked difference in KDM6A WPC frequency between females and males, with remarkably 
similar values of ΔCfix of 6.36 × 10-6 (95% CI: 4.50 × 10-6–9.02 × 10-6) and 6.44 × 10-6 (95% 
CI: 4.85 × 10-6–8.57 × 10-6), respectively (Figure 4.7). This data suggests that in human colon, 
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KDM6A does not escape X-inactivation. Furthermore, there was no difference in intensity of 
KDM6A staining between female and male colonic samples. Therefore, the higher female 
expression reported by Tukiainen and colleagues may not be reflected by protein abundance. 
 
 
Figure 4.7 KDM6A- WPC accumulation in females and males. 
Regression analysis showing very similar ΔCfix for KDM6A- WPC in females (6.36 × 10-6 per 
year) and males (6.44 × 10-6 per year) with 95% margin of error shaded in grey. 
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4.3.4 STAG2 loss confers greater advantage than KDM6A 
The 1231 amino acid protein STAG2 (stromal antigen 2) is a member of the cohesin complex, 
which is highly conserved from yeast to human. There are two types of this four-subunit 
complex. Both contain two structural maintenance proteins SMC1 and SMC3 as well as RAD21 
and one of the two STAG homologs 1 or 2. The complexes function to maintain telomere or 
centromere cohesion, respectively (Canudas & Smith, 2009). Germline mutations in STAG2 
have recently been associated with an X-linked intellectual deficiency syndrome (Soardi et al., 
2017). 
IHC for STAG2 was performed on colonic FFPE sections from 110 patients ranging in age 
from 8–93 years. Scoring of WPC and PPC (Figure 4.8A) frequencies revealed an age-related 
increase for WPC with a ΔCfix of 1.95 × 10-5 (95% CI: 1.56 × 10-5–2.39 × 10-5) (Figure 4.8B) 
and a constant Cpart (Figure 4.8C). The ratio of ΔCfix/Cpart was 0.50 (95% CI: 0.371–0.662), a 
10-fold increase compared to mPAS, MAOA (Figure 4.8D), as well as nearly 2-fold increase 
compared to KDM6A, suggesting a strong advantage in stem cell replacement. Indeed, PR was 
calculated to be 0.999 (95% CI: 0.804-0.999), meaning that a STAG2-deficient stem cell will 
almost certainly populate the crypt. 
 
4.4 Intra-crypt behaviours for cancer-associated marks 
The results obtained for X-linked clonal marks indicate that gene-specific mutations in stem 
cells can result in a range of behaviours in the crypt. Importantly, an advantage was observed 
for loss of KDM6A and STAG2. Such mechanisms could potentially also exist for known 
colorectal cancer drivers, enabling them to increase their likelihood of fixation and therefore 
reaching higher mutant allele burden within the tissue. 
4.4 Intra-crypt behaviours for cancer-associated marks 99 
 
 
Figure 4.8 Inference of stem cell behaviour associated with STAG2 mutation. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for STAG2. 
(B) Regression analysis showing ΔCfix for STAG2 (1.96 × 10-5 per year) with 95% margin of 
error (ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for STAG2 - clones. Bottom panel 
shows PPC frequencies alone on expanded y-axis. 
(D) Plot showing 10-fold higher ratio for ΔCfix/Cpart for STAG2 as compared to mPAS and 
MAOA. Error bars = 95% CI. 
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4.4.1 P53 stabilisation is associated with neutral stem cell dynamics 
The human TP53 gene is located on chromosome 17 and is translated into at least 12 protein 
isoforms, the study of which forms its own field within cancer biology (Khoury & Bourdon, 
2010; Vieler & Sanyal, 2018). P53 levels are normally low in cells due to turnover involving 
the negative regulator MDM2 (Lahav et al., 2004). However, upon activation via stress signals 
such as DNA damage, p53 is stabilised and can, as a dimer of dimers, act as a transcription 
factor to regulate genes involved in processes such as cell cycle arrest, senescence and apoptosis 
(Kitayner et al., 2006; Vousden & Prives, 2009).  
Considering all cancers, TP53 is the most frequently mutated gene (Zehir et al., 2017). About 
56% of MSS stable colorectal cancers harbour mutations in the gene (Giannakis et al. 2016 via 
cBioPortal). Mutations occur across the entire length of the gene and can lead to loss of function 
as well as expression of gain-of-function mutant versions of the protein (Vogelstein, Lane & 
Levine, 2000; Vousden & Prives, 2009; Yue et al., 2017). 
This clonal mark is unique in that it is not loss but stabilisation of TP53 which is detected. IHC 
was performed on FFPE colonic sections from 124 individuals aged 8-90 years and scored for 
WPC and PPC with stabilised p53 (Figure 4.9A). Plotting of WPC frequencies revealed an age-
related increase with a ΔCfix of 3.59 × 10-7 (95% CI: 2.68 × 10-7–4.88 × 10-7) (Figure 4.9B), 
while the frequency of PPC stayed constant (Figure 4.9C). The ratio of ΔCfix/Cpart was 0.073 
(95% CI: 0.044–0.136) (Figure 4.9D), remarkably similar to mPAS, MAOA. The PR was 
calculated to be 0.531 (95% CI: 0.444-0.664). This implied that stem cells with stabilised p53 
behave neutrally in the crypt.  
4.4 Intra-crypt behaviours for cancer-associated marks 101 
 
 
Figure 4.9 Inference of stem cell behaviour associated with stabilisation of p53. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for p53. 
(B) Regression analysis showing ΔCfix for p53 (1.96 × 10-5 per year) with 95% margin of error 
(ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for STAG2- clones. Bottom panel 
shows PPC frequencies alone on condensed y-axis. 
(D) Plot showing 10-fold higher ratio for ΔCfix/Cpart for STAG2 as compared to mPAS and 
MAOA. Error bars = 95% CI. 
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4.4.1.1 P53 stabilisation and HDAC6 loss are not correlated in human 
colon 
A number of studies report regulation of p53 by HDAC6 (Ding et al., 2013; Park et al., 2017). 
To investigate whether such an effect was occurring in human colonic crypts, serial sections 
were stained for p53 and HDAC6. No stabilisation of p53 was observed in HDAC6-negative 
crypts nor were lower levels of HDAC6 observed in crypts with stabilised p53 (Figure 4.10, n 
= 10 sections each). This suggests that HDAC6 is not involved in stabilising p53 in human 
colonic epithelium. 
 
 
Figure 4.10 P53 stabilisation and HDAC6 loss are not correlated in human colonic 
crypts. 
(A) Serial sections stained for (i) p53 and (ii) HDAC6. Crypt with stabilised p53 highlighted. 
(B) Serial sections stained for (i) p53 and (ii) HDAC6. HDAC6-negative crypt highlighted. 
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4.4.2 PTEN loss is associated with neutral stem cell dynamics  
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a phosphatidyl-
inosityol-3,4,5-trisphosphate 3-phosphatase, catalysing the dephosphorylation of PIP3 into 
PIP2 (Maehama & Dixon, 1998). Therefore, the tumour suppressive role of PTEN is mainly 
linked to its role as negative regulator of the PI3K-AKT-mTOR signalling axis (Figure 3.7), 
controlling a number of processes including cell growth, cell cycle progression, and stem cell 
renewal  (Hollander, Blumenthal & Dennis, 2011; Milella et al., 2015; Manning & Toker, 2017; 
Papa & Pandolfi, 2019). However, independent functions including phosphatase activity that 
can bring about cell cycle arrest as well as nuclear functions have also been reported 
(Hlobilkova et al., 2000; Milella et al., 2015). 
Germline mutations in PTEN are associated with a number of tumour predisposition syndromes 
collectively known as PTEN Hamartoma Tumours Syndromes. Affected individuals develop 
cellular overgrowths known as hamartomas in a broad range of tissues including breast, skin 
and brain (Yehia, Ngeow & Eng, 2019). 
Looking broadly across all cancer types, PTEN is one of the 10 most frequently mutated genes 
(Zehir et al. 2017 via cBioPortal). As is common for tumour suppressor genes, mutations occur 
throughout the entire length of the protein. Interestingly, three hotspots can be seen, however 
these do not correlate with specific cancer types (COSMIC database). In addition to mutation, 
promoter hypermethylation has been reported to result in PTEN silencing in a number of 
cancers (Kang, Lee & Kim, 2002; García et al., 2004; Ho et al., 2009). Just over 5% of 
colorectal cancers harbour PTEN mutations (Giannakis et al. 2016 via cBioPortal). Therefore, 
the gene has been classified as a driver in this disease.  
For determination of the effect of PTEN loss on human colonic stem cell dynamics, sections 
from 36 individuals ranging in age from 34–85 years were stained and WPC and PPC scored 
(Figure 4.11A). An age-related increase in WPC with a ΔCfix of 1.06 × 10-6 (95% CI: 7.00 × 10-
7–1.61 × 10-6) (Figure 4.11B) and constant Cpart was observed (Figure 4.11C). For the ratio of 
ΔCfix/Cpart a value of 0.047 (95% CI: 0.024–0.101) was obtained, similar to mPAS and MAOA 
(Figure 4.11D). Also, PR was calculated to be 0.483 (95% CI: 0.397–0.600). This suggests that 
PTEN loss does not confer any bias to affected stem cells.  
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Figure 4.11 Inference of stem cell behaviour associated with PTEN mutation. 
(A) (i) WPC and (ii) PPC in en face tissue sections stained for PTEN. 
(B) Regression analysis showing ΔCfix for PTEN (1.06 × 10-6 per year) with 95% margin of 
error (ME) shaded in grey. 
(C) Frequency plot of WPC (circles) and PPC (squares) for PTEN - clones. Bottom panel shows 
PPC frequencies alone on condensed y-axis. 
(D) Plot showing similar ratio of ΔCfix/Cpart for mPAS, MAOA and PTEN. Error bars = 95% 
CI. 
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4.5 Comparison of all marks 
In summary, staining of normal human FFPE colon sections from a large patient cohort 
followed by scoring of WPC and PPC enabled inference of stem cell behaviours associated with 
gene-specific mutations. A range of behaviours was identified, spanning from the negatively 
biased HDAC6 to strong advantage observed for loss of STAG2. The values obtained for 
ΔCfix/Cpart range from 0.027 to 0.5, which is a nearly 20-fold difference between HDAC6 and 
STAG2 (Figure 4.12 and Table 4.1). These results show that, as in the mouse, mutations can 
change the behaviour of stem cells in the crypt to achieve higher mutant allele burden in the 
tissue than would arise from mutation alone. 
 
 
Figure 4.12 Stem cell behaviour associated with gene-specific mutations.  
Plot showing ΔCfix/Cpart for all clonal marks. Error bars = 95% CI. 
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Table 4.1 Summary of clonal marks data. 
For completeness this includes the previously used neutral marks mPAS and MAOA. 
Mark No. of patients Ages Mean age ΔCfix ΔCfix/Cpart  PR 
HDAC6 66 8-89 66 3.19 × 10-6 0.027 0.432 
KDM6A 120 21-93 68 6.04 × 10-6 0.234 0.760 
MAOA 152 8-93 70 1.76 × 10-6 0.072 0.531 
mPAS 50 37-93 70 5.84 × 10-6 0.056 0.499 
NONO 78 20-93 66 1.44 × 10-6 0.082 0.546 
P53 124 8-90 66 3.59 × 10-7 0.073 0.531 
PTEN 36 34-85 67 1.06 × 10-6 0.048 0.483 
STAG2 110 8-93 67 1.96 × 10-5 0.501 0.999 
 
 
4.6 Inference of mutation rates 
For neutral marks, the frequency of PPC is proportional to the mutation rate. Therefore, the 
following holds true: 
𝐶𝑝𝑎𝑟𝑡 𝑚𝑎𝑟𝑘1
𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑚𝑎𝑟𝑘 1
=
𝐶𝑝𝑎𝑟𝑡  𝑚𝑎𝑟𝑘2
𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑚𝑎𝑟𝑘 2
 
 
Which can be rearranged to: 
𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑚𝑎𝑟𝑘 2 = 𝑚𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑚𝑎𝑟𝑘 1 × 
𝐶𝑝𝑎𝑟𝑡  𝑚𝑎𝑟𝑘 2
𝐶𝑝𝑎𝑟𝑡  𝑚𝑎𝑟𝑘 1
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The de novo mutation rate for mPAS was previously derived from the ratio of single mPAS-
positive cells/total goblet cells (see section 1.4.3.2 and Nicholson et al., 2018). Therefore, using 
the known mPAS mutation rate of 4.44 × 10-6 mutations/mitosis, the mutation rates for the 
neutral marks MAOA, NONO, p53 and PTEN could be derived (Table 4.2). For non-neutral 
marks, the full equation including Ncrypt, and PR was used (Appendix C) (Table 4.2). Mutation 
rates are expected to scale with coding sequence length. Plotting of the values confirmed such 
a trend but revealed HDAC6 and KDM6A as outliers with higher and lower mutation rates than 
expected, respectively (Figure 4.13A). Focusing on the other marks, a trend towards scaling of 
mutation rate with coding sequence length can be observed (Figure 4.13B) 
 
 
Table 4.2 Inferred mutation rates for clonal marks. 
For comparison this includes the previously derived mPAS and MAOA. 
Mark Mutations per mitosis 95% Confidence interval 
HDAC6 6.85 × 10-6 2.91 × 10-6 - 1.64 × 10-5 
KDM6A 9.28 × 10-7  4.29× 10-7 - 1.99× 10-6 
MAOA 1.03 × 10-6 5.13 × 10-7 - 1.99 × 10-6 
mPAS 4.44 × 10-6 2.47 × 10-6 - 7.77 × 10-6 
NONO 7.45 × 10-7  3.42× 10-7 - 1.59 × 10-6 
P53 2.09 × 10-7  8.89 × 10-8 - 4.48 × 10-7  
PTEN 9.36 × 10-7  3.72 × 10-7 - 2.16 × 10-6 
STAG2 1.66 × 10-6 7.89 × 10-7 - 3.34 × 10-6 
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Figure 4.13 Inferred mutation rates scale with coding sequence length. 
MPAS is not included as the causative gene remains unknown. Error bars = 95% CI. 
(A) Mutation rates of clonal marks plotted against coding sequence.  
(B) Same as (A) but with expanded X-axis, excluding HDAC6. 
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4.7 Discussion 
The neutral clonal marks mPAS and MAOA enabled inference of human colonic stem cell 
dynamics (Nicholson et al., 2018). Here, a novel set of clonal marks, validated in chapter 3, 
was used to describe a range of human intestinal stem cell behaviours associated with different 
gene-specific mutations. In a first step, this required staining of FFPE colonic sections from 
hundreds of individuals of a wide range of ages. For all new marks, WPC and PPC were 
observed. Scoring revealed an age-related increase in the frequency of WPC, but a constant 
frequency of the transition forms, PPC, for each clonal mark. The constant value of Cpart 
observed across ages indicates that the rate of de novo mutations giving rise to new clones is 
balanced by loss of PPC either by their resolution to WPC or by clone extinction. The linear 
accumulation of WPC also indicates a constant process during life. These age-related trends are 
predicted by neutral drift theory and can only be observed for a given clonal mark if it arises as 
an irreversible and cell autonomous genetic event. Therefore, the observed age-related 
behaviours serve as validation for the genetic origin of the phenotypes observed for clonal 
marks. If the clones were caused by non-genetic events such as inflammation, the distribution 
of clones would most likely not adhere to this pattern. Furthermore, isolated PPC would not be 
expected. This is particularly relevant to the clonal detection of stabilised p53, where the 
observed phenotype could theoretically be caused by a plethora of mechanisms (see below).  
An interesting observation was made when WPC frequencies for KDM6A were plotted. 
Contrary to the published notion that KDM6A escapes X-inactivation, no difference in clone 
frequency was found between males and females. This suggests that there may be a colon-
specific regulatory mechanism at play. RNA-seq data from fresh tissue or human colonic 
organoids may distinguish mono- from biallelic expression, which could validate this 
observation. 
Following scoring, regression analysis was used to determine the slope for WPC accumulation, 
ΔCfix, and the frequency of PPC, Cpart. The ratio between these two values, ΔCfix/Cpart, 
represents a measure for intra-crypt bias. Importantly, this calculation normalises for mutation 
rate and thus allows for direct comparison between marks. Figure 4.12 shows the range of 
values obtained for all novel clonal marks to the neutral marks mPAS and MAOA.  
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A first striking observation was that three new marks, NONO, p53 and PTEN all exhibited a 
ΔCfix/Cpart that was remarkably similar to the marks previously described as neutral. 
Considering that all scoring is done blinded with regards to sample identity, the finding that 
three additional marks behave in the exact same way as mPAS and MAOA lends further support 
to the claim that these are neutral.  
Loss of NONO has been found to associate with significantly increased tumour size in breast 
cancer (Traish et al., 1997). A greater number of cancer studies report overexpression, with 
examples including malignant melanoma (Schiffner et al., 2011), malignant pleural 
mesothelioma (Vavougios et al., 2015), breast cancer (Zhu et al., 2015) and neuroblastoma (Liu 
et al., 2014). Overexpression is also more common than mutation in colorectal cancer, with the 
COSMIC database reporting 33.28% (610 tested) versus 0.26% (2332 tested) of large intestine 
samples, respectively. A similar 0.8% mutation frequency was found in a different study 
(Giannakis et al. 2016 via cBioPortal). In light of these findings, the result that NONO loss does 
not affect stem cell dynamics in the crypt intuitively makes sense. It seems that the protein can 
exert pro-oncogenic effects when overexpressed, whereas NONO loss is only tumour-
promoting in very specific contexts, such as the breast.  
HDAC6 loss seems to confer a disadvantage to affected stem cells, such that they have a less 
than 50% chance of replacing their neighbour. The main alteration of HDAC6 in cancer 
reported by the COSMIC database is overexpression. As for colorectal cancer, HDAC6 is very 
rarely mutated (1.6% according to Giannakis et al., via cBioPortal) while CNV gain has been 
found in about 15% of samples of a small cohort of 26 patients (TCGA data). Mechanistically, 
HDAC6 seems to be required for Ras-driven oncogenic transformation (Lee et al. 2008) in 
fibroblasts. It has also been reported to promote tumorigenesis via inhibition of p53 (Ding et 
al., 2013; Park et al., 2017) and to regulate immunosuppressive properties of cancer-associated 
fibroblasts in breast cancer (Li et al., 2018). Of note, in our tissue p53 stabilisation was not 
observed in HDAC6-negative crypts. Furthermore, the intra-crypt behaviour of HDAC6-
negative and p53-stabilised crypts was significantly different. Therefore, it seems that HDAC6 
is not involved in regulation of p53 in human colonic crypts. In line with a potential pro-
oncogenic role of HDAC6, selective HDAC6-inhibitors have been reported to slow down the 
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growth of cancer cell lines in vitro (Hideshima et al., 2017; Zhang & Gan, 2017; Hye-Rim et 
al., 2018) and a number of HDAC6 inhibitors are currently being evaluated in clinical trials or 
have been approved for the clinic by the FDA (Suraweera, O’Byrne & Richard, 2018). The 
finding described here, that HDAC6 loss causes a disadvantage within the crypt is consistent 
with these accounts of growth retardation following HDAC6 inhibition. Considering the effect 
of HDAC6 inhibition seen in cell lines, the intra-crypt disadvantage may be related to 
proliferation.  
For KDM6A loss an advantage was found, with a PR of 0.760. KDM6A is the most frequently 
mutated histone modifier in human cancer (van Haaften et al., 2009). Mutation frequencies vary 
significantly between different cancer types. While the MSKCC-IMPACT study observed an 
average frequency of 3.5% across all cancer types (Cheng et al., 2015), mutation frequencies 
of up to 40% have been reported in urothelial carcinoma. For human colon, the COSMIC 
database reports KDM6A point mutations in 2.66% of adenocarcinomas (35 out of 1318 tested). 
For all cancers, missense as well as truncating mutations have been found distributed along the 
entire length of the gene, indicative of tumour suppressive function of KDM6A. The 
mechanism of tumour suppression by KDM6A was first studied in T-cell Acute Lymphoblastic 
Leukaemia, whereby a study demonstrated the requirement for the demethylase catalytic 
function (Van der Meulen et al., 2015). Loss of KDM6A may thus lead to an increase in 
H3K27me3 and therefore cause activation of genes that may drive cancer progression. Such a 
mechanism has been demonstrated in bladder cancer, where KDM6A loss was shown to lead 
to aberrant activation of PCR2-regluated transcription repression (Ler et al., 2017). Importantly, 
re-introduction of wild-type KDM6A into mutant cancer cells markedly reduced proliferation, 
an effect that was accompanied by transcriptional changes (van Haaften et al., 2009). However, 
IHC for H3K27me3 on serial sections did not reveal any increase in this modification in 
KDM6A-negative crypts. This may be due to compensation by other H3K27me3 demethylases 
such as JMJD3 (Agger et al., 2007). Our finding is in line with several reports of loss of 
KDM6A causing no or at most a modest increase in global H3K27me3 levels (van Haaften et 
al., 2009; Ler et al., 2017; Gozdecka et al., 2018). However, the absence of a negative or 
positive control significantly weakens this finding. Validation could be performed by 
comparing KDM6A-/- and tri- or demethylase inhibitor-treated organoids. More recently, a 
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study demonstrated the redundancy of the demethylase function of KDM6A for tumour 
suppression in murine acute myeloid leukaemia (AML). Instead, proteomic data indicated a 
role for protein-protein interactions with tetratricopeptide repeats, leading to activation of 
specific transcriptional programs. Supportive of this finding, the tumour suppressive role of 
KDM6A in AML is shared by the catalytically inactive Y-chromosomal homologue UTY 
(Gozdecka et al., 2018). Therefore, it seems plausible that KDM6A loss can, independently of 
demethylase activity, lead to general chromatin remodelling which may drive the advantaged 
phenotype observed. Of note, LCM and sequencing identified mutations in the JmjC domain of 
KDM6A in 2 out of 11 KDM6A-negative patches (see section 3.5.2). It is thus conceivable that 
mutations in the JmjC domain shift KDM6A function towards recruitment of transcription 
factors via tetratricopeptide repeats, which then promotes a gene expression program driving 
intra-crypt advantage. This hypothesis could be tested by CRISPR/Cas9 in human cell lines or 
organoids followed by RNA-Seq and later ChIP-Seq. 
In the present study, the strongest intra-crypt advantage was associated with STAG2 loss. 
STAG2 is the most commonly mutated of the cohesin complex members. Mutations are most 
common in urothelial carcinoma (16%) (Cosmic database). To a large extent these are 
truncating mutations, consistent with a role as a tumour suppressor (Hill, Kim & Waldman, 
2016). In colorectal cancer, STAG2 mutations are relatively frequent, featuring in about 4.2% 
of adenocarcinomas (Giannakis et al. 2016 via cBioPortal). The consequence of STAG2 loss 
of function is still a matter of debate. In line with its role in sister chromatid cohesion, it was 
initially associated with aneuploidy (Solomon et al., 2011), which can drive cancer progression 
and could explain the intra-crypt bias observed. However, a number of studies have since 
challenged this finding (Balbás-Martínez et al., 2013; Kim et al., 2016). A different cancer-
promoting mechanism of STAG2 loss may involve genomic rearrangements caused by 
prolonged association of telomeric repeats during the cell cycle (Daniloski & Smith, 2017). If 
such a mechanism was at play, the bias observed with STAG2 may be mediated by secondary 
mutations arising from genetic instability. However, Dr Edward Morrissey performed 
modelling of such a scenario, which revealed that this would require the rate of subsequent 
mutation to be increased by an order of 105 (see Appendix C for mathematical model). Such an 
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extreme rate is unlikely to occur and it is thus likely that the clone dynamics described here 
arise directly from STAG2 loss. However, speculation about how STAG2 loss confers stem 
cells with an advantage is currently uncertain. Very generally, as it normally performs a tumour 
suppressive role, it makes sense that loss would lead to a pro-oncogenic effect. 
It is worth discussing the inferred PR of 0.99 for STAG2-deficient stem cells. This is strikingly 
high, effectively corresponding to certain fixation of mutant stem cell clones within the crypt. 
PR was calculated from the full equation containing Ncrypt = 7 and λcrypt = 1.3 
replacements/crypt/year. However, the accelerated fixation of STAG2-negative clones may in 
theory also result from an increased replacement rate. To test this hypothesis, the size 
distribution of partial clones (as fractions of the entire crypt) could be analysed. As PPC are 
underrepresented for advantaged marks, the current dataset would have to be expanded to allow 
for statistically powered modelling.  
Most intriguing was the discovery that both p53 stabilisation and PTEN loss do not appear to 
confer any bias to affected stem cells. As these are both CRC drivers, an advantage might have 
been predicted for these marks. P53 can be stabilised by a variety of mechanisms such as DNA 
damage, hypoxia and oxidative stress. Further, mutant p53 proteins have been reported to be 
stabilised by a variety of mechanisms including interaction with Hsp90 and BAG protein family 
members, short isoforms of MDM2 and post-translational modification (Li, Marchenko & 
Moll, 2011; Zheng et al., 2013; Nguyen et al., 2014; Yue et al., 2016, 2017). The origin of this 
clonal mark may thus be complex, which complicates discussion of the neutral dynamics 
observed. LCM of individual crypts could, in theory, identify the mutations causing 
stabilisation. Importantly, these may not be present in p53 but in one of its interaction partners. 
Due to the poor quality and yield of DNA obtained from FFPE sections, broad coverage by 
sequencing of LCM material is currently not feasible. With the advent of in-situ proteomics, 
investigation of potential effects of post-translational modifications of p53 may become 
accessible in the future. Therefore, current potential explanations for neutral dynamics for 
stabilised p53 can be based on two lines of evidence: Firstly, the mutation rate of TP53 in 
metastases of colorectal cancer is ~80% (Brannon et al., 2014), while they are rarer in benign 
colonic adenomatous polyps, with mutation frequencies of 15-30% reported (Baker et al., 1990; 
Hao et al., 2002; Borras et al., 2016). This indicates that TP53 mutations may play a more 
114 Inference of intra-crypt behaviours 
 
 
prominent role during later stages of colorectal tumourigenesis, rather than during initiation. 
Secondly, in the mouse the dominant negative Tp53 mutation R172H did not confer any bias 
to affected stem cells. Interestingly however, a PR of 0.58, indicating a mild advantage, was 
found when Tp53 mutation was induced in a chronic colitis model (Vermeulen et al., 2013). 
This suggests that the tissue environment may influence the behaviour of p53 mutant clones. It 
would thus be informative to perform a human p53 study in samples from a cohort of 
inflammatory bowel disease (IBD) patients. 
Due to its tumour suppressive role as a negative regulator of PI3K-AKT-mTOR signalling, loss 
of PTEN might have been predicted to cause an advantage, potentially via increased 
proliferation. Indeed, a number of studies report increased stem cell proliferation, however up 
to date no such effect has been described in the colon (Milella et al., 2015). An important aspect 
of PTEN biology is dosage. Partial loss can be sufficient for a pro-oncogenic effect (Alimonti 
et al., 2010). Alternatively, PTEN loss in the absence of further mutations may not cause a 
strong enough effect on signalling to generate a bias in stem cell dynamics.   
In summary, the observed effects of gene-specific mutations on stem cell dynamics can mostly 
be rationalised by examining mutation frequencies in cancers, putative cancer functions and, in 
the case of p53, mouse studies. However, these considerations fail to explain the behaviours on 
a mechanistic level. For such insights, use of the CRISPR/Cas9 system in human colonic 
organoids combined with BrdU labelling, RNA-seq and proteomics could highlight pathways 
of interest. Genetically modified organoids could then be tested in vivo by xenografting into 
mice, as recently published by the Sato group (Sugimoto et al., 2018). Alternatively, inducible 
knock-out mice could be crossed to reporter lines, and used for lineage tracing experiments. 
These could be followed up with isolation of labelled crypts, RNA-Seq and proteomics. 
The data acquired here enabled derivation of mutation rates associated with all clonal marks. 
Plotting the values revealed a linear trend between coding sequence and mutation rate with two 
outliers, KDM6A and HDAC6, with markedly lower or higher than expected mutation rates, 
respectively. Importantly, the mutation rates were calculated from the frequency of clones 
observed following IHC with an antibody. For most clonal marks, the epitope is C-terminal, 
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however, for KDM6A this is not the case, with the antibody raised against a peptide around 
amino acid residue 490 out of 1401. Therefore, it is possible that a number of C-terminal 
mutations are not detected by IHC, leading to an underestimation of mutation rate. When the 
coding sequence of KDM6A is shifted to correspond to 490 amino acids, the inferred mutation 
rate matches that of similarly sized other genes (Figure 4.14). For HDAC6, a potential 
explanation for the high mutation rate lays in gene structure: Using the open access software 
RepeatMasker (Smit, Hubley & Green, no date), it was found that HDAC6 harbours a 
significantly higher GC-content (50%) than the similarly sized STAG2 and KDM6A (both 39%). 
GC content has recently been found associated with higher mutation rates in yeast (Kiktev et 
al., 2018) and may play a role in elevating the mutation rate of HDAC6.  
 
Figure 4.14 Adjusting the coding sequence length of KDM6A may rationalise the inferred 
mutation rate. 
Plot identical to 4.13A but with coding sequence of KDM6A altered to reflect location of the 
epitope recognised by the antibody. 
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The findings presented in this chapter significantly impact our understanding of the earliest 
events during tumour initiation in human colonic crypts. Gene-specific mutations can subvert 
intra-crypt dynamics to achieve an increased probability of fixation, which elevates their allele 
frequency in the tissue and increases the probability of second mutation acquisition. It would 
be interesting to examine whether there are upper limits to advantage and disadvantage within 
the crypt. For this purpose, more clonal marks would have to be developed. Defining severe 
disadvantage may be complicated by the difficulty of detecting PPC clones consisting of only 
a few cells present at low numbers. Extreme advantage, on the other hand, could dramatically 
reduce the frequency of PPC detected, precluding calculation of ΔCfix/Cpart (as division by zero 
is not meaningful). A method for lineage tracing in human colonic tissue in vitro would aid in 
overcoming these challenges by enabling capture and therefore quantification of PPC directly 
after induction, before clone extinction or fixation. 
 
 
 
 
 Chapter 5 Expansion beyond the crypt 
5.1 Introduction 
Due to the dynamics of neutral drift, the fate of neutral somatic mutations arising in stem cells 
of colonic crypts is stochastic. The probability of fixation of a neutral alteration is thus 
proportional to the number of stem cells per crypt. However, as indicated in chapter 4, certain 
gene-specific mutations can subvert intra-crypt dynamics to increase or decrease their 
probability of fixation. As mutations continuously arise in stem cells throughout life, fixed 
clones accumulate in the colonic epithelium in a linear, age-related manner. By altering their 
fixation probability, biased mutations can achieve considerably lower or higher mutant allele 
burden with time. 
As discussed in chapter 1, CRC is thought to initiate in stem cells (Barker et al., 2008; 
Schwitalla et al., 2013), driven by accumulation of mutations (Fearon & Vogelstein, 1990). 
According to the current model, a tumour arises when a critical threshold of factors is exceeded 
in a cell, rather than through sequential sweeps by clones of increasing aggressiveness 
(Sottoriva et al., 2015). Since several alterations are required for transformation, expansion of 
clones with a primary mutation increases the population of cells available for acquisition of 
further hits. 
Indeed, a number of studies support the presence of such ‘field cancerisation’ in the human 
colon. Earliest evidence stems from detection of KRAS mutations in tumour adjacent normal 
samples (Zhu et al., 1997). Further, the discovery of polyclonal tumours suggests the presence 
of a pre-cancerous field that facilitates adenoma formation (Thirlwell et al., 2010). Also, in a 
study of synchronous tumours (cases where two or more primary tumours arise in the same 
individual), methylation patterns were found to be remarkably similar, indicative of an 
underlying field (Galandiuk et al., 2012).  
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To generate mutant fields, clones need to spread in the epithelium. Considering the constraints 
imposed by the architecture of the colon, the most obvious process for this is crypt division.  
5.1.1 Crypt fission 
Crypt division, usually referred to as fission, drives growth of the intestine during postnatal 
development (Clarke, 1972; Cummins et al., 2008). Similar mechanisms are conserved across 
many adult epithelia, such as the lung, kidney and mammary epithelium, which all arise from 
branching of epithelial tubes (Affolter et al., 2003).  
5.1.1.1 Early studies 
The first reports of intestinal crypt fission stemmed from observation of so-called ‘bifurcating 
crypts’ in mouse and rat intestines. A series of seminal papers published in the 1970s and 1980s 
described that crypt fission drives the massive increase in crypt numbers that occurs during 
postnatal growth as well as the recovery from damage by irradiation, chemotherapy and surgical 
resection (Clarke, 1972; Cairnie & Millen, 1975; Maskens, 1978; Maskens & Duhardin-Loits, 
1981; Wright & Al-Nafussi, 1982; Cheng, McCulloch & Bjerknes, 1986). It was also found 
that while crypt fission is highest in young animals, it continues in adulthood, albeit at a much 
lower rate (Clair & Osborne, 1986). At the same time, the presence of bifurcating crypts, 
indicative of low levels of crypt fission, was also reported in adult human colon samples (Cheng 
et al., 1986). This idea lead to the development of the so-called ‘crypt cycle’ model, whereby 
fission occurs when a crypt reaches a certain threshold size. The authors proposed that such 
independent crypt cycling caused a slow but steady increase of intestinal size with age. 
According to their calculations, this would lead to a doubling of crypt numbers every 10-20 
years (the cycle time), which they accommodate by proposing increased folding of the mucosa 
(Cheng et al., 1986; Totafurno, Bjerknes & Cheng, 1987). Importantly, the human model was 
largely based on mouse data. In addition, inference of the rate of fission from the frequency of 
bifurcating crypts in static images requires an assumption about duration of the process, which 
was not available. These factors led to an overestimation of the human crypt fission rate.  
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5.1.1.2 Epigenetic and histochemical analysis  
More recently, human crypt fission was investigated by analysis of methylation patterns. De 
novo methylation of CpG rich regions of the genome, so-called CpG islands, is somatically 
inherited and stochastically acquired at mitosis, leading to age-related increase in number of 
methylated loci (Ahuja et al., 1998). It follows that comparison of the methylation patterns 
between crypts may enable derivation of clonal relationships, whereby crypts originating from 
fission events may display similar methylation patterns while unrelated crypts are, due to the 
stochastic nature of methylation acquisition, very unlikely to do so. An initial analysis of CpG 
islands in three genes (MYOD, CSX and BGN) confirmed the previously reported age-related 
increase in methylation and revealed that methylation patterns varied between crypts (Yatabe, 
Tavaré & Shibata, 2001). A subsequent study of adjacent crypts also found different 
methylation patterns, suggesting that crypt fission is rare in human colon (Kim & Shibata, 2002, 
2004). Importantly, the technical challenges associated with analysis of methylation patterns 
restrict the sample size. In the absence of a priori knowledge about crypt relatedness it is not 
surprising that sampling of low numbers of crypts failed to identify evidence for fission. 
This caveat was overcome by combination of (epi)genetic analysis with clonal marking using 
histochemical detection of loss of CCO activity (see 1.4.2.1). CCO-negative multicrypt patches 
were shown to be clonal by LCM and sequencing and their size was found to increase with age 
(Greaves et al., 2006). Surprisingly, the methylation patterns of adjacent CCO- crypts were not 
closely related. Subsequent LCM and methylation pattern analysis followed by mathematical 
modelling indicated that the dynamic nature of methylation acquisition limits the time window 
during which clonally related crypts can be identified to 10 years (Graham et al., 2011). The 
results obtained by Greaves and colleagues can thus be explained by the fission event taking 
place more than 10 years prior to sample collection. Using methylation patterns is thus likely 
to generate underestimates of crypt fission rates.  
A more potent method was subsequently applied by Baker and colleagues, whereby the human 
crypt fission rate was derived from mathematical modelling based on the size distribution of 
CCO- patches in a cohort of 20 patients of the age range 42-85 years. The authors calculated a 
human crypt fission rate of 0.028 (± 0.007) divisions per crypt per year, which equals 
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approximately 3% of crypts undergoing fission per year and a crypt cycle time of about 36 years 
(Baker et al., 2014). The caveat of this study is the small patient cohort and low numbers of 
crypts (approximately 137,000 in total) analysed, which may have led to an over- or 
underestimation. Therefore, a reliable benchmark was to date still lacking. 
5.1.1.3 Altered crypt fission rates 
Increased crypt fission has been found associated with a number of inflammatory conditions 
such as ulcerative colitis (Cheng et al., 1986). It is also now seen as the main driver of human 
adenoma growth (Preston et al., 2003), a notion supported by dramatically increased crypt 
fission rates in patients with FAP (Araki et al., 1995; Campbell et al., 1998; Wasan et al., 1998; 
Wong et al., 2002; Baker et al., 2014). In the mouse, KRAS activating mutations have been 
found to cause a dramatic up to 30-fold increase in crypt fission rate, therefore driving field 
cancerisation in the intestinal epithelium (Snippert et al., 2013).  
5.1.2 Aims 
Based on the caveats associated with previous studies, a precise quantification of the 
homeostatic human colonic crypt fission rate was required. This benchmark would then enable 
investigation of how gene-specific mutations may subvert this process to achieve field 
cancerisation in the human colonic epithelium. The specific aims of this part of the present 
study were thus to: 
 Quantify the homeostatic human colonic crypt fission rate. 
 Investigate the effect of gene-specific mutations on crypt fission rates. 
 Investigate the expansion of KRAS-mutant clones in normal human colonic epithelium.  
5.1.3 Published work 
The data we obtained for the fission rates of mPAS and MAOA, my data on fission of STAG2-
deficient clones as well as KRAS targeted sequencing I performed on samples from 126 
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individuals were included in our recent publication (Nicholson et al., 2018), on which I am 
second author. 
5.2 Quantification of crypt fission using clonal marks 
For all clonal marks patches of mutant epithelium comprising two or more adjacent crypts were 
observed (Figure 5.1A). For mPAS, MAOA, NONO and HDAC6, patches were mostly 
composed of two crypts. Larger patches were commonly observed for p53, PTEN, STAG2 and 
KDM6A. For the latter, patches were commonly composed of more than 15 crypts (Figure 
5.1B) with the largest detected patch consisting of 71 crypts. Due to the low frequency of clones 
observed for all marks, it was assumed that patches arise from the amplification of a single 
variant crypt by fission. This is also supported by the LCM and sequencing described in chapter 
3, whereby no negative patch was found to carry more than one mutation in the causative gene. 
5.2.1 Gene-specific mutations can promote crypt fission  
Combined with the known age of each patient (for patient numbers for each mark refer to Table 
4.1), the size distribution of multicrypt patches for the different clonal marks enables modelling 
of crypt fission rates. This was performed by our collaborator Dr Edward Morrissey and the 
mathematical methods are described in detail in Appendix C. Importantly, the model used is 
probabilistic, not deterministic. Initially, once a mutation is fixed within a crypt, this crypt must 
divide for a patch of size two to arise. Subsequently, both of the two crypts can undergo fission 
to further increase the patch size. In a deterministic model, both crypts would fission after a 
certain interval, as every crypt has a deterministic rate at which it fissions. In such a model, the 
time it takes to expand a crypt into two is always the same. In a stochastic model, however, the 
time it takes for any given crypt to fission is drawn from a probability distribution governed by 
the fission rate. This means that the two crypts in a patch of two would most likely not undergo 
further fission at the same time, whereas in a deterministic model they must.  
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Figure 5.1 Detection of multicrypt patches for clonal marks. 
(A) Representative images of multicrypt patches for all clonal marks. 
(B) Grouped histogram showing frequency of patch sizes for all marks as proportion of total 
WPC. 15+ denotes patches composed of 15 crypts or more, combined.  
Application of the model to data from all eight clonal marks revealed a spectrum of behaviours. 
Four marks, HDAC6, mPAS, MAOA and NONO exhibit very similar fission rates ranging from 
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0.69% to 0.88% per year (Table 5.1 and Figure 5.2). This was taken to be the homeostatic 
human colonic crypt fission rate, meaning that about 0.7% of normal crypts undergo fission 
every year. Importantly, the rate calculated here is very similar to a recent report using the 
mitochondrial marker CCO in a small cohort of 21 patients, which inferred a rate of 1.1% 
(Baker et al., 2019). For PTEN, STAG2, p53 and KDM6A, fission rates were found to be 2.0% 
2.2%, 2.6% and 3.7% per year, corresponding to about a 3-fold increase for PTEN, STAG2 and 
p53 and about a 4.5-fold increase for KDM6A compared to baseline, respectively (Table 5.1 
and Figure 5.2). Therefore, as well as conferring an advantage to stem cells within the crypt, 
mutations can promote lateral expansion to generate large patches within the epithelium.  
 
 
Table 5.1 Crypt fission rates associated with clonal marks. 
Mark Fission rate per year 95% Credible interval 
HDAC6 0.88% 0.64 - 1.22 
KDM6A 3.65% 3.25 - 4.07 
MAOA 0.73% 0.59 - 0.89 
mPAS 0.69% 0.55 - 0.86 
NONO 0.78% 0.56 - 1.04 
P53 2.64% 1.73 - 3.70 
PTEN 1.99% 1.32 - 2.93 
STAG2 2.16% 1.89 - 2.45 
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Figure 5.2 Gene-specific mutations can increase crypt fission rates. 
Plot showing inferred crypt fission rates for all clonal marks in ascending order. Error bars 
= 95% CI. 
 
5.2.2 Intra-crypt dynamics and crypt fission may be independent 
Juxtaposition of the intra-crypt behaviours (ΔCfix/Cpart, Figure 4.10) and the fission rates 
inferred here (Figure 5.2) revealed a number of patterns for the different clonal marks, some of 
which were unexpected. There are three marks, mPAS, MAOA and NONO, which seem to be 
neutral markers for intra-crypt dynamics as well as fission. STAG2 and KDM6A are also 
consistent in their pattern, in that loss of these genes confers an advantage within the crypt and 
beyond. HDAC6 loss however, while conferring a disadvantage within the crypt, shows neutral 
behaviour for fission. P53 stabilisation and PTEN loss on the other hand do not seem to impact 
on crypt dynamics, but promote fission (Figure 5.3).  
The total mutational burden of the human colonic epithelium thus seems to be a result of three 
independent processes. The first is mutation rate, which dictates the appearance of stem cell 
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clones. The second is fixation within individual crypts. Under neutral conditions this occurs via 
neutral drift. However, certain gene-specific mutations can cause a bias, therefore changing the 
likelihood of fixation. Finally, mutations can spread by crypt fission, which can be accelerated 
by loss of specific proteins.  
 
Figure 5.3 Intra-crypt dynamics and crypt fission may be independent processes. 
Similar behaviour indicated by coloured box. mPAS, MAOA and NONO seem to be completely 
neutral (blue box), p53 stabilisation and PTEN loss confer a fission bias (pink box), HDAC6 
loss confers intra-crypt disadvantage (green box) and loss of KDM6A and STAG2 lead to 
advantage within the crypt as well as fission acceleration (red box). 
(A) Graph showing ΔCfix/Cpart for all marks, equivalent to Figure 4.10 
(B) Graph showing fission rates associated with all marks, equivalent to Figure 5.2. 
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The contributions of these different processes were modelled by Dr Edward Morrissey 
(Figure 5.4). This show that an intra-crypt bias alone (increasing PR from 0.5 to 0.99) 
increases the burden of a variant 7-fold. Equally, elevating the fission rate alone can cause a 
2-fold increase in mutation burden. Combining the two processes results in a 14-fold increase 
by the age of 60 (Figure 5.4). 
 
 
Figure 5.4 Effects of intra-crypt bias and fission bias on total mutation burden. 
Simulated number of mutant crypts plotted against age for genes with a common mutation rate 
of 2 × 10-6 per mitosis. Green = neutral outcome, purple = intra-crypt bias with PR elevated to 
0.99, blue = 3-fold increase in fission rate, red = combined effect of PR = 0.99 and 3-fold 
increase in fission rate, equivalent to STAG2 mutation. 
 
5.3 KRAS mutations in normal human colonic epithelium 
Mutations that promote fission accelerate field cancerisation. Indeed, the results described in 
section 5.2 demonstrate that two alterations commonly found in CRC, p53 stabilisation as well 
as loss of PTEN promote crypt fission, therefore generating mutant patches in the colonic 
epithelium. A key driver gene frequently mutated in CRC is KRAS. Activating mutations most 
commonly occur in codons 12 and 13, which harbour the sequences GGT and GGC, 
5.3 KRAS mutations in normal human colonic epithelium 127 
 
respectively. Specifically, mutations in the second amino acid positions of these two codons, 
which include the most common KRAS activating mutations G12D (caused by a G>A 
transversion at position 2), G12V (a G>T transversion at position 2) as well as G13D (a G>A 
transversion at position 2), can be detected in just over 30% of colorectal cancers (COSMIC 
data). In fact, the G12D activating mutation is detected in just over 11% of colorectal tumours, 
closely followed by G12V with 9%, making them the most common specific mutations in CRC. 
Interestingly, oncogene activation by single nucleotide mutation is several orders of magnitude 
less frequent than the loss-of-function mutations observed for clonal marks. The G>A 
transversion responsible for the KRASG12D mutation occurs at a frequency of about 4 x 10-8 
per year (Tomasetti, Vogelstein & Parmigiani, 2013). Despite this seemingly low rate, high 
MAFs have been described in the normal mucosa of individuals not known to have cancer 
(Dieterle et al., 2004; Kraus et al., 2006; Parsons et al., 2010). KRAS activating mutations have 
also been reported in the adjacent normal epithelium of KRAS-mutant tumours, suggesting the 
presence of an underlying KRAS-mutant field (Zhu et al., 1997). In light of the fission bias 
observed for a number of clonal marks, as well as the finding that KRAS activation promotes 
crypt fission in the mouse (Snippert et al., 2013), an obvious next step was to quantify the 
behaviour of KRAS-mutant clones in the human colonic epithelium. As discussed in chapter 3, 
antibody-based detection of KRASG12D mutations did not yield satisfactory results. Hence a 
next-generation sequencing-based approach was taken. 
5.3.1 A targeted amplicon sequencing approach for KRAS exon 2 
For identification of KRAS activating mutations in human FFPE colonic sections by targeted 
sequencing, DNA was extracted from FFPE tissue sections, the genomic area of interest 
amplified by PCR and then sequenced. Characterisation of DNA extracted from FFPE material 
described in chapter 3 revealed that short (approx. 150 bp) amplicon length is key to successful 
PCR amplification. However, if a KRAS activating mutation occurred in codons 12 and 13 
located in exon 2, then one single PCR amplicon will be sufficient to cover the area of interest 
of 6 base pairs. Importantly, the nature of the DNA material and sequencing method harbour a 
number of sources of potential false positives that merit consideration.  
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5.3.1.1 Sources of artefactual MAFs in DNA from FFPE material 
A well described source of ‘artefactual mutations’ stems from hydrolytic deamination of 
cytosine residues to uracil. In living cells these are removed by uracil-DNA glycosylase and 
then restored by base excision repair. In fixed tissue however, they remain unrepaired. PCR 
amplification of such templates generates artefactual C:G>T:A SNVs as polymerase 
incorporates an adenine opposite to uracil lesions. Another common effect is depurination, 
which generates abasic sites at guanine and adenine residues. Polymerases can incorporate 
adenines opposite of such sites, generating artefactual G:C>T:A and A:T> T:A SNVs (Do & 
Dobrovic, 2015). During sequencing, these processes will produce a number of artefactual 
‘mutant’ reads. Another source of error is PCR amplification. Before sequencing, DNA is 
amplified by PCR twice, first to generate the amplicons and then to add sample-specific 
barcodes. These amplifications can introduce errors that will be sequenced and be falsely called 
as mutations. Finally, the sequencing process in itself occurs by synthesis, which again may 
introduce errors. The rate of errors introduced by PCR and sequencing is low, however, it can 
become significant when attempting to call very low MAFs. To account for all these sources of 
error, a number of control measures were taken. 
5.3.1.2 Strategy for minimisation of artefactual MAFs 
Two primer pairs flanking KRAS codons 12 and 13 were designed to generate off-set amplicons. 
Every DNA sample would thus be amplified in two independent PCR reactions and the base-
pairs of interest probed in different sequencing cycles. This means that if an error occurs in a 
particular sequencing cycle, only half of the amplicons will be affected, allowing for mutation 
calling in the remaining pool. In addition, primers for generation of two ‘mimic amplicons’ 
were designed. These flanked an PITPNM2 gene which contained, at the same position as the 
KRAS amplicons, the sequence context of KRAS codons 12 and 13, GGT GGC. In Sanger 
sequencing data, this leads to perfect synchronisation of the traces in the mimic area (Figure 
5.5), while the rest of the trace appears mixed. The mimic amplicons enable discounting of 
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context-specific PCR or sequencing errors, as these will be present in both the mimic and the 
KRAS amplicons, while real mutations will only be present in KRAS amplicons (Figure 5.6). 
 
 
 
Figure 5.5 KRAS and mimic amplicons synchronise around the KRAS G12 and G13 
context. 
Data for one KRAS – mimic duplex PCR reaction. 
Top: Sanger sequencing trace from reaction with two primer pairs sequenced with both primer 
pairs showing synchronisation in the area of interest.  
Middle and bottom: Sanger sequencing traces from reactions performed with individual primer 
pairs. 
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Figure 5.6 Sources of artefactual MAFs and their elimination by the ‘mimic amplicon 
method’. 
Artefacts can be introduced through fixation as well as during various stages of amplification. 
The pink box outlines scenarios where without mimics, a number of artefactual mutations 
would be falsely identified as real (red “X”). 
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Every DNA sample was thus amplified in two multiplex PCR reactions, each containing a 
KRAS and the corresponding ‘mimic’ primer pair. Figure 5.6 outlines the different scenarios 
for artefactual mutation generation and how the ‘mimic amplicon method’ enables discounting 
of artefactual mutations. Mutations were thus only called if they are present in both KRAS 
amplicons but remained at background noise levels in the mimic amplicons. 
5.3.2 Lateral expansion of KRAS mutations 
The method described in 5.3.1 was applied to DNA from sections from 256 patients ranging in 
age from 20–91 years. FFPE-related artefacts were readily detectable in the samples. In 
particular, a high frequency of artefactual G:C>A:T SNVs were observed at a frequency of 
about 0.05%, which is most likely the effect of deamination of cytosines. Comparatively low 
frequencies of about 0.01%-0.02% were found for other transversions (Figure 5.7A). As 
described above, the mimic amplicons enabled discrimination between real and artefactual 
MAFs. Compellingly, true KRAS mutations can easily be visualised in a plot as standing out in 
pairs (representing the two KRAS amplicons) against the noise observed in all four amplicons 
(Figure 5.7B).  
KRAS activating mutations were found in 35 out of 256 patients tested, corresponding to 13.7% 
of the cohort. 7 types of SNVs leading to amino acid changes at codons 12 and 13 were detected, 
with G12D occurring at the highest frequency, followed by G12V and G12C (Table 5.2). 
Detected MAFs were in the range of 0.12%–2.35% (Figure 5.8A). From the MAFs as well as 
the known crypt numbers obtained from DeCryptICS image analysis of serial sections for each 
sample, the mutant patch sizes could be estimated (Figure 5.8B). 
132 Expansion beyond the crypt 
 
 
 
Figure 5.7 Noise and mutation calling in targeted sequencing data. 
(A) Graph showing frequency of background noise observed for different nucleotide 
transversions observed at position 2 of codon 12 of KRAS. Error bars = standard deviation. 
(B) Graph showing MAFs for KRASG12D in KRAS and mimic amplicons. Samples with 
identified mutations in both KRAS amplicons but not in mimic amplicons circled in red. 
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Table 5.2 KRAS mutations detected in normal human colon samples. 
Amino acid 
change 
Number of samples 
Frequency 
(%) 
G12D 13 31.0 
G12V 11 26.2 
G12C 8 19.0 
G13D 6 14.3 
G12S 2 4.8 
G13C 1 2.4 
G12A 1 2.4 
 
 
Equally, these were used by Dr Edward Morrissey to model the process of KRAS mutation 
accumulation and expansion by fission in the human colon. Briefly, the model requires an 
estimate for ΔCfix, which influences the number of samples that carry mutations as well as the 
fission rate, which determines how many patches will be large enough to be detected by our 
method. Using vague priors, the model then finds optimal values for ΔCfix and the KRAS-mutant 
fission rate that generate the mutant patches observed (For details on mathematical models used 
see Appendix D). This analysis revealed a 17-fold increase in lateral expansion of KRAS-mutant 
crypts. Simulating this elevated fission rate of about 12% per year demonstrated that the 
mutational burden results from a small number of somatic clones that expand dramatically. In 
contrast, clonal marks have a much higher event rate, but due to the more modest expansion 
(fission rates of up to 4% for KDM6A), the overall mutant allele burden in the tissue is lower 
(Figure 5.9). This can be expressed with a lifetime expansion coefficient, Cexp, which is obtained 
by normalising for mutation rate and describing the combined effects of intra-crypt dynamics 
and subsequent fission over time. Cexp thus represents a way to rank mutations according to 
their ability to expand in the human colonic epithelium. The highest Cexp was found for KRAS 
followed by KDM6A and STAG2 mutations, which have an average lifetime expansion 
coefficient that is 2400-, 19- and 13- fold greater than the neutral clonal marks, respectively 
(Figure 5.9). 
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Figure 5.8 Identification of KRAS mutations in normal human colonic epithelium. 
(A) Mutant allele frequency data from 256 individuals plotted against age. 35 individuals 
displayed detectable mutations. 
(B) Estimated KRAS-mutant patch sizes from 256 individuals plotted against age.  
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Figure 5.9 Ranking advantage conferred by gene-specific mutations. 
(A) Average patch size of each clonal mark plotted against inferred total number of clones 
per colon. 
(B) Lifetime expansion coefficient normalised to the neutral mark mPAS (=1). 
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5.4 Crypt fusion  
The findings presented here suggest that in the human colon, about 0.7% of crypts undergo 
fission every year. In addition, mutations can dramatically elevate this rate by several-fold. 
However, the length of the human intestine does not seem to increase significantly with age 
(Hounnou et al., 2002). Therefore, a process that balances crypt fission must occur. Potential 
mechanisms could be crypt death as well as crypt fusion. As for the dramatic effects observed 
for lateral expansion of KRAS-mutant crypts, it seems plausible that, as mutations drive fission 
to increase the crypt density in a defined area, these start to merge at the borders of the mutant 
patch to relieve local overcrowding. The idea of crypt fusion is at least a decade old, with Kim 
and Shibata first speculating about such a process in the discussion of their methylation paper 
(Kim & Shibata, 2004). Recently, crypt fusion has been described by intravital microscopy in 
the mouse small intestine (Bruens et al., 2017). This work showed that, at least in the mouse, 
the processes of crypt fission and fusion occur via opposite mechanisms (Figure 5.10). To 
investigate fusion in human samples, a method to quantify the rate of this process in en face 
colonic sections was devised.  
 
Figure 5.10 Proposed process for crypt fission and fusion. 
Mouse intravital microscopy data suggests that crypt fission occurs as a ‘bottom-up’ process, 
whereas fusion is proposed to be a ‘zipping-down’ between crypts. 
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5.4.1 The fufi 
In human colon samples, quantification of crypt fission processes historically relied on the 
observation and quantification of so-called ‘bifid crypts’ – crypts that contain two ‘arms’ 
indicative of ongoing fission in longitudinal sections (Cummins et al., 2008). In en face colonic 
tissue sections, these structures manifest as two connected circles of cells, previously called ‘8-
shaped’ crypts (Bruens et al., 2017). Up to date, no markers that discriminate crypt fission or 
fusion have been identified. This means that 8-shaped crypts could be snapshots of fusion or 
fission events. The term ‘fufi’ (from FUsion or FIssion) is thus proposed here, as a means of 
agnostically referring to these structures. Fufis were defined stringently as two connected crypts 
without any discernible gap but with two clearly identifiable lumina (Figure 5.11). The latter is 
key to discerning fufis from potential artefacts caused by oblique sectioning of crypts (Figure 
5.11, rightmost schematic).  
 
 
Figure 5.11 Defining the fufi. 
Schematic representations as well as images of real examples with a focus on the key criteria 
of crypt separation and double lumen. 
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To infer fusion rates for gene-specific mutations, fufis comprising at least one mutant crypt 
were analysed. There are two types of such marked fufis: Those comprising two mutant crypts 
(mut fufis) and those containing one wild-type and one mutant crypt (WT-mut fufis) (Figure 
5.11). Importantly, WT-mut fufis were always found exactly half WT and half mutant and were 
thus assumed to represent crypt fusion events. Mut fufis however, could indicate a fission or 
fusion event 
5.4.2 Inference of crypt fusion rates 
The mathematical analysis for inference of fusion rates was performed by Dr Doran Khamis 
and details can be found in Appendix E. Briefly, the observed patch sizes are the output of 
fission and fusion events. Therefore, the fission rates derived from the distribution of patch 
sizes (section 5.2.1) were an important prerequisite for the calculation of fusion rate. 
Importantly, mathematical modelling by Dr Edward Morrissey showed that patch size is 
dominated by fission (Appendix C: Figure C.1). Therefore, fusion rates could not be derived 
from patch sizes but required quantification of fufis. Of note, analysis was restricted to fufis 
neighbouring at least one wild-type crypt, hereafter referred to as patch edge fufis (Figure 5.12).  
 
 
Figure 5.12 Scoring of patch edge fufis and neighbours. 
(A) Schematic representation of patch edge mut fufi with four WT and three mut neighbours. 
(B) Representative image of KDM6A- patch edge fufi with WT and mut neighbours 
highlighted. 
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Of note, single fufis surrounded entirely by WT crypts were scored as patches comprising one 
crypt. Scoring the amount and type (WT or mut) of crypts neighbouring patch edge fufis (Figure 
5.12) enabled calculation of an average number of neighbouring WT and mut crypts for mut 
fufis. This was used to assign the probability of fusion and fission identity to mut fufis. 
Combined with the known fission rate, this enabled calculation of the mark-specific fusion rate 
(for mathematical details see Appendix E).  
5.4.2.1 Inference of the neutral crypt fusion rate from mPAS fufis 
For inference of the homeostatic human crypt fusion rate, mPAS was chosen, as it displays 
neutral behaviour but exhibits a relatively high event rate, which expedited quantification. WT, 
mut and WT-mut fufis were quantified manually in sections from 81 patients of the age range 
33-89 years (Figure 5.13). In total, 26,455 fufis (26,391 WT and 64 mPAS+ fufis) were scored.  
 
Figure 5.13 Identification of mPAS+ fufis. 
Schematic illustration as well as representative images from human colonic tissue sections. 
Left: WT fufi – not used for fusion rate. 
Middle: WT-mut mPAS+ fufi surrounded by WT crypts. 
Right: Mut fufi with WT and mut neighbours. 
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Combined with the known patch size distribution this enabled calculation of the homeostatic 
crypt fusion rate (for mathematical models used see Appendix E), which was found to be 0.77% 
per year (95% CI: 0.46-0.28) (Figure 5.15). Interestingly this is remarkably similar to the mPAS 
fission rate calculated earlier (0.69% per year) (Section 5.2.1 and Figure 5.2), suggesting that 
in homeostasis, human colonic crypt fission and fusion balance each other. 
5.4.2.2 Inference of the fusion rate for KDM6A-negative crypts 
The next important question was whether the local increase in fission that can result from gene-
specific mutations is balanced by an increase in fusion, potentially as a mechanism to relieve 
local overcrowding. To answer this question, KDM6A was chosen, as it is the mark causing the 
strongest increase in crypt fission. WT, mut and WT-mut fufis were quantified in sections from 
90 patients aged 13–93 years (Figure 5.14). In total, 6285 fufis (6227 WT and 58 KDM6A-) 
were scored.  
 
Figure 5.14 Identification of KDM6A-negative fufis. 
Schematic illustration as well as representative images from human colonic tissue sections. 
Left: WT fufi – not used for fusion rate. 
Middle: WT-mut KDM6A- fufi surrounded by WT crypts. 
Right: mut fufi with WT and mutant neighbours. 
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Modelling revealed a fusion rate of 0.61% per year (95% CI: 0.28–1.03) for KDM6A-negative 
crypts, remarkably similar to the fission and fusion rate derived for mPAS (Figure 5.15). This 
indicates that the local increase in crypt fission that results from loss of KDM6A to about 4% 
per year is not balanced by an increase in crypt fusion. Therefore, fission and fusion may be 
independent processes, driven by separate mechanisms. 
 
Figure 5.15 Crypt fission and fusion rates for mPAS and KDM6A. 
Error bars = 95% CI. 
 
5.4.3 Fission and fusion duration 
In the mouse, intravital microscopy revealed that the dynamic part of crypt fission and fusion 
spans around 3-5 days, whereby both processes take the same amount of time. The processes 
cannot currently be directly measured in humans, however, an estimation can be derived. 
Briefly, assuming equal duration of human crypt fission and fusion, they can be modelled as 
two simultaneously occurring processes. Therefore, the frequency of fufis at any given moment 
in time is a snapshot combining ongoing fission and fusion events. It follows that the frequency 
of fufis in a large cohort of individuals of a wide range of ages can be used to derive the duration 
of the process (For details on mathematical models used see Appendix E). To rapidly generate 
a large dataset, the neural network DeCryptICS was trained for fufi detection using the criteria 
described in 5.4.1. Fufi frequencies (defined as the frequency of fufis as a fraction of total 
crypts) were obtained for KDM6A-stained colonic tissue sections from 89 patients ranging in 
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age from 13-93 years. This revealed significant spread between individuals (Figure 5.16A & 
B).  
 
 
Figure 5.16 Inference of human crypt fission and fusion duration. 
(A) Plot showing frequency of fufis as fraction of total crypt number for KDM6A-positive 
(WT) and KDM6A-negative (KDM6A) crypts.  
(B) Plot showing mean fufi frequency for KDM6A-positive (WT) and KDM6A-negative 
(KDM6A) crypts. Error bars = 95% CI. 
(C) Plot of inferred fusion and fission duration for KDM6A-positive (WT) and KDM6A-
negative (KDM6A) crypts. Error bars = 95% CI. 
 
Importantly, to explore a potential difference between the fufi duration in KDM6A-negative 
crypts and the bulk crypt population (KDM6A-positive, hereafter referred to as wild-type, WT), 
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the dataset was divided accordingly. Of note, the mean calculated for WT crypts included 
1,804,580 crypts and 6227 fufis, whereas the KDM6A-negative dataset was much smaller with 
5070 crypts and 58 fufis. Mathematical modelling by Dr Doran Khamis revealed the fission 
and fusion duration to be 103 days (95% CI: 73–133) for WT crypts and 120 days (95% CI: 
88–162) for KDM6A-negative crypts (Figure 5.16C). There is no significant difference 
between these two values, indicating that fission and fusion take about the same amount of time 
in a mutant as well as a wild-type setting. Interestingly, the duration calculated here is about 
30-fold slower than in the mouse.  
5.5 Summary and Discussion 
Lateral expansion of mutations into fields increases the pool of cells available for acquisition 
of a ‘second hit’ and thus promotes cancer initiation. In the mouse colon, this process occurs 
via crypt fission, and can be accelerated by pro-oncogenic mutations such as activation of 
KRAS. Here, lateral expansion was investigated in human colon using clonal marks.  
The distribution of patch sizes across the large cohort of patients of different ages enabled 
calculation of human colonic crypt fission rates associated with gene-specific mutations. The 
neutral rate, inferred from mPAS, MAOA and NONO, was found to be 0.7% per crypt per year. 
A 3-fold increase in crypt fission was found for STAG2, PTEN and p53 and an even stronger 
4.5-fold effect for KDM6A. This demonstrates that gene-specific mutations can increase human 
colonic crypt fission to generate mutant fields. Combined with biased intra-crypt dynamics this 
can significantly increase the mutant allele burden in the epithelium.  
To investigate the effect of KRAS activating mutations a targeted amplicon sequencing 
approach was taken. Importantly, a mimic amplicon strategy was devised, which ensured the 
elimination of artefactual mutations stemming from tissue fixation, PCR amplification and 
sequencing. Noise was particularly prominent for G>A transversions, which is most likely due 
to deamination of cytosines. Treatment of DNA samples with uracil DNA glycosylase prior to 
PCR has been shown to reduce such artefacts (Kim et al., 2017) and should be attempted for 
future experiments.  
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KRAS activating mutations were identified in 13.7% of samples. However, the DNA sequenced 
was bulk extracted from FFPE sections. Therefore, a MAF of 1% may represent a patch of 10 
mutant crypts in a section with 500 crypts, while it may indicate a patch of 400 mutant crypts 
in a section with 20,000 crypts. Therefore, the sensitivity of the method is inversely correlated 
to section size. It is thus likely that a number of small KRAS-mutant patches were not detected 
in large sections, as the resulting MAF in the bulk sample would not exceed our detection 
threshold. This relationship between section size and mutation detection is visible in differences 
between the experimental data and simulation performed by Dr Edward Morissey, whereby the 
former seems to lack predicted low frequency MAFs (Figure 5.17). Potentially, these are 
present in the samples but not detected with the current method. In line with this hypothesis is 
the close correspondence between KDM6A data and simulation. As KDM6A is a clonal mark, 
the sensitivity of mutation detection is at single crypt level and independent of section size. 
For future studies, higher sensitivity could be achieved by subsampling. For example, by 
dividing larger sections into samples of 1000 crypts, patches of 2 crypts would yield MAFs of 
0.1% and would thus be detected. In addition, the simulation reveals an overrepresentation of 
large KRAS-mutant patches in young (<50 years old) individuals in the targeted sequencing 
data (Figure 5.17). It will be interesting to obtain clinical data for these individuals to examine 
potential effects of lifestyle, therapies or genetic background. 
Regardless of these challenges, the data yielded insights into the spread of KRAS activating 
mutations in normal human colonic epithelium. The most frequent mutation identified was 
G12D followed by G12V and G12C. The first two are in line with the frequencies of mutations 
found in CRC, whereby KRASG12D and G12V mutations are the two most frequent specific 
alterations, followed by BRAFV600E and KRASG13D (COSMIC database). Of note, 
modelling by Dr Edward Morrissey revealed that the frequencies of different KRAS activating 
mutations identified here mostly scale with the proportion of colorectal cancers they are found 
in (Figure 5.18, data from cBioPortal). This suggests that they all harbour a similar efficiency 
of conversion into malignancy.  
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Figure 5.17 Comparison between data and simulations. 
Figure kindly provided by Dr Edward Morrissey. 
(A) Comparison between experimental data (left) and three simulations for KRAS MAFs. 
(B) Comparison between experimental data (left) and three simulations for KDM6A. 
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Figure 5.18 Similar efficiency of conversion into malignancy for different KRAS 
activating mutations. 
Modelled frequency of crypts with KRAS activating mutations plotted against the proportion 
of tumours they are found in (data from cBioPortal). 
 
While for the majority of individuals (157 out of 256), only one FFPE tissue block was 
sequenced, for 99 between two to seven independent samples were analysed. Interestingly, 6 
out of these 99 individuals harboured more than one mutation, found in different tissue samples. 
In two of these, the same KRAS activating mutation was found in two independent samples. It 
is possible that these represent one single large expansion, however, in absence of spatial 
information this remains elusive. In the remaining four cases two different KRAS activating 
mutations were found in the samples, suggesting independent mutational events. It will be 
interesting to refer back to clonal marks data to determine whether these individuals exhibit 
high clone frequencies, which may be indicative of a mutator phenotype. Clinical data as well 
as investigation of mismatch repair status may aid in further interpretation of the findings.  
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The mutant patch sizes calculated from MAFs were in the range of 7-1121 crypts. Due to the 
low frequency of KRAS mutations and the fact that blocks usually only contained one type of 
alteration, it can be assumed that these mutant crypts correspond to single large mutant areas 
rather than a number of smaller patches. This hypothesis could be tested by subdivision of 
sections followed by sequencing, as described above. Equally, in-situ hybridisation or even IHC 
could visualize patches in serial sections. However, to date we have not been able to adapt the 
BaseScope™ method to our human FFPE colonic tissue sections. 
The subject of KRAS mutations in colonic epithelium is intimately linked to aberrant crypt foci 
(ACF). First described in rodents treated with azomethane (Bird, 1987) and shortly after in 
human colonic tissue samples (Roncucci et al., 1991) these are single or groups of crypts 
characterised by elevation, oval lumina and thicker epithelial lining. ACF can be further divided 
into hyperplastic and dysplastic ACF. The former show increased proliferation and are thought 
to represent an intermediate stage between normal and adenoma (Morimoto et al., 2002). The 
latter are characterised by an irregular outline, increased overall and nuclear size and loss of 
polarity and are often classified as microadenomas (Gupta et al., 2017). Importantly, a number 
of human studies have found a high frequency of KRAS activating mutations in hyperplastic 
ACF, with the frequency of such alterations observed in different studies ranging from 16.3-
85% of ACF examined (Otori et al., 1995; Takayama et al., 1998, 2001; Quintanilla et al., 
2019). Consistently, dysplastic ACF show a lower frequency of KRAS activating mutations than 
hyperplastic ACF (Takayama et al., 1998, 2001). ACF can be detected in humans by high-
magnification chromoscopic colonoscopy (HMCC), whereby the absorptive dye methylene 
blue enables identification due to a darker appearance (Kudo et al., 1996). As ACF are thought 
to represent precursors to colorectal cancer (Kukitsu et al., 2008; Orlando et al., 2008), they 
have been extensively investigated as biomarkers to identify individuals at high risk of 
developing CRC, including patients with ulcerative colitis and FAP (Roncucci et al., 1991; 
Kukitsu et al., 2008). However, the correlation between ACF and tumour burden is still a matter 
of debate (Takayama et al., 1998; Kukitsu et al., 2008; Orlando et al., 2008; Wargovich, Brown 
& Morris, 2010; Gupta et al., 2017; Quintanilla et al., 2019), an issue most likely related to the 
variability in endoscopic analyses and classification as well as the complication that by far not 
all ACF progress to cancer (Ghosh et al., 2018). Considering the high frequency of KRAS 
148 Expansion beyond the crypt 
 
 
mutations found in ACF and their potential use as predictive biomarkers for CRC, it will be 
very informative to systematically detect such structures in our tissue samples. Ideally, 
DeCryptICS could be trained for this purpose by a histopathologist. In a first step it will be 
important to determine whether the KRAS activating mutations identified here correlate with 
the presence of ACF in serial sections. Identified (KRAS-mutation positive and negative) ACF 
could then be further investigated with IHC (to look for loss of mismatch repair genes) or LCM 
and sequencing of other CRC-associated genes to characterise them further. Combining this 
genetic information with histopathological description of the tissue (ACF or histologically 
normal KRAS-mutant epithelium) and clinical patient data such as high BMI, presence of 
inflammatory conditions and tumour grade, may form the basis for more sophisticated 
classification of different ACF and generation of biomarkers that can be detected by HMCC. 
This may then enable refined patient stratification, whereby detection of certain high CRC risk-
associated features may trigger a chemoprevention or more rigorous surveillance regime. In 
terms of the former, the work presented here defines the timeframe taken for KRAS-mutant 
patches to expand in the human colonic epithelium. Blocking or even slowing down of this 
process to the point where large expansion would be shifted beyond normal human lifespan 
could therefore represent a viable CRC prevention strategy, in particular for tumours that 
initiate from KRAS mutant fields. Short-term MEK inhibition (MEKi) with the MAPK inhibitor 
CI-1040 (PD184352) has been shown to revert the hyperplastic phenotype observed upon 
induction of KRASG12D mutations in the mouse intestine (Feng et al., 2011). The effect of a 
regime of intermittent MEKi could first be tested in human organoids xenografted into mice, a 
method recently published by the Sato group (Sugimoto et al., 2018). 
The dramatic increase in crypt fission observed for KDM6A loss and KRAS activation lead to 
the hypothesis that such an effect may drive crypt fusion events, which could relieve local 
overcrowding caused by increased crypt density. Importantly, an accurate rate of fission could 
be estimated as the outcome of it is observed by the age-related changes in patch sizes. As 
modelling revealed that fusion does not impact on this distribution, the rate of this process could 
be derived. To do so, the term ‘fufi’, was introduced as a means of agnostically referring to 
crypts captured during the fission or fusion process in en face tissue sections. By quantifying 
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mPAS+-containing fufis in sections from 89 patients, around 0.77% of crypts were calculated 
to undergo fusion per year, a value remarkably similar to the homeostatic fission rate derived 
from mPAS, MAOA and NONO patches. This suggests that as part of homeostasis, akin to the 
mouse, human crypts undergo fission and fusion events. Interestingly, a very recent study used 
the histochemical detection of CCO-deficiency to quantify the human crypt fusion rate. In a 
similar way to the method described here, Baker and colleagues quantified CCO--containing 
fufis in 13 patient samples to infer a neutral crypt fusion rate of 1.1% per year (range of medians: 
0.2–2.4) (Baker et al., 2019). This value is very similar to the fusion rate calculated here, albeit 
with much larger error bars reflecting the very small patient cohort. Importantly, the model used 
by Baker and colleagues assumed a balance between fusion and fission rates before performing 
calculations while the approach taken here did not.  
Next, about 0.6% of KDM6A-negative crypts were calculated to undergo fusion per year. This 
value is remarkably similar to the neutral fusion and fission rates calculated for mPAS. It 
indicates that loss of KDM6A, while causing a dramatic increase in crypt fission, does not 
impact on crypt fusion. Therefore, the hypothesis that a local increase in crypt fission rate is 
balanced by accelerated fusion does not hold true for KDM6A. It will be interesting to 
investigate whether the same outcome is also found for other gene-specific mutations associated 
with biased fission such as STAG2, p53, PTEN and KRAS. 
The duration of crypt fission and fusion was inferred from fufi frequencies for KDM6A-
negative and positive crypts. Interestingly, fission and fusion both seem to occur more 
frequently in the mouse small intestine, where at any given point in time about 4% of crypts are 
fissioning and the same percentage fusing. In the human colon it is below 0.5%. For the duration 
of fission and fusion 103 days for KDM6A-positive and 120 days for KDM6A-negative crypts 
were calculated. This suggests that KDM6A loss does not alter the duration of fission and 
fusion. Again, it will be interesting to see if the same holds true for other clonal marks. Fission 
and fusion durations had also been inferred by Baker and colleagues, who analysed samples 
from 10 individuals and obtained a value of 41 days, with a range of medians of 4-41 weeks 
(Baker et al., 2019). Their much larger range can be attributed to the much smaller sample size. 
Regardless of this limitation, the similar values for neutral crypt fusion rate and duration 
obtained by Baker and colleagues support the findings presented here. 
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Considering local overcrowding caused by elevated fission rates, it is plausible that, since such 
clones are rare, the epithelium as a whole is able to absorb the pressure caused by local increases 
in crypt density. Specifically, crypts may rearrange within the epithelium, which may be 
accompanied by stromal remodelling. More intriguing however, is the question of potential 
intra- and intercellular mechanisms driving the different processes. Crypt fission in the mouse 
small intestine has previously been described to be fuelled by proliferation as well as 
positioning of Paneth cells (Snippert et al., 2013; Langlands et al., 2016). However, the 
molecular mechanism remains elusive. Even less is known about the intracellular and 
intercellular pathways that might drive fusion. To gain insights into potential pathways 
regulating the process, RNA-Seq or proteomics experiments could be performed on fufis 
directly isolated from fresh mouse tissue. The fission bias observed for KDM6A could then be 
investigated using inducible KDM6A(lsl) mice crossed to reporter lines. Combined with BrdU 
labelling these experiments could also show whether proliferation plays a role in accelerating 
fission in KDM6A-deficient crypts. The same methodologies could also be applied to 
investigate the fission bias observed for loss of STAG2 and PTEN as well as stabilisation of 
p53. 
Clonal marks as well as targeted sequencing can provide detailed insights into lateral expansion 
of mutant clones in the human colonic epithelium. Both methods used rely on detection of 
specific variants, from which associated behaviours can be inferred. However, the neural 
network-based tool DeCryptICS might in the future enable a more agnostic approach, whereby 
serial sections annotated for clonal marks and fufis could be aligned. Areas with increased clone 
numbers for different marks may indicate underlying local genetic instability while local 
increases in fufi frequency may be suggestive of a hidden fission-promoting mutant field. The 
areas could then be laser capture microdissected and, if large enough, whole genome sequenced 
to find the genetic cause of the phenotype. 
 Chapter 6 Discussion 
6.1 Investigating mutation accumulation in normal human colon 
In recent years, a paradigm shift in the general model for cancer initiation has formed the basis 
for investigations into accumulation of mutations in normal renewing tissues. A number of 
methodologies are available to examine mutation accumulation in human colonic epithelium. 
They are summarised in Table 6.1 and discussed in detail in the following sections. 
Table 6.1 Comparison between different methods for investigation of somatic mutations 
in human colon. 
Method Advantages Disadvantages 
Clonal marks 
Large sample size 
High resolution 
Labour-intensive 
Material limiting 
Targeted 
sequencing 
Large sample size 
Detection limit for small expansions 
No intra-crypt/tissue context 
Organoid 
sequencing 
High resolution 
Small sample size 
No intra-crypt/tissue context 
LCM single crypt 
sequencing 
High resolution 
Labour-intensive 
Small sample size 
No intra-crypt context 
RNA-Seq data 
analysis 
Large sample size 
Detection limit for small expansions 
No intra-crypt/tissue context 
CCO 
histochemistry 
Large sample size 
High resolution 
Not adaptable to other mutations 
In situ 
hybridisation 
Large sample size 
High resolution 
Expensive 
Material limiting 
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6.1.1 Clonal marks for precise quantification in large cohorts 
Here, the fixation and spread of mutations in normal human colon was investigated using 
immunohistochemical detection of somatic variants. By means of an antibody screen the arsenal 
of such clonal marks was expanded to include, in addition to the previously identified mPAS 
and MAOA, the six marks HDAC6, KDM6A, NONO, p53, PTEN and STAG2. These were 
used for IHC on normal human FFPE colonic samples from a large cohort of individuals of a 
wide range of ages, followed by interpretation of age-related trends in clone frequencies.  
This method harbours a number of features that uniquely enable a quantitative description of 
how gene-specific mutations can achieve high mutant allele burden in the colonic epithelium. 
Analysis of sections at 20X magnification allows for single-cell resolution within tissue context. 
Therefore, clonal expansions can be precisely quantified, both on an intra-crypt as well as tissue 
level. The smallest clones detected here comprised fewer than 10 cells, while the largest 
KDM6A-negative patch comprised 71 crypts. The simplicity of clone identification enables 
relatively high throughput analysis of tens of thousands of crypts per individual, totalling 
several million crypts for every mark. In the future, this will be further accelerated by 
improvements in the neural-network based tool DeCryptICS. The large sample size ensures that 
data generated is robust, which is confirmed by statistical analysis and simulation. Finally, as 
tissue is stored long term embedded in paraffin wax, it is readily accessible for testing of new 
hypotheses on serial sections. An example of this is IHC for H3K27me3 to investigate potential 
effects of loss of KDM6A.  
Clonal marks also carry limitations. Immunohistochemical detection of gene-specific mutations 
is limited by the availability of specific antibodies. The antibody screen performed here 
identified around 20% of antibodies as lacking specificity or immunoreactivity. A particular 
challenge is detection of activated oncogenes such as KRASG12D and BRAFV600E, where 
significant cross-reactivity with wild type protein was observed. Initially, clonal marks were 
limited to X-linked genes, whereby due to male hemizygosity and X-inactivation in females, 
mutation of one allele is sufficient for visualisation. However, certain autosomal genes such as 
PTEN were also found to yield negative clones. Whether these correspond to mono- or biallelic 
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loss is not easily determined by IHC. More generally, identification of genetic alterations 
causing the loss of staining has to date only been achieved for MAOA and KDM6A. It will be 
informative to attempt the same for the other marks. In addition, the gene causing the mPAS 
phenotype needs to be identified. Finally, each IHC requires an individual tissue section. Most 
of the FFPE colonic tissue blocks obtained by the Winton laboratory yield between 10 to 30 
sections, in theory enabling investigation with the same number of clonal marks. However, a 
number of sections are used for antibody screens as well as testing of other methods of mutation 
detection. Attempts to multiplex the method by dual-colour (red and brown) staining have to 
date been hampered by challenges in clone detection. Therefore, currently a maximum of 
around 20 marks per tissue block applies. 
6.1.2 Targeted sequencing for inference of mutant patch sizes 
As visualisation by IHC was not successful for KRAS activating mutations, a targeted 
sequencing approach was taken, whereby next-generation sequencing was performed on PCR 
products originating from amplification of DNA extracted from FFPE tissue sections. 
Importantly, a mimic region was also amplified and sequenced, which enabled estimation of 
background noise caused by formalin fixation and tissue storage effects. This resulted in 
detection of KRAS activating mutations in approximately 13% of individuals. MAFs were 
converted to mutant patch sizes, which revealed dramatic expansion of KRAS-mutant clones. 
The method is easily performed on hundreds of samples, and future studies will benefit from 
recent technological advances such as automated FFPE DNA extraction (Haile et al., 2017). 
The targeted sequencing approach developed here requires 1/20 of the DNA from one section 
(in the range of 5-20 ng per reaction) for analysis of mutations in KRAS exon 2. Therefore, 
each section could be probed for at least 20 genes, a number which could be increased further 
by multiplexing. It thus uses considerably less material than mutation detection by IHC, which 
requires one tissue section per gene. However, the targeted sequencing approach has two major 
drawbacks: Firstly, spatial context is lost. Mutant crypt numbers can be inferred from MAFs, 
however, whether these comprise one single large expansion or several smaller patches remains 
elusive. As KRAS activating mutations are rare and blocks were only ever found to contain one 
type (G12D, G12V etc), the former is likely. IHC or in situ hybridisation on serial sections 
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could validate this hypothesis. Secondly, the detection threshold for MAFs is approximately 
0.1%, independently of sample size. The minimum detectable mutant patch size within each 
analysed section is thus proportional to the total number of crypts contained within it. This 
means that in large sections, small clonal expansions are currently not detected. For future 
studies this variability could be reduced by subsampling of larger sections.    
6.1.3 Overview of alternative methodologies 
A number of alternative methods can be used to address questions relating to accumulation of 
somatic mutations in normal human colonic epithelium. These include sequencing-based 
approaches as well as histochemical and in situ hybridisation methods. However, a number of 
factors prevent alternative methods from producing the insights gained here.  
6.1.3.1 Sequencing-based approaches 
Studies based on sequencing can be largely subdivided into two types of strategy: Either a small 
number of crypts were analysed in great detail or large tissue areas examined more broadly. 
6.1.3.1.1 In depth sequencing of small samples 
This is exemplified by sequencing of organoids derived from single cells (Blokzijl et al., 2016) 
and analysis of laser capture microdissected crypts from histologically normal human colon 
(Lee-Six et al., 2018). Blokzijl and colleagues analysed whole genome sequencing data from 
45 organoid cultures derived from single cells from 19 donors of the age range 3-87 years. This 
offered detailed insights into mutational processes associated with ageing of human intestine 
and included a description of the most frequent mutational signatures found in the tissue. 
However, as organoids are grown from single cells after tissue dissociation, intra-crypt 
dynamics as well as clonal expansion could not be investigated. This was achieved by Lee-Six 
and colleagues, who whole genome sequenced just over 2000 crypts isolated by LCM to 
identify mutational signatures. This was complemented by targeted sequencing for 90 putative 
CRC driver genes. Hotspot mutations were detected in the cancer drivers PIK3CA, ERBB2, 
6.1 Investigating mutation accumulation in normal human colon 155 
 
ERBB3 and FBXW7 and truncating mutations in a number of genes including TP53. However, 
no KRAS mutations were identified. Further, apart from two mutations in STAG2 and loss of 
chromosome 10q, which contains PTEN, Lee-Six and colleagues did not detect any recurring 
mutations in the genes used for clonal marks here. In addition, clonal expansions beyond 
patches of two adjacent crypts were not found. These differences can largely be attributed to 
sample size. The clones detected using clonal marks are rare, occurring at frequencies of about 
1:10,000 crypts. It is thus not surprising that, by sequencing just over 2000 crypts, Lee-Six and 
colleagues mostly failed to detect mutations in the genes used for clonal marks. In addition, by 
sampling only around 50 crypts per patient, the chance of capturing entire clonal patches is 
small, a challenge exacerbated by incomplete coverage of the genome. The same holds true for 
KRAS activating mutations, for which MAFs of 0.2-1.8% were found in approximately 13% of 
normal colonic samples tested here. As 2000 crypts roughly corresponds to one of the hundreds 
of samples sequenced here, the chance of finding a KRAS activating mutation Lee-Six et al. 
had in their samples was the frequency of positive samples in our cohort, which is 13%.  
In summary, while the studies by Blokzijl et al., and Lee-Six et al., yielded insights into 
mutational signatures associated with ageing of the human colon, they failed to detect rare 
mutations and were not equipped to investigate intra-crypt mechanisms as well as clonal 
expansion processes. 
6.1.3.1.2 Bulk sequencing  
A bulk sequencing-based approach, on the other hand, was taken by Yizhak and colleagues, 
who developed a method to detect mutations in RNA-Seq data. Applied to normal samples from 
the Genotype-Tissue Expression (GTEx) Project, this identified macroscopic lesions in most 
individuals (Yizhak et al., 2019). Mutations were particularly frequent in sun-exposed skin, 
oesophagus and lung, while large expansions in known CRC drivers were not identified in 
normal colon gene expression data. Most likely, this is linked to sensitivity which in turn relates 
to sample size. While clone expansion in the skin might be so dramatic that it can be detected 
even when diluted out within a large sample, multicrypt patches may be rarer and relatively 
smaller in the colon. When DNA from too many cells is analysed, MAFs of small clonal 
expansions are reduced to below detection threshold. Therefore, to detect mutations by bulk 
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sequencing, the sample size needs to be scaled according to the expected clone size. This was 
not possible for Yizhak et al., who analysed previously acquired data. Therefore, to detect small 
clonal expansions in human colon by sequencing, a method half way between the targeted 
KRAS sequencing approach and the laser capture and sequencing of MAOA and KDM6A-
negative patches would be most appropriate. 
6.1.3.2 Histochemical detection of CCO mutations 
As described in chapter 1, somatic mutations in the mitochondrially encoded gene CCO can be 
detected by histochemistry. This method was previously used to quantify the behaviour of 
human colonic stem cells (Baker et al., 2014). More recently, Baker and colleagues quantified 
CCO-negative crypt containing fufis in samples from 13 individuals to infer a neutral human 
crypt fission and fusion rate of 0.01 per year, with a range of 0.002–0.024 (Baker et al., 2019). 
This is very similar to the result obtained with mPAS here, albeit with a much wider confidence 
interval, caused by a small sample size. Analysis of CCO-deficient crypts can thus yield the 
same insights into neutral intra-crypt dynamics as well as crypt fission and fusion events as can 
be obtained from clonal marks data. However, the method is limited to the CCO gene. 
Therefore, biases in these processes remain unquantifiable. 
6.1.3.3 In situ hybridisation 
An alternative to histochemical detection of mutations is in-situ nucleic acid hybridisation. As 
discussed in chapter 5, a recent development in this area has been the BaseScope™ technology. 
This method relies on hybridisation of so-called Z-probes to target RNAs followed by several 
amplification steps. Specificity is very high, enabling discrimination between wild type and 
mutant transcripts, down to single nucleotide level. This has been successfully used in human 
tumour sections for detection of various oncogene-activating mutations such as KRASG12D or 
BRAFV600E (Baker et al., 2017). However, BaseScope™ is currently very expensive, costing 
around £60 per section. It is therefore presently not feasible to use this method for screening of 
hundreds of sections. Instead, it may aid in validation of sequencing results.  
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A slightly cheaper alternative is RNAScope®, which relies on detection of RNA by 
hybridisation of at least three Z-probes per transcript. It cannot detect SNVs but could be used 
for detection of surrogate markers. Mouse data suggests upregulation of Notum to be indicative 
of loss of Apc (Owen Sansom, personal communication). This provides motivation for 
investigation of APC mutation detection by RNAScope® for NOTUM in human tissue. 
Analogous to histochemical detection, in situ hybridisation approaches harbour the 
disadvantage is that each iteration uses up a tissue section. Therefore, tissue thickness limits the 
number of gene-specific mutations that can be probed for. 
6.2 Gene-specific mutations can subvert normal biology 
Clonal marks and targeted sequencing were used here to describe how gene-specific mutations 
can achieve high mutant allele frequencies within the human colonic epithelium. Importantly, 
this process is intimately linked to the homeostatic behaviour of the resident stem cell 
population, which can be described by neutral drift theory (Lopez-Garcia et al., 2010; Snippert, 
van der Flier, et al., 2010; Baker et al., 2014; Nicholson et al., 2018). Each human colonic crypt 
contains an equipotent population of stem cells that all harbour the same probability of fixation. 
The total colonic MAF for neutral mutations is thus proportional to the mutation rate. However, 
certain gene-specific mutations can increase the probability of fixation of stem cell-derived 
clones within the crypt by biased stem cell replacement. Such an effect was found for loss of 
KDM6A and, to a greater extent, STAG2, whereby stem cells with mutations in the latter were 
found to nearly always populate their resident crypt. Biased replacement is thus a mechanism 
by which mutations can achieve a higher mutant allele burden than would be possible from 
mutation rate alone. Simply describing the mutational burden of a tissue by sequencing or 
otherwise would fail to capture this mechanism, as this only describes the final outcome and 
would thus overestimate the gene-specific mutation rate. 
Once fixed within a crypt, mutant clones can expand in the epithelium by crypt fission. 
Importantly, the present study precisely quantified the homeostatic rate of crypt fission in the 
human colon. Against this baseline, it was found that loss of STAG2, KDM6A and PTEN as 
well as stabilisation of p53 and activation of KRAS can accelerate crypt fission to generate 
158 Discussion 
 
 
large mutant fields within the colonic epithelium. The most dramatic effects were found for loss 
of KDM6A and activation of KRAS, with clones comprising tens and hundreds of crypts, 
respectively. This demonstrates how gene-specific mutations can contribute to a field 
cancerisation effect, which substantially increases the pool of cells available for subsequent 
mutations. Importantly, for description of this process only the mutation rate and the final MAF 
are required. 
The potential effect of crypt fusion was also investigated. Strikingly, the baseline crypt fusion 
rate of human colonic crypts was very similar to the fission rate, suggesting a symmetric balance 
between the two processes that may act to conserve tissue size. A crypt cycle, as proposed in 
the 1980s (Totafurno, Bjerknes & Cheng, 1987), thus seems to exist, but the original hypothesis 
requires addition of crypt fusion. Also, the cycle duration is likely much higher than the 10-20 
years estimated by Totafurno and colleagues, with the data presented here corresponding to 
approximately 150 years. Quantifying the fusion rate for KDM6A-negative crypts revealed that 
some mutations can alter this balance by promoting fission but not fusion. This suggests that 
the two processes may be driven by independent mechanisms. Of note, mathematical modelling 
by Dr Edward Morrissey revealed that increasing the fusion rate for KDM6A would only 
marginally limit the spread of mutant clones.  
For every gene-specific mutation, the intra-crypt dynamics combined with the effect on 
expansion by crypt fission result in the total mutational burden within the colonic epithelium. 
Understanding the rates of these processes enables ranking of different mutations irrespective 
of the specific cellular mechanism through which they arise. This may inform cancer prevention 
strategies to restrict the spread of pro-oncogenic mutations, which may limit cancer risk. 
Importantly, these insights cannot be gained from simple description of the total mutational 
burden in aged human colon, as this does not generate any insights into the mechanisms and 
timings of mutation fixation and spread.  
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6.3 Towards understanding CRC initiation and incidence 
Approximating the frequency of clones detected for the X-linked clonal marks to 1:10,000 
crypts and the human genome to 20,000 protein encoding genes, it follows that every colonic 
crypt in a 60-year old individual carries on average two mutations causing loss of function of 
two different alleles. Furthermore, alterations known to drive CRC are present in normal colon 
– 1 in 10,000 crypts harbours stabilised p53, roughly the same frequency have lost PTEN and 
just over 10% of people carry KRAS activating mutations in patches comprising several hundred 
crypts. The colonic epithelium of aged humans is thus a mosaic of different mutations. In line 
with these findings, a patchwork of mutations was also reported by Lee-Six at al., (2018) and 
Blokzijl et al. (2016). The former study claims that 1% of crypts harbour a CRC driver mutation. 
Taking all these observations into account, the obvious question that arises is: Why is bowel 
cancer not more common?  
To answer this question, a comprehensive description of how common CRC drivers spread in 
the normal human colonic epithelium is required. The present study was focused on describing 
the ways in which mutations can achieve high mutant allele frequency in the human colonic 
epithelium. In terms of CRC driver genes however, only three alterations were considered: 
stabilisation of p53, loss of PTEN and activation of KRAS via mutations in codons 12 and 13.  
6.3.1 Proposed multiplex method 
Considering the large tail of genes commonly mutated in CRC (Figure 1.6) multiplied by the 
fact that most genes exhibit at least a number of mutational hotspots means that capturing the 
full landscape of CRC-associated mutations in normal human colon by in situ detection would 
not be feasible. Equally, from the moderate expansion effects seen for PTEN and p53 it can be 
predicted that a lot of the clones in question will be very small, comprising only a few crypts. 
Even in a relatively small section with 10,000 crypts, this would generate a MAF below 0.1% 
and therefore fail to exceed the detection threshold for the mimic amplicon targeted sequencing 
method. Therefore, a refined hybrid methodology may be called for. For genes harbouring a 
few mutational hotspots, multiplex sequencing may represent a straightforward way of 
detection. To increase sensitivity, sections could be cut into several pieces, effectively 
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representing an intermediate method between single crypt sequencing and the bulk approach 
used for KRAS in chapter 5. For tumour suppressor genes exhibiting mutations along the entire 
length, immunohistochemical detection may still be the most suitable method. Alternatively, 
surrogate markers may be revisited. While attempts to use IHC detection of DUSP6 and p-
4EBP were not successful here, detection of upregulation of NOTUM by RNAScope® may act 
a reliable indicator of loss of APC, the most common alteration in CRC. In addition to gene loss 
and point mutation, copy number changes also need consideration. For this purpose, the recently 
developed iFISH, a DNA hybridisation method which promises to target an ever-expanding 
number of genomic loci, may be used (Gelali et al., 2019).  
Taken together, such studies will enable a comprehensive description of how key CRC driver 
mutations spread in the normal human colon. Comparing these mutant allele burdens to those 
found in tumours will aid in understanding the probability of conversion for different cancer 
drivers in the colon. For example, mutations that are very common in tumours but cannot be 
found in normal tissue could be indicative of certain transformation.  
6.4 Extrinsic factors 
Cancer is a disease caused by somatic mutations and it therefore makes sense that studies have 
so far focused on understanding mutation accumulation in normal tissues. To a large extent, 
this is thought to occur as part of normal ageing, whereby erroneous DNA replication generates 
mutations. However, mammalian tissues are not just a collection of isolated cells whose biology 
is entirely dictated by intrinsic processes. They are part of a multicellular organism and 
therefore heavily influenced by the physiological state of the cells in their immediate 
surroundings as well as the body as a whole and the environment it lives in. Cell extrinsic 
factors can heavily influence the state of tissues and the risk of resident cells progressing to 
cancer. There are in principle two ways in which extrinsic factors can affect the development 
of tumours: They can act as mutagens or they can generate a pro- or anti-tumorigenic milieu. 
Two classic examples for the former are UV radiation from the sun and carcinogens inhaled in 
air, which have the strongest effect on the exposed tissues – the skin and the lung. Indeed, the 
6.4 Extrinsic factors 161 
 
number of mutations found in sun exposed skin is considerably higher than in non-sun exposed 
skin (Yizhak et al., 2019). Cigarette smoke is thought to contain up to 250 carcinogens (Hussain 
et al., 2019). Apart from lung cancer, smoking is associated with a number of cancers including 
oesophageal, stomach, pancreas, kidney and bladder cancer (Hussain et al., 2019). Perhaps 
more intriguing and certainly more complex is the second way in which extrinsic factors can 
promote or hamper the development of cancer, namely by generating a pro-tumourigenic 
setting, within cells or the organism as a whole. Instead of directly causing mutations, these 
factors may increase the proliferation of cells leading to abnormal growths, alter the numbers 
of stem cells in tissues or influence the immune system such that it can more or less effectively 
eliminate cancerous cells. A compelling example for such a mechanism is HPV infection 
causing hyperproliferation in the human female cervix (Burd, 2003). The next sections will 
discuss pro-tumorigenic extrinsic factors in the intestine. 
6.4.1 Niche – stem cell interactions in CRC  
As discussed in the introduction, the self-renewal, pluripotency and proliferation of intestinal 
stem cells at the crypt base is heavily regulated by their niche. While this complex arrangement 
of cellular and extracellular components is key to maintenance of homeostasis as well as repair 
following injury, it can also play a key role in the development of cancer, thereby acting as an 
extrinsic factor. Early during tumourigenesis, the stroma is thought to be anti-tumourigenic, 
however, this changes as more alterations are acquired (de Visser, Eichten & Coussens, 2006). 
Additionally, transformation is associated with progressive loss of normal niche-dependency in 
ISCs (Fujii et al., 2016). Rather, tumour cells rely on a so-called tumour microenvironment, a 
combination of altered surrounding stroma and infiltrating immune cells, which then plays a 
key role in supporting tumour cell proliferation, survival and metastasis. Importantly, pro-
tumourigenic signalling is bidirectional, whereby stromal cells can be modulated by 
transformed epithelial cells and vice versa (Peddareddigari, Wang & Dubois, 2010). For 
example, in homeostasis hedgehog signalling provided by the epithelium regulates the stroma 
(Kosinski et al., 2010), while adenomatous polyps have recently been shown to secrete IL-33, 
which stimulates their niche (Maywald et al., 2015). More generally, cancer cells can release 
signals to activate so-called tumour-associated macrophages, which in turn secrete VEGF to 
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promote angiogenesis and facilitate epithelial-mesenchymal transition of epithelial cells, thus 
contributing to metastasis (Barbera-Guillem et al., 2002; Pollard, 2004; Green et al., 2009; 
Jedinak, Dudhgaonkar & Sliva, 2010). Equally, cancer-associated fibroblasts (CAFs), which 
are thought to arise from local tissue fibroblasts (Mueller et al., 2007), can produce Wnts to 
promote a cancer stem cell phenotype (Aizawa et al., 2019). Furthermore, CAFs at the tumour 
edge can set the stage for blood vessel generation and invasion of adenocarcinomas (Sivridis, 
Giatromanolaki & Koukourakis, 2005). In addition, cancer cells can instruct CAFs to produce 
metalloproteinases, which causes ECM remodelling and promotes invasion (Shay, Lynch & 
Fingleton, 2015). In summary, CRC progression is driven by a complex interplay between 
transformed epithelial cells and their tumour microenvironment.  
6.4.2 Colitis-associated CRC  
A key example for the potent tumour-promoting effect of extrinsic factors is the association 
between IBD, which is the umbrella term for the chronic inflammatory conditions ulcerative 
colitis and Crohn’s disease, and CRC. IBD is thought to result from aberrant immune responses 
to microflora triggered by various environmental insults in the context of susceptibility 
provided by the genetic background of the host (Strober, Fuss & Mannon, 2007). It is 
characterised by recurrent cycles of inflammation, ulceration and repair and associated with 
significantly increased risk for CRC (Eaden, Abrams & Mayberry, 2001; Canavan, Abrams & 
Mayberry, 2006), which in this scenario is termed colitis-associated CRC (CAC) (Feagins, 
Souza & Spechler, 2009). First studies into potential mechanisms were performed in mice, 
whereby it was found that a single injection of azoxymethane resulted in tumours when 
administered on a colitis background (Okayasu et al., 1996). Since then, investigation of human 
CAC tumours as well as mouse models have provided more insights into putative mechanisms. 
Importantly, while sporadic CRC is usually initiated by alterations in Wnt signalling, such as 
APC mutations, this is not the case for CAC (Terzić et al., 2010) Instead, chronic inflammation 
seems to drive the activation of Wnt target genes in the absence of APC mutations (Berg et al., 
1996; Oguma et al., 2008). In addition, chronic inflammation seems to cause DNA damage 
directly and indirectly, as inflammatory cells such as activated macrophages and neutrophils 
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are potent sources of damaging reactive oxygen species (ROS) and reactive nitrogen 
intermediates (RNI) (Meira et al., 2008; Westbrook et al., 2009). Furthermore, inflammatory 
cytokines may prime epithelial cells to ROS and RNI production (Goodman et al., 2004; Shaked 
et al., 2012). This inflammation-associated genotoxicity is exemplified by the observation of 
p53 mutations in inflamed but otherwise normal human mucosa (Kraus & Arber, 2009). 
Inflammatory signalling may also stimulate hyperproliferation of non-initiated stem cells, 
thereby increasing the risk of transformation as well as cause tumour-promoting epigenetic 
changes and inhibit apoptosis (Atreya & Neurath, 2008; Chiba, Marusawa & Ushijima, 2012; 
De Lerma Barbaro et al., 2014). Importantly, chronic inflammation also affects the stroma, 
whereby stromal cells react to immune cell-derived cytokines, which can generate a pro-
tumorigenic milieu (discussed above) (Fritsch et al., 1997; Lang et al., 2009; Owens & 
Simmons, 2013). This is exemplified by the finding that activation of intestinal stromal cells is 
sufficient to initiate intestinal neoplasia in a mouse model of Crohn’s disease (Roulis et al., 
2011). Finally, the repeated cycles of intestinal injury and repair (by crypt fission) that occur in 
colitis can favour the expansion of mutant clones, therefore causing field cancerisation, which 
promotes tumour initiation (Kuraishy, Karin & Grivennikov, 2011). 
In summary, while the accumulation of somatic mutations in epithelial (stem) cells is 
undoubtedly key to tumour initiation, the cells in their immediate surroundings can have a 
potent effect and may in some cases even initiate cancer in the absence of driver mutations. 
 
6.4.3 Other extrinsic factors influencing CRC 
6.4.3.1 The microbiome 
Importantly, IBD and CRC are both linked to alterations in the microbiome, which is the 
collection of over 100 billion bacteria found in the human intestine, the largest proportion of 
which resides in the colon (Drewes, Housseau & Sears, 2016; Chen, Pitmon & Wang, 2017). 
Interestingly, specific strains of bacteria can be associated with advanced colorectal adenomas 
and carcinomas (Zackular et al., 2013; Feng et al., 2015). Animal studies have revealed 
potential mechanisms of CRC promotion by the microbiome, which include modulation of the 
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host’s immune system, production of cancer-associated metabolites and release of genotoxic 
factors (Dahmus et al., 2018). 
6.4.3.2 Diet and obesity 
Red meat consumption, vitamin D deficiency, obesity and Western diet have all been tied to 
increased CRC risk in humans (Shaukat et al., 2017; Turner & Lloyd, 2017; Zheng et al., 2017; 
Bultman, 2018; McCullough et al., 2018). Mouse studies have shed some light on potential 
mechanisms. For high fat diet these may include increased numbers and tumorigenicity of stem 
cells as well as chronic inflammation, the potential effects of which were discussed above (van 
der Heijden et al., 2015; Beyaz et al., 2016). The haemoglobin in red meat is thought to cause 
DNA damage (Bastide, Pierre & Corpet, 2011), while vitamin D is thought to inhibit cell 
proliferation, an effect that was recently demonstrated in human organoids (Fernández-Barral 
et al., 2019). Interestingly, one study suggests that the tumour-promoting effect of high fat diet 
can be reduced in mice by walnut consumption, potentially by reducing systemic inflammation 
(Guan et al., 2018).  
6.4.4 Future directions for investigation of extrinsic factors 
Considering the (non-exhaustive) description of tumour-promoting interactions between 
epithelial cells and their stromal niche as well as the immune system given above, the work 
presented in this thesis took an integrationist approach, whereby potential effects associated 
with intercompartmental signalling between stem cells and the stroma were not investigated on 
a mechanistic level. The possibility that gene-specific mutations in epithelial cells, as observed 
for clonal marks, alter their environment which in turn affects stem cell dynamics, cannot be 
excluded. The absence of marked increases in immune infiltration around clonal patches is an 
indication that such mechanisms, if at play, may only be marginal. However, the subject 
requires more investigation. Importantly, our en face FFPE colon tissue does not represent a 
suitable system to study niche-epithelium interactions on a mechanistic level. First of all, a large 
fraction of the signalling occurs via soluble factors, which are not visualisable in this material. 
Furthermore, specific stromal cells can be found at distinct locations along the crypt axis 
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(Halpern et al., 2019), the study of which requires longitudinal sections. Therefore, a different 
system may be more suitable to investigate the effect of gene-specific mutations on the stroma 
or immune compartment. For example, organoids modified by CRISPR/Cas9 could be co-
cultured directly with cells of interest, seeded on a mesenchymal cell monolayer or interactions 
investigated indirectly in a transwell assay, all of which are published methods (Pastuła et al., 
2016; Pastuła & Marcinkiewicz, 2019).  
While mechanisms of stem cell-niche interplay may not be investigated on a mechanistic level 
with clonal marks, insights into how extrinsic (lifestyle) factors affect stem cell behaviour and 
mutation accumulation may be gained. Importantly, to date little is known about how extrinsic 
factors such as obesity, inflammation and an altered microbiome may affect intestinal stem cell 
behaviour and therefore promote cancer in humans. For lifestyle factors such as BMI and 
smoking, the current patient cohort could be stratified according to these variables. For 
inflammatory conditions as well as microbiome studies, a cohort of patients would need to be 
recruited. Using the neutral clonal marks mPAS, MAOA and NONO the association of different 
extrinsic factors with changes in intestinal stem cell dynamics could be investigated. This 
includes intra-crypt dynamics as well as fission and fusion. Considering all marks, significantly 
higher clone frequencies may be indicative of changes in mutation rates. Elevated rates of 
fission and fusion may provide a mechanism for accelerated field cancerisation. Of note, one 
well-established such connection exists between increased rates of crypt fission and colitis 
(Cheng et al., 1986). This may contribute to the extensive field cancerisation found in patients 
with Crohn’s Ileocolitis. 
Importantly, the effects of extrinsic factors on stem cell behaviours may be subtle. Considering 
the spread of human data, they may only be detectable in very large patient cohorts of several 
hundred people. The Winton laboratory currently holds anonymised clinical data for over 150 
individuals in the patient cohort and is acquiring new informative samples at a rate of 
approximately 100 per year, so analysis of stratified patient data will be possible within the next 
few years. 
As an alternative approach to investigating the effect of extrinsic factors on intestinal stem cell 
dynamics, we are using the clonal marks MAOA, HDAC6 and STAG2 in FFPE colonic tissue 
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sections from a colony of green monkeys (Chlorocebus aethiops) in St. Kitt’s and Nevis. The 
animals are genetically outbred but all adhere to the same lifestyle. Therefore, comparison of 
the spread of human data with that of monkey data may enable quantification of the individual 
contribution of intrinsic (DNA replication errors) and extrinsic (lifestyle) factors to mutation 
accumulation in the colon. 
 
Figure 6.1 Clonal marks can be used in green monkey tissue. 
Representative images of IHC on green monkey FFPE colonic tissue sections. 
(A) Two adjacent MAOA-negative crypts in en face section. 
(B) HDAC6-negative crypt in en face section. 
(C) Two adjacent STAG2-negative crypts in obliquely sectioned tissue. 
 
Taken together, these studies will start to reveal the individual contributions of different 
lifestyle factors on human intestinal stem cell behaviour, which will aid in understanding their 
contribution to cancer development.  
 
6.5 Cancer prevention  
A thorough understanding of the mechanisms of lateral spread of mutations as well as the 
contribution of different extrinsic factors to mutation accumulation and expansion may inform 
cancer prevention strategies. A number of evidence-based recommendations have to varying 
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extents already reached the general public including the beneficial effects of reducing red meat 
consumption and maintaining a healthy weight. Research may also identify the most beneficial 
timing of specific chemopreventive interventions. For example, a drug that reduces crypt fission 
may be given to individuals at a certain age such that their theoretical onset age of CRC is 
shifted beyond natural human lifespan.  
Importantly, all these endeavours are counteracted by the inevitable imperfection of DNA 
replication. Even in the healthiest of individuals, somatic mutations accumulate with age. It 
may be possible to reduce their acquisition and spread by lifestyle modification and 
interventions, but not entirely prevent it. In a sense, this can be seen as the cost of evolution, as 
it is based on DNA replication errors. 
This thesis started with a description of the beginning of life with the most potent of stem cells, 
the zygote. The work presented in the results chapters contributes to a deeper understanding of 
the processes that may prevent as well as accelerate mutation accumulation in the human 
colonic epithelium. Now, by discussing the potential impact of extrinsic factors and the 
inevitability of mutation accumulation, the work has been put into a wider context. I would like 
to conclude by adapting a famous quote from 20th century evolutionary biologist Theodosius 
Dobzhansky: Stem cell biology makes a lot more sense in the light of evolution. 
 
  
 References 
Affolter, M., Bellusci, S., Itoh, N., Shilo, B., Thiery, J.-P., & Werb, Z. (2003) ‘Tube or Not 
Tube: Remodeling Epithelial Tissues by Branching Morphogenesis’, Developmental Cell, 
4(1), pp. 11–18. 
Agger, K., Cloos, P. A. C., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., 
Canaani, E., Salcini, A. E., & Helin, K. (2007) ‘UTX and JMJD3 are histone H3K27 
demethylases involved in HOX gene regulation and development’, Nature, 449, p. 731. 
Ahmad, M. K., Abdollah, N. A., Shafie, N. H., Yusof, N. M., & Razak, S. R. A. (2018) ‘Dual-
specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical 
relevance in cancer’, Cancer biology & medicine, 15(1), pp. 14–28. 
Ahuja, N., Li, Q., Mohan, A. L., Baylin, S. B., & Issa, J.-P. J. (1998) ‘Aging and DNA 
Methylation in Colorectal Mucosa and Cancer’, Cancer Research, 58(23), pp. 5489–5494. 
Aizawa, T., Karasawa, H., Funayama, R., Shirota, M., Suzuki, T., Maeda, S., Suzuki, H., 
Yamamura, A., Naitoh, T., Nakayama, K., & Unno, M. (2019) ‘Cancer-associated fibroblasts 
secrete Wnt2 to promote cancer progression in colorectal cancer’, Cancer medicine. 
2019/08/29. John Wiley and Sons Inc., 8(14), pp. 6370–6382. 
Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., Salmena, 
L., Sampieri, K., Haveman, W. J., Brogi, E., Richardson, A. L., Zhang, J., & Pandolfi, P. P. 
(2010) ‘Subtle variations in Pten dose determine cancer susceptibility’, Nature genetics, 
42(5), pp. 454–458. 
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J., & Vallance, B. A. (2018) 
‘The Intestinal Epithelium: Central Coordinator of Mucosal Immunity’, Trends in 
Immunology, 39(9), pp. 677–696. 
170 References 
 
 
Altmann, G. G. (1983) ‘Morphological observations on mucus-secreting nongoblet cells in 
the deep crypts of the rat ascending colon.’, American Journal of Anatomy, 167(1), pp. 95–
117. 
Aoyagi, S. & Archer, T. K. (2005) ‘Modulating molecular chaperone Hsp90 functions 
through reversible acetylation’, Trends in Cell Biology, 15(11), pp. 565–567. 
Araki, K., Ogata, T., Kobayashi, M., & Yatani, R. (1995) ‘A morphological study on the 
histogenesis of human colorectal hyperplastic polyps’, Gastroenterology, 109(5), pp. 1468–
1474. 
Arming, S., Wipfler, D., Mayr, J., Merling, A., Vilas, U., Schauer, R., Schwartz-Albiez, R., & 
Vlasak, R. (2011) ‘The human Cas1 protein: A sialic acid-specific O-acetyltransferase?’, 
Glycobiology , 21(5), pp. 553–564. 
Atreya, R. & Neurath, M. (2008) ‘Signaling molecules: the pathogenic role of the IL-
6/STAT3 trans signaling pathway in intestinal inflammation and in colonic cancer.’, Current 
Drug Targets, 9(5), pp. 369–374. 
Baker, A.-M., Cereser, B., Melton, S., Fletcher, A. G., Rodriguez-Justo, M., Tadrous, P. J., 
Humphries, A., Elia, G., McDonald, S. A. C., Wright, N. A., Simons, B. D., Jansen, M., & 
Graham, T. A. (2014) ‘Quantification of Crypt and Stem Cell Evolution in the Normal and 
Neoplastic Human Colon’, Cell Reports, 8(4), pp. 940–947. 
Baker, A.-M., Huang, W., Wang, X.-M. M., Jansen, M., Ma, X.-J., Kim, J., Anderson, C. M., 
Wu, X., Pan, L., Su, N., Luo, Y., Domingo, E., Heide, T., Sottoriva, A., Lewis, A., Beggs, A. 
D., Wright, N. A., Rodriguez-Justo, M., Park, E., Tomlinson, I., & Graham, T. A. (2017) 
‘Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal 
evolution’, Nature Communications, 8(1), p. 1998. 
Baker, A.-M., Gabbutt, C., Williams, M. J., Cereser, B., Jawad, N., Rodriguez-Justo, M., 
Jansen, M., Barnes, C. P., Simons, B. D., McDonald, S. A. C., Graham, T. A., & Wright, N. 
A. (2019) ‘Crypt fusion as a homeostatic mechanism in the human colon’, Gut, p. gutjnl-
References 171 
 
2018-317540. 
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V, 
Hamilton, S., & Vogelstein, B. (1990) ‘p53 Gene Mutations Occur in Combination with 17p 
Allelic Deletions as Late Events in Colorectal Tumorigenesis’, Cancer Research, 50(23), pp. 
7717–7722. 
Balbás-Martínez, C., Sagrera, A., Carrillo-de-Santa-Pau, E., Earl, J., Márquez, M., Vazquez, 
M., Lapi, E., Castro-Giner, F., Beltran, S., Bayés, M., Carrato, A., Cigudosa, J. C., 
Domínguez, O., Gut, M., Herranz, J., Juanpere, N., Kogevinas, M., Langa, X., López-
Knowles, E., Lorente, J. A., Lloreta, J., Pisano, D. G., Richart, L., Rico, D., Salgado, R. N., 
Tardón, A., Chanock, S., Heath, S., Valencia, A., Losada, A., Gut, I., Malats, N., & Real, F. 
X. (2013) ‘Recurrent inactivation of STAG2 in bladder cancer is not associated with 
aneuploidy’, Nature genetics, 45(12), pp. 1464–1469. 
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. 
D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., James, J. A., Salto-Tellez, M., & 
Hamilton, P. W. (2017) ‘QuPath: Open source software for digital pathology image analysis’, 
Scientific Reports, 7(1), p. 16878. 
Barbera-Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C. R., & Sampsel, J. W. (2002) 
‘Vascular Endothelial Growth Factor Secretion by Tumor-infiltrating Macrophages 
Essentially Supports Tumor Angiogenesis, and IgG Immune Complexes Potentiate the 
Process’, Cancer Research, 62(23), pp. 7042 LP – 7049. 
Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., 
Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., & Clevers, H. (2007) ‘Identification of 
stem cells in small intestine and colon by marker gene Lgr5’, Nature, 449(7165), pp. 1003–
1007. 
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, 
M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2008) ‘Crypt stem cells as 
the cells-of-origin of intestinal cancer’, Nature, 457(7229), pp. 608–611. 
Bastide, N. M., Pierre, F. H. F., & Corpet, D. E. (2011) ‘Heme Iron from Meat and Risk of 
172 References 
 
 
Colorectal Cancer: A Meta-analysis and a Review of the Mechanisms Involved’, Cancer 
Prevention Research, 4(2), pp. 177 LP – 184. 
Behjati, S., Huch, M., van Boxtel, R., Karthaus, W., Wedge, D. C., Tamuri, A. U., 
Martincorena, I., Petljak, M., Alexandrov, L. B., Gundem, G., Tarpey, P. S., Roerink, S., 
Blokker, J., Maddison, M., Mudie, L., Robinson, B., Nik-Zainal, S., Campbell, P., Goldman, 
N., van de Wetering, M., Cuppen, E., Clevers, H., & Stratton, M. R. (2014) ‘Genome 
sequencing of normal cells reveals developmental lineages and mutational processes’, Nature, 
513(7518), pp. 422–425. 
Berg, D. J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, 
L., Leach, M. W., & Rennick, D. (1996) ‘Enterocolitis and colon cancer in interleukin-10-
deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like 
responses’, The Journal of clinical investigation, 98(4), pp. 1010–1020. 
Bergmann, O., Spalding, K. L., & Frisén, J. (2015) ‘Adult Neurogenesis in Humans’, Cold 
Spring Harbor Perspectives in Biology , 7(7). 
Bertos, N. R., Gilquin, B., Chan, G. K. T., Yen, T. J., Khochbin, S., & Yang, X.-J. (2004) 
‘Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in 
Cytoplasmic Retention’, Journal of Biological Chemistry , 279(46), pp. 48246–48254. 
Betschinger, J. & Knoblich, J. A. (2004) ‘Dare to Be Different: Asymmetric Cell Division in 
Drosophila, C. elegans and Vertebrates’, Current Biology, 14(16), pp. R674–R685. 
Beyaz, S., Mana, M. D., Roper, J., Kedrin, D., Saadatpour, A., Hong, S.-J., Bauer-Rowe, K. 
E., Xifaras, M. E., Akkad, A., Arias, E., Pinello, L., Katz, Y., Shinagare, S., Abu-Remaileh, 
M., Mihaylova, M. M., Lamming, D. W., Dogum, R., Guo, G., Bell, G. W., Selig, M., 
Nielsen, G. P., Gupta, N., Ferrone, C. R., Deshpande, V., Yuan, G.-C., Orkin, S. H., Sabatini, 
D. M., & Yilmaz, Ö. H. (2016) ‘High-fat diet enhances stemness and tumorigenicity of 
intestinal progenitors’, Nature, 531(7592), pp. 53–58. 
Bird, R. P. (1987) ‘Observation and quantification of aberrant crypts in the murine colon 
References 173 
 
treated with a colon carcinogen: Preliminary findings’, Cancer Letters, 37(2), pp. 147–151. 
Bjerknes, M. & Cheng, H. (1999) ‘Clonal analysis of mouse intestinal epithelial progenitors’, 
Gastroenterology, 116(1), pp. 7–14. 
Blanpain, C. & Fuchs, E. (2006) ‘Epidermal stem cells of the skin’, Annual review of cell and 
developmental biology, 22, pp. 339–373. 
Blokzijl, F., de Ligt, J., Jager, M., Sasselli, V., Roerink, S., Sasaki, N., Huch, M., Boymans, 
S., Kuijk, E., Prins, P., Nijman, I. J., Martincorena, I., Mokry, M., Wiegerinck, C. L., 
Middendorp, S., Sato, T., Schwank, G., Nieuwenhuis, E. E. S., Verstegen, M. M. A., van der 
Laan, L. J. W., de Jonge, J., IJzermans, J. N. M., Vries, R. G., van de Wetering, M., Stratton, 
M. R., Clevers, H., Cuppen, E., & van Boxtel, R. (2016) ‘Tissue-specific mutation 
accumulation in human adult stem cells during life’, Nature, 538(7624), pp. 260–264. 
Bond, C. S. & Fox, A. H. (2009) ‘Paraspeckles: nuclear bodies built on long noncoding 
RNA’, The Journal of Cell Biology, 186(5), pp. 637–644. 
Borras, E., San Lucas, F. A., Chang, K., Zhou, R., Masand, G., Fowler, J., Mork, M. E., You, 
Y. N., Taggart, M. W., McAllister, F., Jones, D. A., Davies, G. E., Edelmann, W., Ehli, E. A., 
Lynch, P. M., Hawk, E. T., Capella, G., Scheet, P., & Vilar, E. (2016) ‘Genomic Landscape 
of Colorectal Mucosa and Adenomas’, Cancer prevention research (Philadelphia, Pa.), 9(6), 
pp. 417–427. 
Bortolato, M., Chen, K., & Shih, J. C. (2008) ‘Monoamine oxidase inactivation: From 
pathophysiology to therapeutics’, Advanced Drug Delivery Reviews, 60(13–14), pp. 1527–
1533. 
Brannon, A. R., Vakiani, E., Sylvester, B. E., Scott, S. N., McDermott, G., Shah, R. H., 
Kania, K., Viale, A., Oschwald, D. M., Vacic, V., Emde, A.-K., Cercek, A., Yaeger, R., 
Kemeny, N. E., Saltz, L. B., Shia, J., D’Angelica, M. I., Weiser, M. R., Solit, D. B., & Berger, 
M. F. (2014) ‘Comparative sequencing analysis reveals high genomic concordance between 
matched primary and metastatic colorectal cancer lesions’, Genome biology, 15(8), p. 454. 
Brosh, R. & Rotter, V. (2009) ‘When mutants gain new powers: news from the mutant p53 
174 References 
 
 
field’, Nature Reviews Cancer, 9, p. 701. 
Bruens, L., Ellenbroek, S. I. J., van Rheenen, J., & Snippert, H. J. (2017) ‘In Vivo Imaging 
Reveals Existence of Crypt Fission and Fusion in Adult Mouse Intestine’, Gastroenterology, 
153(3), pp. 674-677.e3. 
Buczacki, S. J. A., Zecchini, H. I., Nicholson, A. M., Russell, R., Vermeulen, L., Kemp, R., & 
Winton, D. J. (2013) ‘Intestinal label-retaining cells are secretory precursors expressing 
Lgr5’, Nature, 495(7439), pp. 65–69. 
Buffet, C., Hecale-Perlemoine, K., Bricaire, L., Dumont, F., Baudry, C., Tissier, F., Bertherat, 
J., Cochand-Priollet, B., Raffin-Sanson, M.-L., Cormier, F., & Groussin, L. (2017) ‘DUSP5 
and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling 
activation in BRAF mutated thyroid cancers’, PloS one, 12(9), pp. e0184861–e0184861. 
Bultman, S. J. (2018) ‘A Reversible Epigenetic Link between Obesity and Cancer Risk’, 
Trends in Endocrinology & Metabolism, 29(8), pp. 529–531. 
Burd, E. M. (2003) ‘Human papillomavirus and cervical cancer’, Clinical microbiology 
reviews, 16(1), pp. 1–17. 
Bussey, H. (1975) ‘Familial polyposis coli: Family studies, histopathology, differential 
diagnosis and results of treatment’, in. Baltimore: Johns Hopkins University Press, pp. 47–49. 
Cairnie, A. B. & Millen, B. H. (1975) ‘Fission of crypts in the small intestine of the irradiated 
mouse.’, Cell Tissue Kinet., 8(2), pp. 189–96. 
Campbell, F., Appleton, M. A. C., Fuller, C. E., Greeff, M. P., Hallgrimsson, J., Katoh, R., 
Ng, O. L. I., Satir, A., Williams, G. T., & Williams, E. D. (1994) ‘Racial variation in the O-
acetylation phenotype of human colonic mucosa’, The Journal of Pathology, 174(3), pp. 169–
174. 
Campbell, F., Geraghty, J. M., Appleton, M. A. C., Williams, E. D., & Williams, G. T. (1998) 
‘Increased stem cell somatic mutation in the non-neoplastic colorectal mucosa of patients with 
References 175 
 
familial adenomatous polyposis’, Human Pathology, 29(12), pp. 1531–1535. 
Campos, F. G. (2014) ‘Surgical treatment of familial adenomatous polyposis: dilemmas and 
current recommendations’, World journal of gastroenterology, 20(44), pp. 16620–16629. 
Canavan, C., Abrams, K. R., & Mayberry, J. (2006) ‘Meta-analysis: colorectal and small 
bowel cancer risk in patients with Crohn’s disease’, Alimentary Pharmacology & 
Therapeutics. John Wiley & Sons, Ltd (10.1111), 23(8), pp. 1097–1104. 
Cancer Research UK (2015) Cancer Research UK. available 
at:https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/bowel-cancer2015. 
Canudas, S. & Smith, S. (2009) ‘Differential regulation of telomere and centromere cohesion 
by the Scc3 homologues SA1 and SA2, respectively, in human cells’, The Journal of Cell 
Biology, 187(2), pp. 165–173. 
Carlston, C. M., Bleyl, S. B., Andrews, A., Meyers, L., Brown, S., Bayrak-Toydemir, P., 
Bale, J. F., & Botto, L. D. (2019) ‘Expanding the genetic and clinical spectrum of the NONO-
associated X-linked intellectual disability syndrome’, American Journal of Medical Genetics 
Part A, 179(5), pp. 792–796. 
Carpenter, B., Gelman, A., Hoffman, M. D., Lee, D., Goodrich, B., Betancourt, M., Brubaker, 
M., Guo, J., Li, P., & Riddell, A. (2017) ‘Stan: A Probabilistic Programming Language’, 
Journal of Statistical Software; Vol 1, Issue 1 (2017)  . 
Carrel, L., Cottle, A. A., Goglin, K. C., & Willard, H. F. (1999) ‘A first-generation X-
inactivation profile of the human X chromosome’, Proceedings of the National Academy of 
Sciences, 96(25), pp. 14440–14444. 
Chen, J., Pitmon, E., & Wang, K. (2017) ‘Microbiome, inflammation and colorectal cancer’, 
Seminars in Immunology, 32, pp. 43–53. 
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, 
R., Liu, Z. Y., Won, H. H., Scott, S. N., Brannon, A. R., O’Reilly, C., Sadowska, J., 
Casanova, J., Yannes, A., Hechtman, J. F., Yao, J., Song, W., Ross, D. S., Oultache, A., 
176 References 
 
 
Dogan, S., Borsu, L., Hameed, M., Nafa, K., Arcila, M. E., Ladanyi, M., & Berger, M. F. 
(2015) ‘Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer 
Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing 
Clinical Assay for Solid Tumor Molecular Oncology’, The Journal of molecular diagnostics : 
JMD, 17(3), pp. 251–264. 
Cheng, H., Bjerknes, M., Amar, J., & Gardiner, G. (1986) ‘Crypt production in normal and 
diseased human colonic epithelium’, The Anatomical Record, 216(1), pp. 44–48. 
Cheng, H. & Leblond, C. P. (1974a) ‘Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four 
epithelial cell types.’, Am J Anat., 141(4), pp. 537–561. 
Cheng, H. & Leblond, C. P. (1974b) ‘Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine I. Columnar cell’, American Journal of 
Anatomy, 141(4), pp. 461–479. 
Cheng, H., McCulloch, C., & Bjerknes, M. (1986) ‘Effects of 30% intestinal resection on 
whole population cell kinetics of mouse intestinal epithelium’, The Anatomical Record, 
215(1), pp. 35–41. 
Chiba, T., Marusawa, H., & Ushijima, T. (2012) ‘Inflammation-Associated Cancer 
Development in Digestive Organs: Mechanisms and Roles for Genetic and Epigenetic 
Modulation’, Gastroenterology. Elsevier, 143(3), pp. 550–563. 
Cho, Y.-W., Hong, T., Hong, S., Guo, H., Yu, H., Kim, D., Guszczynski, T., Dressler, G. R., 
Copeland, T. D., Kalkum, M., & Ge, K. (2007) ‘PTIP associates with MLL3- and MLL4-
containing histone H3 lysine 4 methyltransferase complex’, The Journal of biological 
chemistry, 282(28), pp. 20395–20406. 
Clair, W. H. S. & Osborne, J. W. (1986) ‘Crypt fission in the small intestine of the rat’, The 
British Journal of Cancer. Supplement, 7, pp. 39–41. 
Clarke, R. M. (1972) ‘The effect of growth and of fasting on the number of villi and crypts in 
References 177 
 
the small intestine of the albino rat’, Journal of anatomy, 112(Pt 1), pp. 27–33. 
Clevers, H., Loh, K. M., & Nusse, R. (2014) ‘An integral program for tissue renewal and 
regeneration: Wnt signaling and stem cell control’, Science, 346(6205), p. 1248012. 
Cummins, A. G., Catto-Smith, A. G., Cameron, D. J., Couper, R. T., Davidson, G. P., Day, A. 
S., Hammond, P. D., Moore, D. J., & Thompson, F. M. (2008) ‘Crypt Fission Peaks Early 
During Infancy and Crypt Hyperplasia Broadly Peaks During Infancy and Childhood in the 
Small Intestine of Humans’, Journal of Pediatric Gastroenterology and Nutrition, 47(2), pp. 
153–157. 
Curtius, K., Wright, N. A., & Graham, T. A. (2017) ‘An evolutionary perspective on field 
cancerization’, Nature Reviews Cancer, 18, p. 19. 
Dahmus, J. D., Kotler, D. L., Kastenberg, D. M., & Kistler, C. A. (2018) ‘The gut 
microbiome and colorectal cancer: a review of bacterial pathogenesis’, Journal of 
gastrointestinal oncology, 9(4), pp. 769–777. 
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) ‘Breast cancer intrinsic 
subtype classification, clinical use and future trends’, American journal of cancer research, 
5(10), pp. 2929–2943. 
Daniloski, Z. & Smith, S. (2017) ‘Loss of Tumor Suppressor STAG2 Promotes Telomere 
Recombination and Extends the Replicative Lifespan of Normal Human Cells’, Cancer 
research, 77(20), pp. 5530–5542. 
Deakin, N. O. & Turner, C. E. (2014) ‘Paxillin inhibits HDAC6 to regulate microtubule 
acetylation, Golgi structure, and polarized migration’, The Journal of cell biology, 206(3), pp. 
395–413. 
Degirmenci, B., Valenta, T., Dimitrieva, S., Hausmann, G., & Basler, K. (2018) ‘GLI1-
expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells’, 
Nature, 558(7710), pp. 449–453. 
Dieterle, C. P., Conzelmann, M., Linnemann, U., & Berger, M. R. (2004) ‘Detection of 
Isolated Tumor Cells by Polymerase Chain Reaction-Restriction Fragment Length 
178 References 
 
 
Polymorphism for K-ras Mutations in Tissue Samples of 199 Colorectal Cancer Patients’, 
Clinical Cancer Research, 10(2), pp. 641–650. 
Dietrich, D., Uhl, B., Sailer, V., Holmes, E. E., Jung, M., Meller, S., & Kristiansen, G. (2013) 
‘Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-
Embedded Tissues by Overcoming PCR Inhibition’, PLOS ONE, 8(10), p. e77771. 
Ding, G., Liu, H.-D., Huang, Q., Liang, H.-X., Ding, Z.-H., Liao, Z.-J., & Huang, G. (2013) 
‘HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional 
activity’, FEBS Letters, 587(7), pp. 880–886. 
Do, H. & Dobrovic, A. (2015) ‘Sequence Artifacts in DNA from Formalin-Fixed Tissues: 
Causes and Strategies for Minimization’, Clinical Chemistry, 61(1), pp. 64–71. 
Drewes, J. L., Housseau, F., & Sears, C. L. (2016) ‘Sporadic colorectal cancer: microbial 
contributors to disease prevention, development and therapy’, British Journal Of Cancer, 
115(3), pp. 273–280. 
Dunford, A., Weinstock, D. M., Savova, V., Schumacher, S. E., Cleary, J. P., Yoda, A., 
Sullivan, T. J., Hess, J. M., Gimelbrant, A. A., Beroukhim, R., Lawrence, M. S., Getz, G., & 
Lane, A. A. (2017) ‘Tumor suppressor genes that escape from X-inactivation contribute to 
cancer sex bias’, Nature genetics, 49(1), pp. 10–16. 
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) ‘The risk of colorectal cancer in 
ulcerative colitis: a meta-analysis’, Gut, 48(4), pp. 526–535. 
Eberle, F. C., Hanson, J. C., Killian, J. K., Wei, L., Ylaya, K., Hewitt, S. M., Jaffe, E. S., 
Emmert-Buck, M. R., & Rodriguez-Canales, J. (2010) ‘Immunoguided Laser Assisted 
Microdissection Techniques for DNA Methylation Analysis of Archival Tissue Specimens’, 
The Journal of Molecular Diagnostics : JMD, 12(4), pp. 394–401. 
Ekerot, M., Stavridis, M. P., Delavaine, L., Mitchell, M. P., Staples, C., Owens, D. M., 
Keenan, I. D., Dickinson, R. J., Storey, K. G., & Keyse, S. M. (2008) ‘Negative-feedback 
regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets 
References 179 
 
factor binding to a conserved site within the DUSP6/MKP-3 gene promoter’, The 
Biochemical journal, 412(2), pp. 287–298. 
Ellegren, H. (2004) ‘Microsatellites: simple sequences with complex evolution’, Nature 
Reviews Genetics, 5(6), pp. 435–445. 
Emmert-Buck, M. R., Bonner, R. F., Smith, P. D., Chuaqui, R. F., Zhuang, Z., Goldstein, S. 
R., Weiss, R. A., & Liotta, L. A. (1996) ‘Laser Capture Microdissection’, Science, 274(5289), 
pp. 998–1001. 
van Es, J. H., Sato, T., van de Wetering, M., Lyubimova, A., Yee Nee, A. N., Gregorieff, A., 
Sasaki, N., Zeinstra, L., van den Born, M., Korving, J., Martens, A. C. M., Barker, N., van 
Oudenaarden, A., & Clevers, H. (2012) ‘Dll1+ secretory progenitor cells revert to stem cells 
upon crypt damage’, Nat Cell Biol, 14(10), pp. 1099–1104. 
Espina, V., Wulfkuhle, J. D., Calvert, V. S., VanMeter, A., Zhou, W., Coukos, G., Geho, D. 
H., Petricoin, E. F., & Liotta, L. A. (2006) ‘Laser-capture microdissection’, Nature Protocols, 
1(2), pp. 586–603. 
Evans, M. J. & Kaufman, M. H. (1981) ‘Establishment in culture of pluripotential cells from 
mouse embryos’, Nature, 292(5819), pp. 154–156. 
Farin, H. F., Jordens, I., Mosa, M. H., Basak, O., Korving, J., Tauriello, D. V. F., de Punder, 
K., Angers, S., Peters, P. J., Maurice, M. M., & Clevers, H. (2016) ‘Visualization of a short-
range Wnt gradient in the intestinal stem-cell niche’, Nature, 530(7590), pp. 340–343. 
Feagins, L. A., Souza, R. F., & Spechler, S. J. (2009) ‘Carcinogenesis in IBD: potential 
targets for the prevention of colorectal cancer’, Nature Reviews Gastroenterology & 
Hepatology, 6(5), pp. 297–305. 
Fearon, E. R. & Vogelstein, B. (1990) ‘A genetic model for colorectal tumorigenesis’, Cell, 
61(5), pp. 759–767. 
Feil, R., Brocard, J., Mascrez, B., LeMeur, M., Metzger, D., & Chambon, P. (1996) ‘Ligand-
activated site-specific recombination in mice’, Proceedings of the National Academy of 
Sciences of the United States of America, 93(20), pp. 10887–10890. 
180 References 
 
 
Feng, Q., Liang, S., Jia, H., Stadlmayr, A., Tang, L., Lan, Z., Zhang, D., Xia, H., Xu, 
Xiaoying, Jie, Z., Su, L., Li, Xiaoping, Li, Xin, Li, J., Xiao, L., Huber-Schönauer, U., 
Niederseer, D., Xu, Xun, Al-Aama, J. Y., Yang, H., Wang, Jian, Kristiansen, K., Arumugam, 
M., Tilg, H., Datz, C., & Wang, Jun (2015) ‘Gut microbiome development along the 
colorectal adenoma–carcinoma sequence’, Nature Communications, 6, p. 6528. 
Feng, Y., Bommer, G. T., Zhao, J., Green, M., Sands, E., Zhai, Y., Brown, K., Burberry, A., 
Cho, K. R., & Fearon, E. R. (2011) ‘Mutant KRAS promotes hyperplasia and alters 
differentiation in the colon epithelium but does not expand the presumptive stem cell pool’, 
Gastroenterology, 141(3), pp. 1003-1013.e10. 
Fernández-Barral, A., Costales-Carrera, A., Buira, S. P., Jung, P., Ferrer-Mayorga, G., 
Larriba, M. J., Bustamante-Madrid, P., Domínguez, O., Real, F. X., Guerra-Pastrián, L., 
Lafarga, M., García-Olmo, D., Cantero, R., Del Peso, L., Batlle, E., Rojo, F., Muñoz, A., & 
Barbáchano, A. (2019) ‘Vitamin D differentially regulates colon stem cells in patient-derived 
normal and tumor organoids’, The FEBS Journal. John Wiley & Sons, Ltd (10.1111), 
n/a(n/a). 
Fevr, T., Robine, S., Louvard, D., & Huelsken, J. (2007) ‘Wnt/β-Catenin Is Essential for 
Intestinal Homeostasis and Maintenance of Intestinal Stem Cells’, Molecular and Cellular 
Biology, 27(21), pp. 7551–7559. 
Fox, A. H., Lam, Y. W., Leung, A. K. L., Lyon, C. E., Andersen, J., Mann, M., & Lamond, A. 
I. (2002) ‘Paraspeckles: A Novel Nuclear Domain’, Current Biology, 12(1), pp. 13–25. 
Fritsch, C., Simon-Assmann, P., Kedinger, M., & Evans, G. S. (1997) ‘Cytokines modulate 
fibroblast phenotype and epithelial-stroma interactions in rat intestine’, Gastroenterology, 
112(3), pp. 826–838. 
Frumkin, D., Wasserstrom, A., Kaplan, S., Feige, U., & Shapiro, E. (2005) ‘Genomic 
variability within an organism exposes its cell lineage tree’, PLoS computational biology, 
1(5), pp. e50–e50. 
References 181 
 
Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., 
Toshimitsu, K., Nakazato, Y., Kawasaki, K., Uraoka, T., Watanabe, T., Kanai, T., & Sato, T. 
(2016) ‘A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche 
Factor Requirements during Tumorigenesis’, Cell Stem Cell, 18(6), pp. 827–838. 
Fuller, C. E., Davies, R. P., Williams, G. T., & Williams, E. D. (1990) ‘Crypt restricted 
heterogeneity of goblet cell mucus glycoprotein in histologically normal human colonic 
mucosa: a potential marker of somatic mutation.’, British Journal of Cancer, 61(3), pp. 382–
384. 
Fürthauer, M. & González-Gaitán, M. (2009) ‘Endocytosis, asymmetric cell division, stem 
cells and cancer: Unus pro omnibus, omnes pro uno’, Molecular Oncology, 3(4), pp. 339–
353. 
Galandiuk, S., Rodriguez-Justo, M., Jeffery, R., Nicholson, A. M., Cheng, Y., Oukrif, D., 
Elia, G., Leedham, S. J., McDonald, S. A. C., Wright, N. A., & Graham, T. A. (2012) ‘Field 
cancerization in the intestinal epithelium of patients with Crohn’s ileocolitis’, 
Gastroenterology, 142(4), pp. 855-864.e8. 
García, J. M., Silva, J., Peña, C., Garcia, V., Rodríguez, R., Cruz, M. A., Cantos, B., 
Provencio, M., España, P., & Bonilla, F. (2004) ‘Promoter methylation of the PTEN gene is a 
common molecular change in breast cancer’, Genes, Chromosomes and Cancer, 41(2), pp. 
117–124. 
Garcia, S. B., Park, H. S., Novelli, M., & Wright, N. A. (1999) ‘Field cancerization, clonality, 
and epithelial stem cells: the spread of mutated clones in epithelial sheets’, The Journal of 
Pathology, 187(1), pp. 61–81. 
Gelali, E., Girelli, G., Matsumoto, M., Wernersson, E., Custodio, J., Mota, A., Schweitzer, 
M., Ferenc, K., Li, X., Mirzazadeh, R., Agostini, F., Schell, J. P., Lanner, F., Crosetto, N., & 
Bienko, M. (2019) ‘iFISH is a publically available resource enabling versatile DNA FISH to 
study genome architecture’, Nature Communications, 10(1), p. 1636. 
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., 
Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, 
182 References 
 
 
M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., 
Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A. (2014) ‘Clonal hematopoiesis 
and blood-cancer risk inferred from blood DNA sequence’, The New England journal of 
medicine, 371(26), pp. 2477–2487. 
Gerbe, F., van Es, J. H., Makrini, L., Brulin, B., Mellitzer, G., Robine, S., Romagnolo, B., 
Shroyer, N. F., Bourgaux, J.-F., Pignodel, C., Clevers, H., & Jay, P. (2011) ‘Distinct ATOH1 
and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal 
epithelium’, The Journal of Cell Biology , 192(5), pp. 767–780. 
Ghosh, S., Gupta, B., Verma, P., Vishnubathla, S., Pal, S., Dash, N. R., Gupta, S. D., & Das, 
P. (2018) ‘Topographic, histological and molecular study of aberrant crypt foci identified in 
human colon in different clinical groups’, Intestinal research. 2018/01/18. Korean 
Association for the Study of Intestinal Diseases, 16(1), pp. 116–125. 
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, 
Y., Amin-Mansour, A., Yamauchi, M., Sukawa, Y., Stewart, C., Rosenberg, M., Mima, K., 
Inamura, K., Nosho, K., Nowak, J. A., Lawrence, M. S., Giovannucci, E. L., Chan, A. T., Ng, 
K., Meyerhardt, J. A., Van Allen, E. M., Getz, G., Gabriel, S. B., Lander, E. S., Wu, C. J., 
Fuchs, C. S., Ogino, S., & Garraway, L. A. (2016) ‘Genomic Correlates of Immune-Cell 
Infiltrates in Colorectal Carcinoma’, Cell Reports, 17(4), p. 1206. 
Gilbert, S. (2000) ‘Early Mammalian Development’, in Developmental Biology. 6th editio. 
Sunderland (MA): Sinauer Associates. 
Gillooly, J. F., Hein, A., & Damiani, R. (2015) ‘Nuclear DNA Content Varies with Cell Size 
across Human Cell Types’, Cold Spring Harbor perspectives in biology, 7(7), pp. a019091–
a019091. 
Gjorevski, N. & Nelson, C. M. (2011) ‘Integrated morphodynamic signalling of the mammary 
gland’, Nature Reviews Molecular Cell Biology, 12, p. 581. 
Glinka, A., Dolde, C., Kirsch, N., Huang, Y.-L., Kazanskaya, O., Ingelfinger, D., Boutros, 
References 183 
 
M., Cruciat, C.-M., & Niehrs, C. (2011) ‘LGR4 and LGR5 are R-spondin receptors mediating 
Wnt/β-catenin and Wnt/PCP signalling’, EMBO reports, 12(10), pp. 1055–1061. 
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., 
Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) ‘Frequent Inactivation 
of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic 
Colorectal Cancers’, Cancer Research, 64(9), pp. 3014–3021. 
Goodman, J. E., Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004) ‘Nitric oxide and p53 in 
cancer-prone chronic inflammation and oxyradical overload disease’, Environmental and 
Molecular Mutagenesis. John Wiley & Sons, Ltd, 44(1), pp. 3–9. 
Gozdecka, M., Meduri, E., Mazan, M., Tzelepis, K., Dudek, M., Knights, A. J., Pardo, M., 
Yu, L., Choudhary, J. S., Metzakopian, E., Iyer, V., Yun, H., Park, N., Varela, I., Bautista, R., 
Collord, G., Dovey, O., Garyfallos, D. A., De Braekeleer, E., Kondo, S., Cooper, J., Göttgens, 
B., Bullinger, L., Northcott, P. A., Adams, D., Vassiliou, G. S., & Huntly, B. J. P. (2018) 
‘UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis 
through noncatalytic inverse regulation of ETS and GATA programs’, Nature Genetics, 
50(6), pp. 883–894. 
Graf, T. (2002) ‘Differentiation plasticity of hematopoietic cells’, Blood, 99(9), pp. 3089–
3101. 
Graham, T. A., Humphries, A., Sanders, T., Rodriguez–Justo, M., Tadrous, P. J., Preston, S. 
L., Novelli, M. R., Leedham, S. J., McDonald, S. A. C., & Wright, N. A. (2011) ‘Use of 
Methylation Patterns to Determine Expansion of Stem Cell Clones in Human Colon Tissue’, 
Gastroenterology, 140(4), pp. 1241-1250.e9. 
Greaves, L. C., Preston, S. L., Tadrous, P. J., Taylor, R. W., Barron, M. J., Oukrif, D., 
Leedham, S. J., Deheragoda, M., Sasieni, P., Novelli, M. R., Jankowski, J. A. Z., Turnbull, D. 
M., Wright, N. A., & McDonald, S. A. C. (2006) ‘Mitochondrial DNA mutations are 
established in human colonic stem cells, and mutated clones expand by crypt fission’, 
Proceedings of the National Academy of Sciences of the United States of America, 103(3), pp. 
714–719. 
184 References 
 
 
Greaves, L. C., Elson, J. L., Nooteboom, M., Grady, J. P., Taylor, G. A., Taylor, R. W., 
Mathers, J. C., Kirkwood, T. B. L., & Turnbull, D. M. (2012) ‘Comparison of Mitochondrial 
Mutation Spectra in Ageing Human Colonic Epithelium and Disease: Absence of Evidence 
for Purifying Selection in Somatic Mitochondrial DNA Point Mutations’, PLoS Genet, 8(11), 
p. e1003082. 
Green, C. E., Liu, T., Montel, V., Hsiao, G., Lester, R. D., Subramaniam, S., Gonias, S. L., & 
Klemke, R. L. (2009) ‘Chemoattractant signaling between tumor cells and macrophages 
regulates cancer cell migration, metastasis and neovascularization’, PloS one. Public Library 
of Science, 4(8), pp. e6713–e6713. 
Grimsby, J., Chen, K., Wang, L. J., Lan, N. C., & Shih, J. C. (1991) ‘Human monoamine 
oxidase A and B genes exhibit identical exon-intron organization.’, Proceedings of the 
National Academy of Sciences, 88(9), pp. 3637–3641. 
Guan, F., Tabrizian, T., Novaj, A., Nakanishi, M., Rosenberg, D. W., & Huffman, D. M. 
(2018) ‘Dietary Walnuts Protect Against Obesity-Driven Intestinal Stem Cell Decline and 
Tumorigenesis’, Frontiers in Nutrition, p. 37. 
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, 
L., Roepman, P., Nyamundanda, G., Angelino, P., Bot, B. M., Morris, J. S., Simon, I. M., 
Gerster, S., Fessler, E., De Sousa E Melo, F., Missiaglia, E., Ramay, H., Barras, D., 
Homicsko, K., Maru, D., Manyam, G. C., Broom, B., Boige, V., Perez-Villamil, B., Laderas, 
T., Salazar, R., Gray, J. W., Hanahan, D., Tabernero, J., Bernards, R., Friend, S. H., Laurent-
Puig, P., Medema, J. P., Sadanandam, A., Wessels, L., Delorenzi, M., Kopetz, S., Vermeulen, 
L., & Tejpar, S. (2015) ‘The consensus molecular subtypes of colorectal cancer’, Nature 
Medicine, 21(11), pp. 1350–1356. 
Gupta, B., Das, P., Ghosh, S., Manhas, J., Sen, S., Pal, S., Sahni, P., Upadhyay, A. D., Panda, 
S. K., & Gupta, S. D. (2017) ‘Identification of High-Risk Aberrant Crypt Foci and Mucin-
Depleted Foci in the Human Colon With Study of Colon Cancer Stem Cell Markers’, Clinical 
Colorectal Cancer, 16(3), pp. 204–213. 
References 185 
 
Gupta, V., Khan, A. A., Sasi, B. K., & Mahapatra, N. R. (2015) ‘Molecular mechanism of 
monoamine oxidase A gene regulation under inflammation and ischemia-like conditions: key 
roles of the transcription factors GATA2, Sp1 and TBP’, Journal of Neurochemistry, 134(1), 
pp. 21–38. 
Gutierrez-Gonzalez, L., Deheragoda, M., Elia, G., Leedham, S. J., Shankar, A., Imber, C., 
Jankowski, J. A., Turnbull, D. M., Novelli, M., Wright, N. A., & McDonald, S. A. C. (2009) 
‘Analysis of the clonal architecture of the human small intestinal epithelium establishes a 
common stem cell for all lineages and reveals a mechanism for the fixation and spread of 
mutations’, The Journal of Pathology, 217(4), pp. 489–496. 
van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Futreal, P. A., et al. 
(2009) ‘Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer’, 
Nature genetics, 41(5), pp. 521–523. 
Hadac, J. N., Leystra, A. A., Paul Olson, T. J., Maher, M. E., Payne, S. N., Yueh, A. E., 
Schwartz, A. R., Albrecht, D. M., Clipson, L., Pasch, C. A., Matkowskyj, K. A., Halberg, R. 
B., & Deming, D. A. (2015) ‘Colon Tumors with the Simultaneous Induction of Driver 
Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma 
Sequence’, Cancer prevention research (Philadelphia, Pa.). 2015/08/14, 8(10), pp. 952–961. 
Haile, S., Pandoh, P., McDonald, H., Corbett, R. D., Tsao, P., Kirk, H., MacLeod, T., Jones, 
M., Bilobram, S., Brooks, D., Smailus, D., Steidl, C., Scott, D. W., Bala, M., Hirst, M., 
Miller, D., Moore, R. A., Mungall, A. J., Coope, R. J., Ma, Y., Zhao, Y., Holt, R. A., Jones, S. 
J., & Marra, M. A. (2017) ‘Automated high throughput nucleic acid purification from 
formalin-fixed paraffin-embedded tissue samples for next generation sequence analysis’, 
PLOS ONE, 12(6), p. e0178706. 
Halpern, K. B., Massalha, H., Zwick, R. K., Moor, A. E., Castillo-Azofeifa, D., Rozenberg, 
M., Farack, L., Egozi, A., Miller, D. R., Averbukh, I., Harnik, Y., Weinberg-Corem, N., de 
Sauvage, F. J., Amit, I., Klein, O. D., Shoshkes-Carmel, M., & Itzkovitz, S. (2019) ‘Lgr5+ 
telocytes are a signaling hub at the intestinal villus tip’, bioRxiv, p. 850909. 
Hao, X. P., Frayling, I. M., Sgouros, J. G., Du, M. Q., Willcocks, T. C., Talbot, I. C., & 
186 References 
 
 
Tomlinson, I. P. M. (2002) ‘The spectrum of p53 mutations in colorectal adenomas differs 
from that in colorectal carcinomas’, Gut, 50(6), pp. 834–839. 
He, X. C., Zhang, J., Tong, W.-G., Tawfik, O., Ross, J., Scoville, D. H., Tian, Q., Zeng, X., 
He, X., Wiedemann, L. M., Mishina, Y., & Li, L. (2004) ‘BMP signaling inhibits intestinal 
stem cell self-renewal through suppression of Wnt–β-catenin signaling’, Nature Genetics, 
36(10), pp. 1117–1121. 
van der Heijden, R. A., Bijzet, J., Meijers, W. C., Yakala, G. K., Kleemann, R., Nguyen, T. 
Q., de Boer, R. A., Schalkwijk, C. G., Hazenberg, B. P. C., Tietge, U. J. F., & Heeringa, P. 
(2015) ‘Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is 
associated with acceleration of age-dependent renal amyloidosis’, 5, p. 16474. 
Hideshima, T., Mazitschek, R., Qi, J., Mimura, N., Tseng, J.-C., Kung, A. L., Bradner, J. E., 
& Anderson, K. C. (2017) ‘HDAC6 inhibitor WT161 downregulates growth factor receptors 
in breast cancer’, Oncotarget, 8(46), pp. 80109–80123. 
Hill, V. K., Kim, J.-S., & Waldman, T. (2016) ‘Cohesin mutations in human cancer’, 
Biochimica et biophysica acta, 1866(1), pp. 1–11. 
Hlobilkova, A., Guldberg, P., Thullberg, M., Zeuthen, J., Lukas, J., & Bartek, J. (2000) ‘Cell 
Cycle Arrest by the PTEN Tumor Suppressor Is Target Cell Specific and May Require 
Protein Phosphatase Activity’, Experimental Cell Research, 256(2), pp. 571–577. 
Ho, C.-M., Lin, M.-C., Huang, S.-H., Huang, C.-J., Lai, H.-C., Chien, T.-Y., & Chang, S.-F. 
(2009) ‘PTEN promoter methylation and LOH of 10q22–23 locus in PTEN expression of 
ovarian clear cell adenocarcinomas’, Gynecologic Oncology, 112(2), pp. 307–313. 
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) ‘PTEN loss in the continuum of 
common cancers, rare syndromes and mouse models’, Nature Reviews Cancer, 11(4), pp. 
289–301. 
Hounnou, G., Destrieux, C., Desme, J., & Bertrand, P. (2002) ‘Anatomical study of the length 
of the human intestine’, Surgical and Radiologic Anatomy, 24(5), pp. 290–294. 
References 187 
 
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., Suarez, C. J., Berghoff, A. 
S., Cremolini, C., Falcone, A., Loupakis, F., Birner, P., Preusser, M., Lenz, H.-J., & Curtis, C. 
(2019) ‘Quantitative evidence for early metastatic seeding in colorectal cancer’, Nature 
Genetics, 51(7), pp. 1113–1122. 
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, 
X.-F., & Yao, T.-P. (2002) ‘HDAC6 is a microtubule-associated deacetylase’, Nature, 417, p. 
455. 
Hussain, A., Dulay, P., Rivera, M. N., Aramouni, C., & Saxena, V. (2019) ‘Neoplastic 
Pathogenesis Associated with Cigarette Carcinogens’, Cureus, 11(1), pp. e3955–e3955. 
Hye-Rim, W., Hyun-Wook, R., Dong-Hee, S., Soo-Keun, Y., Hoon, L. D., & Hee, K. S. 
(2018) ‘A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity 
of chemotherapeutic agents in colorectal cancer cells’, Molecular Carcinogenesis, 57(10), pp. 
1383–1395. 
Ireland, H., Houghton, C., Howard, L., & Winton, D. J. (2005) ‘Cellular inheritance of a Cre-
activated reporter gene to determine paneth cell longevity in the murine small intestine’, 
Developmental Dynamics, 233(4), pp. 1332–1336. 
Jadhav, U., Saxena, M., O’Neill, N. K., Saadatpour, A., Yuan, G.-C., Herbert, Z., Murata, K., 
& Shivdasani, R. A. (2017) ‘Dynamic Reorganization of Chromatin Accessibility Signatures 
during Dedifferentiation of Secretory Precursors into Lgr5+ Intestinal Stem Cells’, Cell Stem 
Cell, 21(1), pp. 65-77.e5. 
Jager, M., Blokzijl, F., Sasselli, V., Boymans, S., Janssen, R., Besselink, N., Clevers, H., van 
Boxtel, R., & Cuppen, E. (2017) ‘Measuring mutation accumulation in single human adult 
stem cells by whole-genome sequencing of organoid cultures’, Nature Protocols, 13(1), pp. 
59–78. 
Jaks, V., Kasper, M., & Toftgård, R. (2010) ‘The hair follicle—a stem cell zoo’, Experimental 
Cell Research, 316(8), pp. 1422–1428. 
Jedinak, A., Dudhgaonkar, S., & Sliva, D. (2010) ‘Activated macrophages induce metastatic 
188 References 
 
 
behavior of colon cancer cells’, Immunobiology, 215(3), pp. 242–249. 
Jenny, M., Uhl, C., Roche, C., Duluc, I., Guillermin, V., Guillemot, F., Jensen, J., Kedinger, 
M., & Gradwohl, G. (2002) ‘Neurogenin3 is differentially required for endocrine cell fate 
specification in the intestinal and gastric epithelium’, The EMBO Journal. Oxford, UK, 
21(23), pp. 6338–6347. 
Van Kaer, L. & Olivares-Villagómez, D. (2018) ‘Development, Homeostasis, and Functions 
of Intestinal Intraepithelial Lymphocytes’, The Journal of Immunology, 200(7), pp. 2235 LP – 
2244. 
Kang, Y., Lee, H., & Kim, W. (2002) ‘Promoter methylation and silencing of PTEN in gastric 
carcinoma.’, Lab Invest., 82(3), pp. 285–91. 
Khoury, M. P. & Bourdon, J.-C. (2010) ‘The isoforms of the p53 protein’, Cold Spring 
Harbor perspectives in biology, 2(3), pp. a000927–a000927. 
Kiktev, D. A., Sheng, Z., Lobachev, K. S., & Petes, T. D. (2018) ‘GC content elevates 
mutation and recombination rates in the yeast Saccharomyces cerevisiae’, Proceedings of the 
National Academy of Sciences, 115(30), pp. E7109–E7118. 
Kim, J.-S., He, X., Orr, B., Wutz, G., Hill, V., Peters, J.-M., Compton, D. A., & Waldman, T. 
(2016) ‘Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring 
Tumor-Derived Mutations in STAG2’, PLoS genetics, 12(2), pp. e1005865–e1005865. 
Kim, J. H. & Kang, G. H. (2014) ‘Molecular and prognostic heterogeneity of microsatellite-
unstable colorectal cancer’, World journal of gastroenterology, 20(15), pp. 4230–4243. 
Kim, K.-M. & Shibata, D. (2002) ‘Methylation reveals a niche: stem cell succession in human 
colon crypts’, Oncogene, 21(35), pp. 5441–5449. 
Kim, K.-M. & Shibata, D. (2004) ‘Tracing ancestry with methylation patterns: most crypts 
appear distantly related in normal adult human colon’, BMC gastroenterology, 4, p. 8. 
Kim, S., Park, C., Ji, Y., Kim, D. G., Bae, H., van Vrancken, M., Kim, D.-H., & Kim, K.-M. 
References 189 
 
(2017) ‘Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the 
Era of Precision Medicine’, The Journal of Molecular Diagnostics, 19(1), pp. 137–146. 
Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & 
Shakked, Z. (2006) ‘Structural Basis of DNA Recognition by p53 Tetramers’, Molecular Cell, 
22(6), pp. 741–753. 
Knoblich, J. A. (2008) ‘Mechanisms of Asymmetric Stem Cell Division’, Cell, 132(4), pp. 
583–597. 
Knott, G. J., Bond, C. S., & Fox, A. H. (2016) ‘The DBHS proteins SFPQ, NONO and 
PSPC1: a multipurpose molecular scaffold’, Nucleic acids research, 44(9), pp. 3989–4004. 
Kornack, D. R. & Rakic, P. (2001) ‘The generation, migration, and differentiation of olfactory 
neurons in the adult primate brain’, Proceedings of the National Academy of Sciences, 98(8), 
pp. 4752–4757. 
Kosinski, C., Stange, D. E., Xu, C., Chan, A. S., Ho, C., Yuen, S. T., Mifflin, R. C., Powell, 
D. W., Clevers, H., Leung, S. Y., & Chen, X. (2010) ‘Indian hedgehog regulates intestinal 
stem cell fate through epithelial-mesenchymal interactions during development’, 
Gastroenterology. 2010/06/11, 139(3), pp. 893–903. 
Kozar, S., Morrissey, E., Nicholson, A. M., van der Heijden, M., Zecchini, H. I., Kemp, R., 
Tavaré, S., Vermeulen, L., & Winton, D. J. (2013) ‘Continuous Clonal Labeling Reveals 
Small Numbers of Functional Stem Cells in Intestinal Crypts and Adenomas’, Cell Stem Cell, 
13(5), pp. 626–633. 
Kraus, M. C., Seelig, M. H., Linnemann, U., & Berger, M. (2006) ‘The balanced induction of 
K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues.’, 
International Journal of Oncology, 29(4), pp. 957–964. 
Kraus, S. & Arber, N. (2009) ‘Inflammation and colorectal cancer’, Current Opinion in 
Pharmacology, 9(4), pp. 405–410. 
Kudo, S., Tamura, S., Nakajima, T., Yamano, H., Kusaka, H., & Watanabe, H. (1996) 
‘Diagnosis of colorectal tumorous lesions by magnifying endoscopy’, Gastrointestinal 
190 References 
 
 
Endoscopy. Elsevier, 44(1), pp. 8–14. 
Kukitsu, T., Takayama, T., Miyanishi, K., Nobuoka, A., Katsuki, S., Sato, Y., Takimoto, R., 
Matsunaga, T., Kato, J., Sonoda, T., Sakamaki, S., & Niitsu, Y. (2008) ‘Aberrant Crypt Foci 
as Precursors of the Dysplasia-Carcinoma Sequence in Patients with Ulcerative Colitis’, 
Clinical Cancer Research, 14(1), pp. 48 LP – 54. 
Kuraishy, A., Karin, M., & Grivennikov, S. I. (2011) ‘Tumor promotion via injury- and 
death-induced inflammation’, Immunity, 35(4), pp. 467–477. 
Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A. J., Elowitz, M. B., & 
Alon, U. (2004) ‘Dynamics of the p53-Mdm2 feedback loop in individual cells’, Nature 
Genetics, 36(2), pp. 147–150. 
Lander, A. D., Gokoffski, K. K., Wan, F. Y. M., Nie, Q., & Calof, A. L. (2009) ‘Cell 
Lineages and the Logic of Proliferative Control’, PLOS Biology, 7(1), p. e1000015. 
Lane, D. P. (1992) ‘p53, guardian of the genome’, Nature, 358(6381), pp. 15–16. 
Lang, M., Schlechtweg, M., Kellermeier, S., Brenmoehl, J., Falk, W., Schlalmerich, J., 
Herfarth, H., Rogler, G., & Hausmann, M. (2009) ‘Gene expression profiles of mucosal 
fibroblasts from strictured and nonstrictured areas of patients with Crohn’s disease’, 
Inflammatory bowel diseases, 15, pp. 212–223. 
Langlands, A. J., Almet, A. A., Appleton, P. L., Newton, I. P., Osborne, J. M., & Näthke, I. S. 
(2016) ‘Paneth Cell-Rich Regions Separated by a Cluster of Lgr5+ Cells Initiate Crypt 
Fission in the Intestinal Stem Cell Niche’, PLoS biology, 14(6), pp. e1002491–e1002491. 
Lee-Six, H., Ellis, P., Osborne, R. J., Sanders, M. A., Moore, L., Georgakopoulos, N., 
Torrente, F., Noorani, A., Goddard, M., Robinson, P., Coorens, T. H. H., O&#039;Neill, L., 
Alder, C., Wang, J., Fitzgerald, R. C., Zilbauer, M., Coleman, N., Saeb-Parsy, K., 
Martincorena, I., Campbell, P. J., & Stratton, M. R. (2018) ‘The landscape of somatic 
mutation in normal colorectal epithelial cells’, bioRxiv. 
References 191 
 
Lee, Y.-S., Lim, K.-H., Guo, X., Kawaguchi, Y., Gao, Y., Barrientos, T., Ordentlich, P., 
Wang, X.-F., Counter, C. M., & Yao, T.-P. (2008) ‘The Cytoplasmic Deacetylase HDAC6 Is 
Required for Efficient Oncogenic Tumorigenesis’, Cancer Research, 68(18), pp. 7561–7569. 
Ler, L. D., Ghosh, S., Chai, X., Thike, A. A., Heng, H. L., Siew, E. Y., Dey, S., Koh, L. K., 
Lim, J. Q., Lim, W. K., Myint, S. S., Loh, J. L., Ong, P., Sam, X. X., Huang, D., Lim, T., Tan, 
P. H., Nagarajan, S., Cheng, C. W. S., Ho, H., Ng, L. G., Yuen, J., Lin, P.-H., Chuang, C.-K., 
Chang, Y.-H., Weng, W.-H., Rozen, S. G., Tan, P., Creasy, C. L., Pang, S.-T., McCabe, M. 
T., Poon, S. L., & Teh, B. T. (2017) ‘Loss of tumor suppressor KDM6A amplifies PRC2-
regulated transcriptional repression in bladder cancer and can be targeted through inhibition 
of EZH2’, Science Translational Medicine, 9(378), p. eaai8312. 
De Lerma Barbaro, A., Perletti, G., Bonapace, I. M., & Monti, E. (2014) ‘Inflammatory cues 
acting on the adult intestinal stem cells and the early onset of cancer (review)’, International 
journal of oncology. 2014/06/10. D.A. Spandidos, 45(3), pp. 959–968. 
Leystra, A. A., Deming, D. A., Zahm, C. D., Farhoud, M., Olson, T. J. P., Hadac, J. N., 
Nettekoven, L. A., Albrecht, D. M., Clipson, L., Sullivan, R., Washington, M. K., Torrealba, 
J. R., Weichert, J. P., & Halberg, R. B. (2012) ‘Mice expressing activated PI3K rapidly 
develop advanced colon cancer’, Cancer research. 2012/04/23, 72(12), pp. 2931–2936. 
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) ‘Histone deacetylase 6 regulates the 
immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the 
STAT3–COX2-dependent pathway’, Oncogene, 37(45), pp. 5952–5966. 
Li, D., Marchenko, N. D., & Moll, U. M. (2011) ‘SAHA shows preferential cytotoxicity in 
mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 
chaperone axis’, Cell death and differentiation, 18(12), pp. 1904–1913. 
Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G., & Evan, G. I. (1995) ‘A 
modified oestrogen receptor ligand-binding domain as an improved switch for the regulation 
of heterologous proteins’, Nucleic acids research, 23(10), pp. 1686–1690. 
Liu, P. Y., Erriquez, D., Marshall, G. M., Tee, A. E., Polly, P., Wong, M., Liu, B., Bell, J. L., 
Zhang, X. D., Milazzo, G., Cheung, B. B., Fox, A., Swarbrick, A., Hüttelmaier, S., Kavallaris, 
192 References 
 
 
M., Perini, G., Mattick, J. S., Dinger, M. E., & Liu, T. (2014) ‘Effects of a Novel Long 
Noncoding RNA, lncUSMycN, on N-Myc Expression and Neuroblastoma Progression’, 
JNCI: Journal of the National Cancer Institute, 106(7). 
Lloyd-Lewis, B., Davis, F. M., Harris, O. B., Hitchcock, J. R., & Watson, C. J. (2018) 
‘Neutral lineage tracing of proliferative embryonic and adult mammary stem/progenitor 
cells’, Development, 145(14), p. dev164079. 
Lodato, M. A., Rodin, R. E., Bohrson, C. L., Coulter, M. E., Barton, A. R., Kwon, M., 
Sherman, M. A., Vitzthum, C. M., Luquette, L. J., Yandava, C. N., Yang, P., Chittenden, T. 
W., Hatem, N. E., Ryu, S. C., Woodworth, M. B., Park, P. J., & Walsh, C. A. (2018) ‘Aging 
and neurodegeneration are associated with increased mutations in single human neurons’, 
Science, 359(6375), pp. 555–559. 
Lopez-Garcia, C., Klein, A. M., Simons, B. D., & Winton, D. J. (2010) ‘Intestinal Stem Cell 
Replacement Follows a Pattern of Neutral Drift’, Science, 330(6005), pp. 822–825. 
Ludgate, J. L., Wright, J., Stockwell, P. A., Morison, I. M., Eccles, M. R., & Chatterjee, A. 
(2017) ‘A streamlined method for analysing genome-wide DNA methylation patterns from 
low amounts of FFPE DNA’, BMC medical genomics, 10(1), p. 54. 
Maehama, T. & Dixon, J. E. (1998) ‘The Tumor Suppressor, PTEN/MMAC1, 
Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate’, 
Journal of Biological Chemistry , 273(22), pp. 13375–13378. 
Manning, B. D. & Toker, A. (2017) ‘AKT/PKB Signaling: Navigating the Network’, Cell, 
169(3), pp. 381–405. 
Margueron, R. & Reinberg, D. (2011) ‘The Polycomb complex PRC2 and its mark in life’, 
Nature, 469(7330), pp. 343–349. 
Martin, G. R. (1981) ‘Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells’, Proceedings of the National Academy of 
Sciences of the United States of America, 78(12), pp. 7634–7638. 
References 193 
 
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. 
C., Fullam, A., Alexandrov, L. B., Tubio, J. M., Stebbings, L., Menzies, A., Widaa, S., 
Stratton, M. R., Jones, P. H., & Campbell, P. J. (2015) ‘Tumor evolution. High burden and 
pervasive positive selection of somatic mutations in normal human skin’, Science, 348(6237), 
pp. 880–886. 
Martincorena, I., Fowler, J. C., Wabik, A., Lawson, A. R. J., Abascal, F., Hall, M. W. J., 
Cagan, A., Murai, K., Mahbubani, K., Stratton, M. R., Fitzgerald, R. C., Handford, P. A., 
Campbell, P. J., Saeb-Parsy, K., & Jones, P. H. (2018) ‘Somatic mutant clones colonize the 
human esophagus with age’, Science, 362(6417), pp. 911–917. 
Maskens, A. (1978) ‘Histogenesis of colon glands during postnatal growth’, Acta Anat 
(Basel)., 100(1), pp. 17–26. 
Maskens, A. P. & Duhardin-Loits, R. M. (1981) ‘Kinetics of tissue proliferation in colorectal 
mucosa during post-natal growth.’, Cell Tissue Kinet., 14(5), pp. 467–77. 
Maywald, R. L., Doerner, S. K., Pastorelli, L., De Salvo, C., Benton, S. M., Dawson, E. P., 
Lanza, D. G., Berger, N. A., Markowitz, S. D., Lenz, H.-J., Nadeau, J. H., Pizarro, T. T., & 
Heaney, J. D. (2015) ‘IL-33 activates tumor stroma to promote intestinal polyposis’, 
Proceedings of the National Academy of Sciences of the United States of America. 
2015/04/27. National Academy of Sciences, 112(19), pp. E2487–E2496. 
McCullough, M. L., Zoltick, E. S., Weinstein, S. J., Fedirko, V., Wang, M., Smith-Warner, S. 
A., et al. (2018) ‘Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling 
Project of 17 Cohorts’, JNCI: Journal of the National Cancer Institute, 111(2), pp. 158–169. 
Meira, L. B., Bugni, J. M., Green, S. L., Lee, C.-W., Pang, B., Borenshtein, D., Rickman, B. 
H., Rogers, A. B., Moroski-Erkul, C. A., McFaline, J. L., Schauer, D. B., Dedon, P. C., Fox, 
J. G., & Samson, L. D. (2008) ‘DNA damage induced by chronic inflammation contributes to 
colon carcinogenesis in mice’, The Journal of clinical investigation. American Society for 
Clinical Investigation, 118(7), pp. 2516–2525. 
Meran, L., Baulies, A., & Li, V. S. W. (2017) ‘Intestinal Stem Cell Niche : The Extracellular 
Matrix and Cellular Components’, Stem Cells International, 2017. 
194 References 
 
 
Metzger, D., Ali, S., Bornert, J.-M., & Chambon, P. (1995) ‘Characterization of the Amino-
terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and 
Yeast Cells’, Journal of Biological Chemistry , 270(16), pp. 9535–9542. 
Van der Meulen, J., Sanghvi, V., Mavrakis, K., Durinck, K., Fang, F., Matthijssens, F., 
Rondou, P., Rosen, M., Pieters, T., Vandenberghe, P., Delabesse, E., Lammens, T., De 
Moerloose, B., Menten, B., Van Roy, N., Verhasselt, B., Poppe, B., Benoit, Y., Taghon, T., 
Melnick, A. M., Speleman, F., Wendel, H.-G., & Van Vlierberghe, P. (2015) ‘The 
H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute 
lymphoblastic leukemia’, Blood, 125(1), pp. 13–21. 
Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G., & Attardi, G. (1999) ‘Aging-
Dependent Large Accumulation of Point Mutations in the Human mtDNA Control Region for 
Replication’, Science, 286(5440), pp. 774–779. 
Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N., 
Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., & Ciuffreda, L. (2015) ‘PTEN: Multiple 
Functions in Human Malignant Tumors’, Frontiers in oncology, 5, p. 24. 
Miller, S. A., Mohn, S. E., & Weinmann, A. S. (2010) ‘Jmjd3 and UTX play a demethylase-
independent role in chromatin remodeling to regulate T-box family member-dependent gene 
expression’, Molecular cell, 40(4), pp. 594–605. 
Montgomery, R. K., Carlone, D. L., Richmond, C. A., Farilla, L., Kranendonk, M. E. G., 
Henderson, D. E., Baffour-Awuah, N. Y., Ambruzs, D. M., Fogli, L. K., Algra, S., & Breault, 
D. T. (2011) ‘Mouse telomerase reverse transcriptase (mTert) expression marks slowly 
cycling intestinal stem cells’, Proceedings of the National Academy of Sciences , 108(1), pp. 
179–184. 
Morimoto, L. M., Newcomb, P. A., Ulrich, C. M., Bostick, R. M., Lais, C. J., & Potter, J. D. 
(2002) ‘Risk Factors for Hyperplastic and Adenomatous Polyps’, Cancer Epidemiology 
Biomarkers &amp;amp; Prevention, 11(10), pp. 1012 LP – 1018. 
References 195 
 
Mueller, L., Goumas, F. A., Affeldt, M., Sandtner, S., Gehling, U. M., Brilloff, S., Walter, J., 
Karnatz, N., Lamszus, K., Rogiers, X., & Broering, D. C. (2007) ‘Stromal fibroblasts in 
colorectal liver metastases originate from resident fibroblasts and generate an inflammatory 
microenvironment’, The American journal of pathology. 2007/10/04. American Society for 
Investigative Pathology, 171(5), pp. 1608–1618. 
Muñoz, J., Stange, D. E., Schepers, A. G., van de Wetering, M., Koo, B.-K., Itzkovitz, S., 
Volckmann, R., Kung, K. S., Koster, J., Radulescu, S., Myant, K., Versteeg, R., Sansom, O. 
J., van Es, J. H., Barker, N., van Oudenaarden, A., Mohammed, S., Heck, A. J. R., & Clevers, 
H. (2012) ‘The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent 
“+4” cell markers’, The EMBO journal. Nature Publishing Group, 31(14), pp. 3079–3091. 
Muto, T., Bussey, H. J., & Morson, B. C. (1975) ‘The evolution of cancer of the colon and 
rectum.’, Cancer, 36(6), pp. 2251–70. 
Nakayama, M. & Oshima, M. (2018) ‘Mutant p53 in colon cancer’, Journal of molecular cell 
biology. Oxford University Press, 11(4), pp. 267–276. 
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) ‘Mutant TP53 
posttranslational modifications: challenges and opportunities’, Human mutation, 35(6), pp. 
738–755. 
Nicholson, A. M., Olpe, C., Hoyle, A., Thorsen, A.-S., Rus, T., Colombé, M., Brunton-Sim, 
R., Kemp, R., Marks, K., Quirke, P., Malhotra, S., ten Hoopen, R., Ibrahim, A., Lindskog, C., 
Myers, M. B., Parsons, B., Tavaré, S., Wilkinson, M., Morrissey, E., & Winton, D. J. (2018) 
‘Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium’, Cell Stem 
Cell, 22(6), pp. 909-918.e8. 
Niikawa, N., Matsuura, N., Fukushima, Y., Ohsawa, T., & Kajii, T. (1981) ‘Kabuki make-up 
syndrome: A syndrome of mentalretardation, unusual facies, large and protruding ears, and 
postnatal growth deficiency’, The Journal of Pediatrics, 99(4), pp. 565–569. 
Nooteboom, M., Johnson, R., Taylor, R. W., Wright, N. A., Lightowlers, R. N., Kirkwood, T. 
B. L., Mathers, J. C., Turnbull, D. M., & Greaves, L. C. (2010) ‘Age-associated mitochondrial 
DNA mutations lead to small but significant changes in cell proliferation and apoptosis in 
196 References 
 
 
human colonic crypts’, Aging Cell, 9(1), pp. 96–99. 
Novelli, M., Cossu, A., Oukrif, D., Quaglia, A., Lakhani, S., Poulsom, R., Sasieni, P., Carta, 
P., Contini, M., Pasca, A., Palmieri, G., Bodmer, W., Tanda, F., & Wright, N. (2003) ‘X-
inactivation patch size in human female tissue confounds the assessment of tumor clonality’, 
Proceedings of the National Academy of Sciences , 100(6), pp. 3311–3314. 
Novelli, M. R., Williamson, J. A., Tomlinson, I. P. M., Elia, G., Hodgson, S. V, Talbot, I. C., 
Bodmer, W. F., & Wright, N. A. (1996) ‘Polyclonal Origin of Colonic Adenomas in an 
XO/XY Patient with FAP’, Science, 272(5265), pp. 1187–1190. 
Nowak, J. A., Polak, L., Pasolli, H. A., & Fuchs, E. (2008) ‘Hair follicle stem cells are 
specified and function in early skin morphogenesis’, Cell stem cell, 3(1), pp. 33–43. 
Nowell, P. C. (1976) ‘The clonal evolution of tumor cell populations’, Science, 194(4260), 
pp. 23–28. 
Oguma, K., Oshima, H., Aoki, M., Uchio, R., Naka, K., Nakamura, S., Hirao, A., Saya, H., 
Taketo, M. M., & Oshima, M. (2008) ‘Activated macrophages promote Wnt signalling 
through tumour necrosis factor-alpha in gastric tumour cells’, The EMBO journal. 
2008/05/29. Nature Publishing Group, 27(12), pp. 1671–1681. 
Okayasu, I., Ohkusa, T., Kajiura, K., Kanno, J., & Sakamoto, S. (1996) ‘Promotion of 
colorectal neoplasia in experimental murine ulcerative colitis’, Gut, 39(1), pp. 87–92. 
Orlando, F. A., Tan, D., Baltodano, J. D., Khoury, T., Gibbs, J. F., Hassid, V. J., Ahmed, B. 
H., & Alrawi, S. J. (2008) ‘Aberrant crypt foci as precursors in colorectal cancer progression’, 
Journal of surgical oncology, 98(3), pp. 207–213. 
Otori, K., Sugiyama, K., Hasebe, T., Fukushima, S., & Esumi, H. (1995) ‘Emergence of 
Adenomatous Aberrant Crypt Foci (ACF) from Hyperplastic ACF with Concomitant Increase 
in Cell Proliferation’, Cancer Research, 55(21), pp. 4743 LP – 4746. 
Owens, B. M. J. & Simmons, A. (2013) ‘Intestinal stromal cells in mucosal immunity and 
References 197 
 
homeostasis’, Mucosal Immunology, 6(2), pp. 224–234. 
Pantazis, P. & Bollenbach, T. (2012) ‘Transcription factor kinetics and the emerging 
asymmetry in the early mammalian embryo’, Cell Cycle, 11(11), pp. 2055–2058. 
Papa, A. & Pandolfi, P. P. (2019) ‘The PTEN−PI3K Axis in Cancer’, Biomolecules, 9(4), p. 
153. 
Park, S.-Y., Phorl, S., Jung, S., Sovannarith, K., Lee, S., Noh, S., Han, M., Naskar, R., Kim, 
J.-Y., Choi, Y.-J., & Lee, J.-Y. (2017) ‘HDAC6 deficiency induces apoptosis in mesenchymal 
stem cells through p53 K120 acetylation’, Biochemical and Biophysical Research 
Communications, 494(1), pp. 51–56. 
Parsons, B., Marchant-Miros, K., Delongchamp, R., Verkler, T., Patterson, T., McKinzie, P., 
& Kim, L. (2010) ‘ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant 
fraction in colon tumor and non-tumor tissue.’, Cancer Invest., 28(4), pp. 364–375. 
Passon, D. M., Lee, M., Rackham, O., Stanley, W. A., Sadowska, A., Filipovska, A., Fox, A. 
H., & Bond, C. S. (2012) ‘Structure of the heterodimer of human NONO and paraspeckle 
protein component 1 and analysis of its role in subnuclear body formation’, Proceedings of 
the National Academy of Sciences of the United States of America, 109(13), pp. 4846–4850. 
Pastuła, A., Middelhoff, M., Brandtner, A., Tobiasch, M., Höhl, B., Nuber, A. H., Demir, I. 
E., Neupert, S., Kollmann, P., Mazzuoli-Weber, G., & Quante, M. (2016) ‘Three-Dimensional 
Gastrointestinal Organoid Culture in Combination with Nerves or Fibroblasts: A Method to 
Characterize the Gastrointestinal Stem Cell Niche’, Stem cells international. 2015/11/30. 
Hindawi Publishing Corporation, 2016, p. 3710836. 
Pastuła, A. & Marcinkiewicz, J. (2019) ‘Cellular Interactions in the Intestinal Stem Cell 
Niche’, Archivum immunologiae et therapiae experimentalis. 2018/09/21. Springer 
International Publishing, 67(1), pp. 19–26. 
Peddareddigari, V. G., Wang, D., & Dubois, R. N. (2010) ‘The tumor microenvironment in 
colorectal carcinogenesis’, Cancer microenvironment : official journal of the International 
Cancer Microenvironment Society. Springer Netherlands, 3(1), pp. 149–166. 
198 References 
 
 
Petti, E., Buemi, V., Zappone, A., Schillaci, O., Broccia, P. V., Dinami, R., Matteoni, S., 
Benetti, R., & Schoeftner, S. (2019) ‘SFPQ and NONO suppress RNA:DNA-hybrid-related 
telomere instability’, Nature Communications, 10(1), p. 1001. 
Pickhardt, P. J., Kim, D. H., Pooler, B. D., Hinshaw, J. L., Barlow, D., Jensen, D., 
Reichelderfer, M., & Cash, B. D. (2013) ‘Assessment of volumetric growth rates of small 
colorectal polyps with CT colonography: a longitudinal study of natural history’, The Lancet. 
Oncology. 2013/06/07, 14(8), pp. 711–720. 
Pollard, J. W. (2004) ‘Tumour-educated macrophages promote tumour progression and 
metastasis’, Nature Reviews Cancer, 4(1), pp. 71–78. 
Potten, C. S., Hume, W. J., Reid, P., & Cairns, J. (1978) ‘The segregation of DNA in 
epithelial stem cells’, Cell. Elsevier, 15(3), pp. 899–906. 
Potten, C. S. & Loeffler, M. (1990) ‘Stem cells: attributes, cycles, spirals, pitfalls and 
uncertainties. Lessons for and from the crypt’, Development, 110(4), pp. 1001–1020. 
Potten, C. S., Owen, G., & Booth, D. (2002) ‘Intestinal stem cells protect their genome by 
selective segregation of template DNA strands’, Journal of Cell Science, 115(11), pp. 2381 
LP – 2388. 
Preston, S. L., Wong, W.-M., Chan, A. O.-O., Poulsom, R., Jeffery, R., Goodlad, R. A., 
Mandir, N., Elia, G., Novelli, M., Bodmer, W. F., Tomlinson, I. P., & Wright, N. A. (2003) 
‘Bottom-up Histogenesis of Colorectal Adenomas’, Cancer Research, 63(13), pp. 3819–3825. 
Pruitt, K. D., Harrow, J., Harte, R. A., Wallin, C., Diekhans, M., Maglott, D. R., Searle, S., 
Farrell, C. M., Loveland, J. E., Ruef, B. J., Hart, E., Suner, M.-M., Landrum, M. J., Aken, B., 
Ayling, S., Baertsch, R., Fernandez-Banet, J., Cherry, J. L., Curwen, V., Dicuccio, M., Kellis, 
M., Lee, J., Lin, M. F., Schuster, M., Shkeda, A., Amid, C., Brown, G., Dukhanina, O., 
Frankish, A., Hart, J., Maidak, B. L., Mudge, J., Murphy, M. R., Murphy, T., Rajan, J., 
Rajput, B., Riddick, L. D., Snow, C., Steward, C., Webb, D., Weber, J. A., Wilming, L., Wu, 
W., Birney, E., Haussler, D., Hubbard, T., Ostell, J., Durbin, R., & Lipman, D. (2009) ‘The 
References 199 
 
consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set 
for the human and mouse genomes’, Genome research, 19(7), pp. 1316–1323. 
Quintanilla, I., López-Cerón, M., Jimeno, M., Cuatrecasas, M., Zabalza, M., Moreira, L., 
Alonso, V., Rodríguez de Miguel, C., Muñoz, J., Castellvi-Bel, S., Llach, J., Castells, A., 
Balaguer, F., Camps, J., & Pellisé, M. (2019) ‘Rectal Aberrant Crypt Foci in Humans Are Not 
Surrogate Markers for Colorectal Cancer Risk’, Clinical and Translational Gastroenterology, 
10(6). 
Ritsma, L., Ellenbroek, S. I. J., Zomer, A., Snippert, H. J., de Sauvage, F. J., Simons, B. D., 
Clevers, H., & van Rheenen, J. (2014) ‘Intestinal crypt homeostasis revealed at single-stem-
cell level by in vivo live imaging’, Nature, 507(7492), pp. 362–365. 
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & 
Mesirov, J. P. (2011) ‘Integrative genomics viewer’, Nature biotechnology, 29(1), pp. 24–26. 
Rojo, F., Najera, L., Lirola, J., Jiménez, J., Guzmán, M., Sabadell, M. D., Baselga, J., & 
Cajal, S. R. y (2007) ‘4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that 
Correlates with Pathologic Grade and Prognosis’, Clinical Cancer Research, 13(1), pp. 81–
89. 
Roncucci, L., Stamp, D., Medline, A., Cullen, J. B., & Robert Bruce, W. (1991) 
‘Identification and quantification of aberrant crypt foci and microadenomas in the human 
colon’, Human Pathology, 22(3), pp. 287–294. 
Rothenberg, M. E., Nusse, Y., Kalisky, T., Lee, J. J., Dalerba, P., Scheeren, F., Lobo, N., 
Kulkarni, S., Sim, S., Qian, D., Beachy, P. A., Pasricha, P. J., Quake, S. R., & Clarke, M. F. 
(2012) ‘Identification of a cKit(+) colonic crypt base secretory cell that supports Lgr5(+) stem 
cells in mice’, Gastroenterology, 142(5), pp. 1195-1205.e6. 
Roulis, M., Armaka, M., Manoloukos, M., Apostolaki, M., & Kollias, G. (2011) ‘Intestinal 
epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like 
pathology’, Proceedings of the National Academy of Sciences of the United States of America. 
2011/03/14. National Academy of Sciences, 108(13), pp. 5396–5401. 
200 References 
 
 
Rozen, S. & Skaletsky, H. (2000) ‘Primer3 on the WWW for general users and for biologist 
programmers.’, Methods in Molecular Biology, 132, pp. 365–86. 
Sangiorgi, E. & Capecchi, M. R. (2008) ‘Bmi1 is expressed in vivo in intestinal stem cells’, 
Nat Genet, 40(7), pp. 915–920. 
Sasaki, N., Sachs, N., Wiebrands, K., Ellenbroek, S. I. J., Fumagalli, A., Lyubimova, A., 
Begthel, H., van den Born, M., van Es, J. H., Karthaus, W. R., Li, V. S. W., López-Iglesias, 
C., Peters, P. J., van Rheenen, J., van Oudenaarden, A., & Clevers, H. (2016) ‘Reg4+ deep 
crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon’, Proceedings 
of the National Academy of Sciences of the United States of America, 113(37), pp. E5399–
E5407. 
Sato, T., van Es, J. H., Snippert, H. J., Stange, D. E., Vries, R. G., van den Born, M., Barker, 
N., Shroyer, N. F., van de Wetering, M., & Clevers, H. (2011) ‘Paneth cells constitute the 
niche for Lgr5 stem cells in intestinal crypts’, Nature, 469(7330), pp. 415–418. 
Schiffner, S., Zimara, N., Schmid, R., & Bosserhoff, A.-K. (2011) ‘p54 nrb is a new regulator 
of progression of malignant melanoma ’, Carcinogenesis, 32(8), pp. 1176–1182. 
Schmidt, G. H., Winton, D. J., & Ponder, B. A. (1988) ‘Development of the pattern of cell 
renewal in the crypt-villus unit of chimaeric mouse small intestine’, Development, 103(4), pp. 
785–790. 
Schmitt, M., Schewe, M., Sacchetti, A., Feijtel, D., van de Geer, W. S., Teeuwssen, M., 
Sleddens, H. F., Joosten, R., van Royen, M. E., van de Werken, H. J. G., van Es, J., Clevers, 
H., & Fodde, R. (2018) ‘Paneth Cells Respond to Inflammation and Contribute to Tissue 
Regeneration by Acquiring Stem-like Features through SCF/c-Kit Signaling’, Cell Reports, 
24(9), pp. 2312-2328.e7. 
Schonhoff, S. E., Giel-Moloney, M., & Leiter, A. B. (2004) ‘Neurogenin 3-expressing 
progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-
endocrine cell types’, Developmental Biology, 270(2), pp. 443–454. 
References 201 
 
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., 
Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., Rupec, R. A., Gerhard, M., Schmid, R., 
Barker, N., Clevers, H., Lang, R., Neumann, J., Kirchner, T., Taketo, M. M., van den Brink, 
G. R., Sansom, O. J., Arkan, M. C., & Greten, F. R. (2013) ‘Intestinal Tumorigenesis Initiated 
by Dedifferentiation and Acquisition of Stem-Cell-like Properties’, Cell, 152(1), pp. 25–38. 
Shaked, H., Hofseth, L. J., Chumanevich, A., Chumanevich, A. A., Wang, J., Wang, Y., 
Taniguchi, K., Guma, M., Shenouda, S., Clevers, H., Harris, C. C., & Karin, M. (2012) 
‘Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation 
through iNOS up-regulation’, Proceedings of the National Academy of Sciences of the United 
States of America. 2012/08/14. National Academy of Sciences, 109(35), pp. 14007–14012. 
Shaukat, A., Dostal, A., Menk, J., & Church, T. R. (2017) ‘BMI Is a Risk Factor for 
Colorectal Cancer Mortality’, Digestive Diseases and Sciences, 62(9), pp. 2511–2517. 
Shay, G., Lynch, C. C., & Fingleton, B. (2015) ‘Moving targets: Emerging roles for MMPs in 
cancer progression and metastasis’, Matrix biology : journal of the International Society for 
Matrix Biology. 2015/01/31, 44–46, pp. 200–206. 
Shoshkes-Carmel, M., Wang, Y. J., Wangensteen, K. J., Tóth, B., Kondo, A., Massassa, E. E., 
Itzkovitz, S., & Kaestner, K. H. (2018) ‘Subepithelial telocytes are an important source of 
Wnts that supports intestinal crypts’, Nature. 
Siegmund, K. D., Marjoram, P., Tavaré, S., & Shibata, D. (2009) ‘Many colorectal cancers 
are “flat” clonal expansions’, Cell Cycle. Taylor & Francis, 8(14), pp. 2187–2193. 
Sievers, C. K., Zou, L. S., Pickhardt, P. J., Matkowskyj, K. A., Albrecht, D. M., Clipson, L., 
Bacher, J. W., Pooler, B. D., Moawad, F. J., Cash, B. D., Reichelderfer, M., Vo, T. N., 
Newton, M. A., Larget, B. R., & Halberg, R. B. (2017) ‘Subclonal diversity arises early even 
in small colorectal tumours and contributes to differential growth fates’, Gut. 2016/09/08. 
BMJ Publishing Group, 66(12), pp. 2132–2140. 
Silva, J. M., Bagni, R. K., Ruggero, D., & McCormick, F. (2017) ‘Abstract B11: Oncogenic 
KRAS regulates 4E-BP1, a repressor of cap-dependent translation, independently of growth 
factor activity’, Cancer Research, 77(6 Supplement), p. B11. 
202 References 
 
 
Sivridis, E., Giatromanolaki, A., & Koukourakis, M. I. (2005) ‘Proliferating fibroblasts at the 
invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers 
of hypoxia, acidity, and oxidative stress’, Journal of clinical pathology. Copyright 2005 
Journal of Clinical Pathology, 58(10), pp. 1033–1038. 
Smit, A. F. A., Hubley, R., & Green, P. (no date) ‘RepeatMasker Open-4.0.’ 
Snippert, H. J., Haegebarth, A., Kasper, M., Jaks, V., van Es, J. H., Barker, N., van de 
Wetering, M., van den Born, M., Begthel, H., Vries, R. G., Stange, D. E., Toftgård, R., & 
Clevers, H. (2010) ‘&lt;em&gt;Lgr6&lt;/em&gt; Marks Stem Cells in the Hair Follicle That 
Generate All Cell Lineages of the Skin’, Science, 327(5971), pp. 1385 LP – 1389. 
Snippert, H. J., van der Flier, L. G., Sato, T., van Es, J. H., van den Born, M., Kroon-
Veenboer, C., Barker, N., Klein, A. M., van Rheenen, J., Simons, B. D., & Clevers, H. (2010) 
‘Intestinal Crypt Homeostasis Results from Neutral Competition between Symmetrically 
Dividing Lgr5 Stem Cells’, Cell, 143(1), pp. 134–144. 
Snippert, H. J., Schepers, A. G., van Es, J. H., Simons, B. D., & Clevers, H. (2013) ‘Biased 
competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal 
expansion’, EMBO reports, p. e201337799. 
Snyder, C. & Hampel, H. (2019) ‘Hereditary Colorectal Cancer Syndromes’, Seminars in 
Oncology Nursing, 35(1), pp. 58–78. 
Soardi, F. C., Machado-Silva, A., Linhares, N. D., Zheng, G., Qu, Q., Pena, H. B., Martins, T. 
M. M., Vieira, H. G. S., Pereira, N. B., Melo-Minardi, R. C., Gomes, C. C., Gomez, R. S., 
Gomes, D. A., Pires, D. E. V, Ascher, D. B., Yu, H., & Pena, S. D. J. (2017) ‘Familial 
STAG2 germline mutation defines a new human cohesinopathy’, NPJ Genomic Medicine, 
2(1), p. 7. 
Solomon, D. A., Kim, T., Diaz-Martinez, L. A., Fair, J., Elkahloun, A. G., Harris, B. T., 
Toretsky, J. A., Rosenberg, S. A., Shukla, N., Ladanyi, M., Samuels, Y., James, C. D., Yu, H., 
Kim, J.-S., & Waldman, T. (2011) ‘Mutational Inactivation of <em>STAG2</em> Causes 
References 203 
 
Aneuploidy in Human Cancer’, Science, 333(6045), pp. 1039–1043. 
Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J., Marjoram, P., 
Siegmund, K., Press, M. F., Shibata, D., & Curtis, C. (2015) ‘A Big Bang model of human 
colorectal tumor growth’, Nature genetics, 47(3), pp. 209–216. 
Spalding, K. L., Bhardwaj, R. D., Buchholz, B. A., Druid, H., & Frisén, J. (2005) 
‘Retrospective Birth Dating of Cells in Humans’, Cell, 122(1), pp. 133–143. 
Spit, M., Koo, B.-K., & Maurice, M. M. (2018) ‘Tales from the crypt: intestinal niche signals 
in tissue renewal, plasticity and cancer’, Open biology. The Royal Society, 8(9), p. 180120. 
Staffa, L., Echterdiek, F., Nelius, N., Benner, A., Werft, W., Lahrmann, B., Grabe, N., 
Schneider, M., Tariverdian, M., von Knebel Doeberitz, M., Bläker, H., & Kloor, M. (2015) 
‘Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome – Molecular Alterations and 
Association with Clinical Parameters’, PLOS ONE, 10(3), p. e0121980. 
Sternberg, N. & Hamilton, D. (1981) ‘Bacteriophage P1 site-specific recombination: I. 
Recombination between loxP sites’, Journal of Molecular Biology, 150(4), pp. 467–486. 
Strober, W., Fuss, I., & Mannon, P. (2007) ‘The fundamental basis of inflammatory bowel 
disease’, The Journal of clinical investigation. American Society for Clinical Investigation, 
117(3), pp. 514–521. 
Sugimoto, S., Ohta, Y., Fujii, M., Matano, M., Shimokawa, M., Nanki, K., Date, S., 
Nishikori, S., Nakazato, Y., Nakamura, T., Kanai, T., & Sato, T. (2018) ‘Reconstruction of 
the Human Colon Epithelium In Vivo’, Cell Stem Cell, 22(2), pp. 171-176.e5. 
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) ‘Combination Therapy With Histone 
Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic 
Potential of HDACi’, Frontiers in oncology. Frontiers Media S.A., 8, p. 92. 
Takayama, T., Katsuki, S., Takahashi, Y., Ohi, M., Nojiri, S., Sakamaki, S., Kato, J., Kogawa, 
K., Miyake, H., & Niitsu, Y. (1998) ‘Aberrant Crypt Foci of the Colon as Precursors of 
Adenoma and Cancer’, New England Journal of Medicine. Massachusetts Medical Society, 
339(18), pp. 1277–1284. 
204 References 
 
 
Takayama, T., Ohi, M., Hayashi, T., Miyanishi, K., Nobuoka, A., Nakajima, T., Satoh, T., 
Takimoto, R., Kato, J., Sakamaki, S., & Niitsu, Y. (2001) ‘Analysis of K-<em>ras</em>, 
<em>APC</em>, and &#x3b2;-<em>catenin</em> in aberrant crypt foci in sporadic 
adenoma, cancer, and familial adenomatous polyposis’, Gastroenterology. Elsevier, 121(3), 
pp. 599–611. 
Takeda, N., Jain, R., LeBoeuf, M. R., Wang, Q., Lu, M. M., & Epstein, J. A. (2011) 
‘Interconversion Between Intestinal Stem Cell Populations in Distinct Niches’, Science, 
334(6061), pp. 1420–1424. 
Taylor, R. W., Barron, M. J., Borthwick, G. M., Gospel, A., Chinnery, P. F., Samuels, D. C., 
Taylor, G. A., Plusa, S. M., Needham, S. J., Greaves, L. C., Kirkwood, T. B. L., & Turnbull, 
D. M. (2003) ‘Mitochondrial DNA mutations in human colonic crypt stem cells’, The Journal 
of Clinical Investigation, 112(9), pp. 1351–1360. 
Taylor, R. W. & Turnbull, D. M. (2005) ‘Mitochondrial DNA mutations in human disease’, 
Nat Rev Genet, 6(5), pp. 389–402. 
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) ‘Inflammation and Colon Cancer’, 
Gastroenterology. Elsevier, 138(6), pp. 2101-2114.e5. 
Thirlwell, C., Will, O. C. C., Domingo, E., Graham, T. A., McDonald, S. A. C., Oukrif, D., 
Jeffrey, R., Gorman, M., Rodriguez–Justo, M., Chin–Aleong, J., Clark, S. K., Novelli, M. R., 
Jankowski, J. A., Wright, N. A., Tomlinson, I. P. M., & Leedham, S. J. (2010) ‘Clonality 
Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of 
Colorectal Adenomas’, Gastroenterology, 138(4), pp. 1441-1454.e7. 
Tian, H., Biehs, B., Warming, S., Leong, K. G., Rangell, L., Klein, O. D., & de Sauvage, F. J. 
(2011) ‘A reserve stem cell population in small intestine renders Lgr5-positive cells 
dispensable’, Nature, 478(7368), pp. 255–259. 
Tomasetti, C., Li, L., & Vogelstein, B. (2017) ‘Stem cell divisions, somatic mutations, cancer 
etiology, and cancer prevention’, Science, 355(6331), pp. 1330–1334. 
References 205 
 
Tomasetti, C. & Vogelstein, B. (2015) ‘Variation in cancer risk among tissues can be 
explained by the number of stem cell divisions’, Science, 347(6217), pp. 78–81. 
Tomasetti, C., Vogelstein, B., & Parmigiani, G. (2013) ‘Half or more of the somatic 
mutations in cancers of self-renewing tissues originate prior to tumor initiation’, Proceedings 
of the National Academy of Sciences of the United States of America, 110(6), pp. 1999–2004. 
Totafurno, J., Bjerknes, M., & Cheng, H. (1987) ‘The crypt cycle. Crypt and villus production 
in the adult intestinal epithelium’, Biophysical journal, 52(2), pp. 279–294. 
Traish, A. M., Huang, Y.-H., Ashba, J., Pronovost, M., Pavao, M., McAneny, D. B., & 
Moreland, R. B. (1997) ‘Loss of Expression of a 55 kDa Nuclear Protein (nmt55) in Estrogen 
Receptor-Negative Human Breast Cancer.’, Diagnostic Molecular Pathology, 6(4), pp. 209–
221. 
Tukiainen, T., Villani, A.-C., Yen, A., Rivas, M. A., Marshall, J. L., MacArthur, D. G., et al. 
(2017) ‘Landscape of X chromosome inactivation across human tissues’, Nature, 550(7675), 
pp. 244–248. 
Turner, N. D. & Lloyd, S. K. (2017) ‘Association between red meat consumption and colon 
cancer: A systematic review of experimental results’, Experimental biology and medicine, 
242(8), pp. 813–839. 
Unni, A. M., Harbourne, B., Oh, M. H., Wild, S., Ferrarone, J. R., Lockwood, W. W., & 
Varmus, H. (2018) ‘Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS 
mutation-driven lung adenocarcinoma cells’, eLife, 7, p. e33718. 
Vavougios, G. D., Solenov, E. I., Hatzoglou, C., Baturina, G. S., Katkova, L. E., Molyvdas, P. 
A., Gourgoulianis, K. I., & Zarogiannis, S. G. (2015) ‘Computational genomic analysis of 
PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring 
survival in malignant pleural mesothelioma’, American Journal of Physiology-Lung Cellular 
and Molecular Physiology, 309(7), pp. L677–L686. 
Veh, R. W., Meessen, D., Kuntz, H. D., & May, B. (1982) ‘A new method for histochemical 
demonstration of side chain substituted sialic acids.’, Colonic Carcinogenesis, pp. 355–365. 
206 References 
 
 
Verdel, A., Curtet, S., Brocard, M.-P., Rousseaux, S., Lemercier, C., Yoshida, M., & 
Khochbin, S. (2000) ‘Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the 
cytoplasm’, Current Biology, 10(12), pp. 747–749. 
Vermeulen, L., Morrissey, E., van der Heijden, M., Nicholson, A. M., Sottoriva, A., 
Buczacki, S., Kemp, R., Tavaré, S., & Winton, D. J. (2013) ‘Defining Stem Cell Dynamics in 
Models of Intestinal Tumor Initiation’, Science, 342(6161), pp. 995–998. 
Vieler, M. & Sanyal, S. (2018) ‘p53 Isoforms and Their Implications in Cancer’, Cancers, 
10(9), p. 288. 
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) ‘Paradoxical roles of the immune 
system during cancer development’, Nature Reviews Cancer, 6(1), pp. 24–37. 
Vogelstein, B., Lane, D., & Levine, A. J. (2000) ‘Surfing the p53 network’, Nature, 
408(6810), pp. 307–310. 
Vousden, K. H. & Prives, C. (2009) ‘Blinded by the Light: The Growing Complexity of p53’, 
Cell, 137(3), pp. 413–431. 
Walport, L. J., Hopkinson, R. J., Vollmar, M., Madden, S. K., Gileadi, C., Oppermann, U., 
Schofield, C. J., & Johansson, C. (2014) ‘Human UTY(KDM6C) Is a Male-specific N(ϵ)-
Methyl Lysyl Demethylase’, The Journal of Biological Chemistry, 289(26), pp. 18302–
18313. 
Wargovich, M. J., Brown, V. R., & Morris, J. (2010) ‘Aberrant crypt foci: the case for 
inclusion as a biomarker for colon cancer’, Cancers. MDPI, 2(3), pp. 1705–1716. 
Wasan, H. S., Park, H.-S., Liu, K. C., Mandir, N. K., Winnett, A., Sasieni, P., Bodmer, W. F., 
Goodlad, R. A., & Wright, N. A. (1998) ‘APC in the regulation of intestinal crypt fission’, 
The Journal of Pathology, 185(3), pp. 246–255. 
Weissman, I. L. (2000) ‘Stem cells: units of development, units of regeneration, and units in 
evolution.’, Cell, 100(1), pp. 157–168. 
References 207 
 
Weissman, I. L. & Shizuru, J. A. (2008) ‘The origins of the identification and isolation of 
hematopoietic stem cells, and their capability to induce donor-specific transplantation 
tolerance and treat autoimmune diseases’, Blood, 112(9), pp. 3543–3553. 
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Wilson, R. K., et al. (2012) 
‘The origin and evolution of mutations in acute myeloid leukemia’, Cell, 150(2), pp. 264–278. 
Westbrook, A. M., Wei, B., Braun, J., & Schiestl, R. H. (2009) ‘Intestinal mucosal 
inflammation leads to systemic genotoxicity in mice’, Cancer research, 69(11), pp. 4827–
4834. 
Winner, B., Cooper-Kuhn, C. M., Aigner, R., Winkler, J., & Kuhn, H. G. (2002) ‘Long-term 
survival and cell death of newly generated neurons in the adult rat olfactory bulb’, European 
Journal of Neuroscience, 16(9), pp. 1681–1689. 
Winton, D. J., Blount, M. A., & Ponder, B. A. J. (1988) ‘A clonal marker induced by 
mutation in mouse intestinal epithelium’, Nature, 333(6172), pp. 463–466. 
Wong, W.-M., Mandir, N., Goodlad, R. A., Wong, B. C. Y., Garcia, S. B., Lam, S.-K., & 
Wright, N. A. (2002) ‘Histogenesis of human colorectal adenomas and hyperplastic polyps: 
the role of cell proliferation and crypt fission’, Gut, 50(2), pp. 212 LP – 217. 
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. 
M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., 
Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., 
Dawson, D., Shipitsin, M., Willson, J. K. V, Sukumar, S., Polyak, K., Park, B. H., 
Pethiyagoda, C. L., Pant, P. V. K., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R., 
Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani, G., Kinzler, K. W., 
Velculescu, V. E., & Vogelstein, B. (2007) ‘The Genomic Landscapes of Human Breast and 
Colorectal Cancers’, Science, 318(5853), pp. 1108–1113. 
Wright, N. A. & Al-Nafussi, A. (1982) ‘The kinetics of villus cell populations in the mouse 
small intestine. II. Studies on growth control after death of proliferative cells induced by 
cytosine arabinoside, with special reference to negative feedback mechanisms.’, Cell Tissue 
Kinet., 15(6), pp. 611–21. 
208 References 
 
 
Wu, S., Powers, S., Zhu, W., & Hannun, Y. A. (2016) ‘Substantial contribution of extrinsic 
risk factors to cancer development’, Nature, 529(7584), pp. 43–47. 
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., 
Schmidt, H. K., Yellapantula, V., Miller, C. A., Ozenberger, B. A., Welch, J. S., Link, D. C., 
Walter, M. J., Mardis, E. R., Dipersio, J. F., Chen, F., Wilson, R. K., Ley, T. J., & Ding, L. 
(2014) ‘Age-related mutations associated with clonal hematopoietic expansion and 
malignancies’, Nature medicine, 20(12), pp. 1472–1478. 
Yan, K. S., Chia, L. A., Li, X., Ootani, A., Su, J., Lee, J. Y., Su, N., Luo, Y., Heilshorn, S. C., 
Amieva, M. R., Sangiorgi, E., Capecchi, M. R., & Kuo, C. J. (2012) ‘The intestinal stem cell 
markers Bmi1 and Lgr5 identify two functionally distinct populations’, Proceedings of the 
National Academy of Sciences, 109(2), pp. 466 LP – 471. 
Yan, K. S., Gevaert, O., Zheng, G. X. Y., Anchang, B., Probert, C. S., Larkin, K. A., Davies, 
P. S., Cheng, Z.-F., Kaddis, J. S., Han, A., Roelf, K., Calderon, R. I., Cynn, E., Hu, X., 
Mandleywala, K., Wilhelmy, J., Grimes, S. M., Corney, D. C., Boutet, S. C., Terry, J. M., 
Belgrader, P., Ziraldo, S. B., Mikkelsen, T. S., Wang, F., von Furstenberg, R. J., Smith, N. R., 
Chandrakesan, P., May, R., Chrissy, M. A. S., Jain, R., Cartwright, C. A., Niland, J. C., Hong, 
Y.-K., Carrington, J., Breault, D. T., Epstein, J., Houchen, C. W., Lynch, J. P., Martin, M. G., 
Plevritis, S. K., Curtis, C., Ji, H. P., Li, L., Henning, S. J., Wong, M. H., & Kuo, C. J. (2017) 
‘Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem 
Cell Activity’, Cell stem cell, 21(1), pp. 78-90.e6. 
Yang, C.-Y., Tseng, J.-Y., Chen, C.-F., Chou, T.-Y., Gao, H.-W., Hua, C.-L., Lin, C.-H., Lin, 
J.-K., & Jiang, J.-K. (2015) ‘Genome-wide copy number changes and CD133 expression 
characterized distinct subset of colon polyps: differentiation between incidental polyps and 
cancer-associated polyps’, International Journal of Colorectal Disease, 30(12), pp. 1617–
1626. 
Yatabe, Y., Tavaré, S., & Shibata, D. (2001) ‘Investigating stem cells in human colon by 
using methylation patterns’, Proceedings of the National Academy of Sciences of the United 
References 209 
 
States of America, 98(19), pp. 10839–10844. 
Yau, S., Li, A., & So, K.-F. (2015) ‘Involvement of Adult Hippocampal Neurogenesis in 
Learning and Forgetting’, Neural plasticity, 2015, p. 717958. 
Yehia, L., Ngeow, J., & Eng, C. (2019) ‘PTEN-opathies: from biological insights to evidence-
based precision medicine.’, The Journal of Clinical Investigation, 129(2), pp. 452–464. 
Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., Frazer, R., Zhang, H., 
Haradhvala, N. J., Rosebrock, D., Livitz, D., Li, X., Arich-Landkof, E., Shoresh, N., Stewart, 
C., Segrè, A. V, Branton, P. A., Polak, P., Ardlie, K. G., & Getz, G. (2019) ‘RNA sequence 
analysis reveals macroscopic somatic clonal expansion across normal tissues’, Science, 
364(6444), p. eaaw0726. 
Yu, S., Tong, K., Zhao, Y., Balasubramanian, I., Yap, G. S., Ferraris, R. P., Bonder, E. M., 
Verzi, M. P., & Gao, N. (2018) ‘Paneth Cell Multipotency Induced by Notch Activation 
following Injury’, Cell stem cell. 2018/06/07, 23(1), pp. 46-59.e5. 
Yue, X., Zhao, Y., Huang, G., Li, J., Zhu, J., Feng, Z., & Hu, W. (2016) ‘A novel mutant p53 
binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in 
tumorigenesis’, Cell discovery, 2, p. 16039. 
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) ‘Mutant p53 in Cancer: 
Accumulation, Gain-of-Function, and Therapy’, Journal of molecular biology, 429(11), pp. 
1595–1606. 
Yurgelun, M. B. & Hampel, H. (2018) ‘Recent Advances in Lynch Syndrome: Diagnosis, 
Treatment, and Cancer Prevention’, American Society of Clinical Oncology Educational 
Book, (38), pp. 101–109. 
Zackular, J. P., Baxter, N. T., Iverson, K. D., Sadler, W. D., Petrosino, J. F., Chen, G. Y., & 
Schloss, P. D. (2013) ‘The Gut Microbiome Modulates Colon Tumorigenesis’, mBio, 4(6), 
pp. e00692-13. 
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Berger, M. F., et al. (2017) 
‘Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 
210 References 
 
 
10,000 patients’, Nature Medicine, 23(6), pp. 703–713. 
Zhang, G. & Gan, Y.-H. (2017) ‘Synergistic antitumor effects of the combined treatment with 
an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN’, Oncology Reports, 
38(5), pp. 2657–2666. 
Zhang, X., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J., Olashaw, N., 
Parsons, J. T., Yang, X.-J., Dent, S. R., Yao, T.-P., Lane, W. S., & Seto, E. (2007) ‘HDAC6 
modulates cell motility by altering the acetylation level of cortactin’, Molecular cell, 27(2), 
pp. 197–213. 
Zheng, J., Zhao, M., Li, J., Lou, G., Yuan, Y., Bu, S., & Xi, Y. (2017) ‘Obesity-associated 
digestive cancers: A review of mechanisms and interventions’, Tumor Biology, 39(3), p. 
1010428317695020. 
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, 
W. (2013) ‘Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function 
in tumorigenesis’, Nature communications, 4, p. 2996. 
Zhu, D., Keohavong, P., Finkelstein, S. D., Swalsky, P., Bakker, A., Weissfeld, J., Srivastava, 
S., & Whiteside, T. L. (1997) ‘K-ras Gene Mutations in Normal Colorectal Tissues from K-
ras Mutation-positive Colorectal Cancer Patients’, Cancer Research, 57(12), pp. 2485–2492. 
Zhu, Z., Zhao, X., Zhao, L., Yang, H., Liu, L., Li, J., Wu, J., Yang, F., Huang, G., & Liu, J. 
(2015) ‘p54nrb/NONO regulates lipid metabolism and breast cancer growth through SREBP-
1A’, Oncogene, 35(11), pp. 1399–1410. 
 
 
 
  
 
 Appendix A Patients included  
Patient ID = Number assigned in the Winton laboratory for anonymisation. 
Columns 4–15 denote different experimental parts.  
TRUE = Patient used, FALSE = Patient not used 
 
Patient_ID Age Sex HDAC6 KDM6A MAOA mPAS NONO P53 PTEN STAG2 KRAS 
mPAS  
fusion 
KDM6A  
fusion 
Fusion  
duration 
CDA_00002 59 M FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00003 85 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00005 60 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00008 84 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00010 60 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00013 52 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00016 66 F FALSE TRUE TRUE FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CDA_00019 66 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00021 88 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00022 66 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00024 87 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00025 66 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00026 78 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00027 76 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00028 84 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00029 78 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00030 64 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00031 79 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00033 68 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00034 73 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00035 69 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00037 91 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00039 84 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00041 72 F FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00043 76 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00046 77 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00048 77 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00049 78 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00050 73 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00051 79 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00052 85 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00054 64 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00058 58 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00060 60 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
A-2                                                                                     Patients included 
 
 
CDA_00061 73 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00063 76 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00064 52 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00065 67 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00066 84 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00067 88 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00068 81 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00069 68 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00070 88 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00071 62 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00073 76 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00074 79 M FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00075 78 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00076 81 M FALSE TRUE TRUE FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CDA_00077 66 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00078 43 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00080 64 M FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CDA_00081 70 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CDA_00082 76 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00083 61 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00084 45 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00086 83 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00087 79 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CDA_00088 41 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CDA_00089 82 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
CDA_00090 72 M FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00091 86 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00093 43 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00095 81 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00096 80 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
CDA_00097 77 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
CDA_00099 87 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00100 66 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00102 83 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00104 72 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00105 67 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00107 84 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00108 85 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00109 59 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00111 78 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00112 33 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00113 62 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00115 53 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CDA_00116 68 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CDA_00163 63 M FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00117 73 M FALSE TRUE TRUE TRUE TRUE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00118 74 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00119 83 M FALSE FALSE TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00121 60 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00125 75 M TRUE TRUE TRUE TRUE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00126 70 M FALSE TRUE TRUE TRUE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00127 85 M FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
Patients included A-3 
 
CRA_00128 70 F FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE FALSE TRUE TRUE 
CRA_00129 93 M FALSE TRUE TRUE TRUE TRUE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
CRA_00130 55 F TRUE TRUE TRUE TRUE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
CRA_00131 62 M TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00132 74 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00133 68 F FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE FALSE FALSE 
CRA_00134 64 F TRUE TRUE TRUE TRUE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
CRA_00182 68 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00183 69 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00184 64 F FALSE FALSE TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00185 86 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00186 66 M FALSE FALSE TRUE TRUE TRUE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00294 89 M TRUE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00295 85 F FALSE TRUE TRUE TRUE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00296 50 M TRUE FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00297 50 M TRUE TRUE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
CRA_00298 76 F FALSE TRUE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
CRA_00299 37 F FALSE TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00300 60 F TRUE TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00301 69 M FALSE TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00302 83 M TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 
CRA_00303 57 F TRUE TRUE TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00304 60 M TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00305 51 M TRUE TRUE TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 
CRA_00306 76 F TRUE TRUE TRUE TRUE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00307 62 F TRUE TRUE TRUE TRUE FALSE FALSE FALSE TRUE FALSE TRUE TRUE TRUE 
CRA_00308 73 F TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00309 80 F TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00310 78 F FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE FALSE FALSE FALSE 
CRA_00311 62 M FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE TRUE FALSE 
CRA_00312 67 M TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00313 57 M FALSE TRUE TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00314 89 M FALSE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00315 60 F FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00316 85 M FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00317 69 M FALSE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00318 48 M FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00319 89 F FALSE FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00347 68 M FALSE TRUE TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00348 56 F FALSE TRUE TRUE TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00349 37 M TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00350 70 M FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00351 68 F TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00353 83 F TRUE FALSE TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00354 83 F FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE FALSE FALSE 
CRA_00355 65 F TRUE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE FALSE FALSE 
CRA_00356 82 M FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00357 79 M FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00358 87 F FALSE TRUE TRUE TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00359 69 M TRUE TRUE TRUE TRUE TRUE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00360 65 F FALSE TRUE TRUE TRUE TRUE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00361 65 F FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00362 85 F FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE FALSE FALSE FALSE 
CRA_00363 72 M FALSE TRUE TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
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CRA_00364 74 M FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00365 74 F TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00366 77 F FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
CRA_00367 82 M FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE FALSE FALSE 
CRA_00370 69 M FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE 
CRA_00371 60 F FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00372 81 M FALSE TRUE TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00373 73 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
CRA_00374 84 M FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE FALSE TRUE TRUE 
CRA_00409 77 F FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
CRA_00410 55 F FALSE FALSE TRUE TRUE TRUE TRUE FALSE TRUE TRUE TRUE FALSE FALSE 
CRA_00411 90 M FALSE TRUE TRUE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
CRA_00412 68 F TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00413 65 F FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00414 72 F TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00415 85 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00418 81 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00419 46 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE FALSE TRUE TRUE TRUE 
CRA_00420 67 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00421 77 M TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00422 30 M TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00423 31 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00424 55 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00425 36 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00426 64 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00427 67 F TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00428 73 F TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00429 63 M TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE TRUE TRUE 
CRA_00430 69 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
CRA_00431 75 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE TRUE TRUE 
CRA_00432 73 M TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00433 80 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE 
CRA_00434 76 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00435 72 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE 
CRA_00436 84 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00437 55 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00438 76 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE 
CRA_00439 71 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE 
CRA_00440 65 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00441 69 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE 
CRA_00442 64 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00443 82 M TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00444 59 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00445 61 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00446 44 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00447 78 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00448 48 F TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00449 79 F TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00450 40 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00451 84 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE 
CRA_00452 33 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00453 34 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE 
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CRA_00454 48 F FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00455 82 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00456 80 M FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00457 80 M FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00458 70 F FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00459 85 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00460 48 F FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00461 72 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00462 84 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00463 72 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE FALSE FALSE 
CRA_00464 80 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00465 73 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00466 35 M FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00467 50 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00468 79 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00469 66 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00470 45 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00471 75 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00472 66 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
CRA_00473 85 F TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE 
CRA_00474 79 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00475 54 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00476 60 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00477 69 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00478 83 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00479 61 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
CRA_00480 57 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00481 64 M TRUE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00482 72 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00483 63 M TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00484 71 M TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00485 80 M TRUE TRUE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00486 80 M TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00487 52 M TRUE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00488 79 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00489 79 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00490 38 F FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE 
CRA_00491 47 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00492 89 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00493 59 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00494 83 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00495 75 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00496 39 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00497 84 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00498 57 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00499 77 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00500 65 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00501 79 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00502 71 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00503 74 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00504 71 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00505 72 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00506 61 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00507 56 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
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CRA_00508 70 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00509 81 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00510 75 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00511 76 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00512 87 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00513 60 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00514 67 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00516 58 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00517 47 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00518 76 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00519 59 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00520 70 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00521 86 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00522 87 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00523 74 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00524 65 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00525 72 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00526 33 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00527 42 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00528 75 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
CRA_00529 62 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDA_00123 42 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDA_00124 60 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00245 81 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00247 85 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE 
NDX_00248 36 F FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00252 45 F FALSE TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00253 56 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00254 82 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00255 21 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00258 49 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00259 84 F FALSE TRUE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00260 53 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00261 71 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00262 40 M FALSE TRUE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00263 66 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00264 82 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00265 58 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00266 13 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00320 69 M FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00322 72 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00323 20 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00324 33 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
NDX_00325 77 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00326 64 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
NDX_00327 69 M TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
NDX_00328 34 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00329 81 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00330 91 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00331 83 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00332 50 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00333 72 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
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NDX_00334 73 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00335 75 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
NDX_00336 41 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00337 74 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00338 65 F/M FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE FALSE FALSE 
NDX_00339 74 F TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE 
NDX_00341 64 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00342 42 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00343 74 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE 
NDX_00344 64 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00369 68 F FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE TRUE TRUE FALSE 
NDX_00370 68 M FALSE FALSE TRUE TRUE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00371 76 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00372 58 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00373 58 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00374 60 M FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00375 74 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00376 64 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00377 65 F FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00378 62 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00379 62 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00380 59 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00381 57 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00382 65 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00383 71 F TRUE FALSE FALSE FALSE TRUE TRUE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00384 8 M TRUE FALSE TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00385 43 M TRUE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00386 68 F TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00387 58 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00388 69 F FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00389 63 F TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE FALSE FALSE 
NDX_00390 79 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00393 78 M FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
NDX_00394 73 F FALSE TRUE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00396 80 F FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE TRUE FALSE FALSE 
NDX_00397 75 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00398 59 M FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE TRUE TRUE 
NDX_00399 84 M FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00400 65 F FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
NDX_00401 70 M FALSE FALSE FALSE FALSE TRUE TRUE FALSE TRUE FALSE FALSE FALSE FALSE 
NDX_00402 44 F FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00403 64 M FALSE TRUE FALSE FALSE TRUE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
NDX_00404 81 F/M FALSE TRUE TRUE FALSE TRUE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NDX_00405 59 M FALSE TRUE FALSE FALSE TRUE FALSE FALSE TRUE TRUE FALSE TRUE TRUE 
NDX_00406 74 M FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE TRUE TRUE 
NDX_00407 71 M TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE TRUE TRUE TRUE 
NDX_00408 41 M FALSE FALSE TRUE FALSE FALSE FALSE FALSE TRUE TRUE FALSE FALSE FALSE 
NRA_00345 72 F FALSE TRUE TRUE FALSE FALSE TRUE FALSE TRUE TRUE FALSE FALSE FALSE 
NRA_00346 49 F TRUE TRUE TRUE TRUE FALSE TRUE FALSE TRUE FALSE TRUE TRUE TRUE 
NRA_00368 79 F FALSE TRUE TRUE TRUE FALSE TRUE FALSE TRUE TRUE TRUE TRUE TRUE 
NRA_00369 72 F TRUE TRUE TRUE FALSE FALSE TRUE FALSE TRUE FALSE FALSE TRUE TRUE 
NRA_00416 77 F FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE TRUE TRUE 
NRA_00417 46 F FALSE TRUE FALSE FALSE FALSE TRUE FALSE FALSE TRUE FALSE FALSE FALSE 
 
  
 
 Appendix B Primers 
Table B.1 Primers used for FFPE DNA PCR amplicon size test 
Primer names include gene name and size of resulting amplicon. LOC = non-coding RNA 
107985193. 
Primer Sequence (5' -> 3') 
MAOA_150_F1 ACCCATCAGTTACTCCTTCCC 
MAOA_150_R1 GGGATTAAAGCTGGGAGTTTCT 
MAOA_150_F2 TAGCAGGGCCTTGAATCTGT 
MAOA_150_R2 GATAGTGCCCAGAGTCACCA 
STAG2_150_F1 GGAGAAGAAGACACAGTTGGATG 
STAG2_150_R1 TTCTGTGAGGCATTTAGGGAAAA 
STAG2_150_F2 CCTATGCTCGCACAACTATGAG 
STAG2_150_R2 GGAAGCCACACATCCTCTCT 
CASD1_150_F1 ACCTGGAAACCCTATGCTCAA 
CASD1_150_R1 TGCAGCTATACATGCCAACC 
LOC_150_F1 TCGTCTGCTTCATCCTCCTC 
LOC_150_R1 GCCTAACATGCTTGGACCAC 
MAOA_250_F1 TGCAAGTCTTAGGTTGGTTGC 
MAOA_250_R1 TCAGTAATGGGTCATGTGCAAA 
MAOA_250_F2 AAGACATGTAGGGTTGGGGC 
MAOA_250_R2 CAGAACACCCTGCTCTAACCT 
STAG2_250_F1 GACTCTAAGGCCAGGTCAGG 
STAG2_250_R1 GGAGGTGAGTTGTGGTGTCT 
STAG2_250_F2 GCCTAATCATTCTCCCTGACCT 
STAG2_250_R2 TGGTGTCAAAATCCATTCCCTC 
CASD1_250_F1 GGTTAGAGGAAGACAAAAGTGGA 
CASD1_250_R1 CCTCAGTCCACACTTTGATACAC 
LOC_250_F1 AGCTTACCTCTTTGTCTCTTCCT 
LOC_250_R1 CAACCTCAAAGTATCACGTGGA 
MAOA_350_F1 TTCCTTCAGAAATTGAATCCTTG 
MAOA_350_R1 CCTGGGAGAAAGCAAAATCA 
MAOA_350_F2 TCCCGGAGTATCAGCAAAAG 
MAOA_350_R2 CATGAGAGACCCCCAAACAC 
STAG2_350_F1 TCCGAATATTTTTGGTGCATT 
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STAG2_350_R1 CAGAGCCTTGATGAGTGCTG 
STAG2_350_F2 TCTGAAGGAATGCTATGGTATGAA 
STAG2_350_R2 TTGTCAAGGGTCATAGACACAA 
CASD1_350_F1 CTTTGGGAAGCTTTGCGTAAAA 
CASD1_350_R1 CGATTCAGGAAGATGTAAGCCA 
LOC_350_F1 TCAGGAATGATGGTCTACGTGA 
LOC_350_R1 TCTCAGCTCTATTCCGTGAGT 
 
Table B.2 Primers used for amplification of MAOA. 
Number = amplicon number, F = forward primer, R = reverse primer. Sequence includes 
Fluidigm CS adapters. 
Primer Sequence (5' -> 3') 
1_F ACACTGACGACATGGTTCTACACTCCTGTGCCTACGACCC 
1_R TACGGTAGCAGAGACTTGGTCTGTTCCCCTACCCCTCACTG 
2_F ACACTGACGACATGGTTCTACATAAGCATTTGAATGTTACGTTGCT 
2_R TACGGTAGCAGAGACTTGGTCTATATGTTCTTCCTCCAACCCTGT 
3_F ACACTGACGACATGGTTCTACATGCTGCCAAACTCTTGACTG 
3_R TACGGTAGCAGAGACTTGGTCTCTGTGATTTCCAGTGGTGCC 
4_F ACACTGACGACATGGTTCTACATTTATAGGGGAGATGTAAGGCAC 
4_R TACGGTAGCAGAGACTTGGTCTGTTGGTCCCACATAAGCTCC 
5_F ACACTGACGACATGGTTCTACATGATTACGTAGATGTTGGTGGAG 
5_R TACGGTAGCAGAGACTTGGTCTAATGCTTCCCTATCAGTCACTT 
6_F ACACTGACGACATGGTTCTACACATTTCGGGGCGCCTTTC 
6_R TACGGTAGCAGAGACTTGGTCTTGGGTCATGTGCAAACTGAAC 
7_F ACACTGACGACATGGTTCTACACCGAGAAGAGGTGGCAGTTA 
7_R TACGGTAGCAGAGACTTGGTCTACTTTGTCCAGCAGATTTTGTCA 
8_F ACACTGACGACATGGTTCTACAGAGGCTCAACATGCTGACAA 
8_R TACGGTAGCAGAGACTTGGTCTGTTGTTAAGAAAAGCACTGCAGT 
9_F ACACTGACGACATGGTTCTACAACATGACATTCTCTGACTCCTGT 
9_R TACGGTAGCAGAGACTTGGTCTCCCCGCACTGCTTCACATA 
10_F ACACTGACGACATGGTTCTACAATGTGACCTCTGAGCCTCAC 
10_R TACGGTAGCAGAGACTTGGTCTTGCCCTGGGAGAAAGCAAAA 
11_F ACACTGACGACATGGTTCTACATTTTCCTTCCTTGGGCTTTCAT 
11_R TACGGTAGCAGAGACTTGGTCTAGTGACAGGATGGTTCAGCT 
12_F ACACTGACGACATGGTTCTACAAAGTGAGCGAACGGATAATGG 
12_R TACGGTAGCAGAGACTTGGTCTACTGCAAAAGACACAAGGCC 
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13_F ACACTGACGACATGGTTCTACACACAAAGACTGCAGCTCACAT 
13_R TACGGTAGCAGAGACTTGGTCTTGCACTTAATGACAGCTCCCA 
14_F ACACTGACGACATGGTTCTACAGATCCCTCCGACCTTGACTG 
14_R TACGGTAGCAGAGACTTGGTCTACATGAATAATAGCAGCCTACCC 
15_F ACACTGACGACATGGTTCTACATGTGTGTATGGGTGTCTCTGA 
15_R TACGGTAGCAGAGACTTGGTCTCACCCTGCTCTAACCTACCC 
16_F ACACTGACGACATGGTTCTACAGAGGAGGAGGGTCTGAGAGA 
16_R TACGGTAGCAGAGACTTGGTCTCCTTATGTAGCTTAGCAAGTCGA 
17_F ACACTGACGACATGGTTCTACATTCTTGCCCGGAAAGCTG 
17_R TACGGTAGCAGAGACTTGGTCTGTGAAGTACTGTGTTTTTCCTCAT 
18_F ACACTGACGACATGGTTCTACATACCCATCAGTTACTCCTTCCC 
18_R TACGGTAGCAGAGACTTGGTCTGGGATTAAAGCTGGGAGTTTC 
19_F ACACTGACGACATGGTTCTACATTTCTTCCCCACTGAACTGC 
19_R TACGGTAGCAGAGACTTGGTCTAGGTCTTGGATTAATTGGCGT 
20_F ACACTGACGACATGGTTCTACACCCACCTTCCCAAGTAACTC 
20_R TACGGTAGCAGAGACTTGGTCTTTCCTGCTTACCTCCCTAGC 
21_F ACACTGACGACATGGTTCTACATACATGGAAGGGGCAGTTGA 
21_R TACGGTAGCAGAGACTTGGTCTATGAGTGAGGGGCAGAGAAA 
22_F ACACTGACGACATGGTTCTACAGCAGGGCCTTGAATCTGTAG 
22_R TACGGTAGCAGAGACTTGGTCTAGATAGTGCCCAGAGTCACC 
23_F ACACTGACGACATGGTTCTACATTTTGCTCATGATCTGTGTTCC 
23_R TACGGTAGCAGAGACTTGGTCTGTACAGCACAAACCCCAGG 
24_F ACACTGACGACATGGTTCTACATGGCCTGCTGAAGATCATTG 
24_R TACGGTAGCAGAGACTTGGTCTTGACACAGCCTTTAAACTTGTC 
 
Table B.3 Primers used for amplification of KDM6A. 
Number = amplicon number, F = forward primer, R = reverse primer. Sequence includes 
Fluidigm CS adapters. 
Primer Sequence (5' -> 3') 
1_F ACACTGACGACATGGTTCTACACGCTTTCGGTGATGAGGAAA 
1_R TACGGTAGCAGAGACTTGGTCTCCGTACCTGTCCAGTCCG 
2_F ACACTGACGACATGGTTCTACATCTTTCAGGGCAATTAAAGCATT 
2_R TACGGTAGCAGAGACTTGGTCTACAACCTACCTTTAAACTAGACTCA 
3_F ACACTGACGACATGGTTCTACAGTACAATTGGACCATGGCCA 
3_R TACGGTAGCAGAGACTTGGTCTAGTGCAGAGGTATTACTACAACTT 
4_F ACACTGACGACATGGTTCTACACAGGATGCCATTAAATGCTACTT 
4_R TACGGTAGCAGAGACTTGGTCTTCTGGGGAAATATGTGGCTTT 
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5_F ACACTGACGACATGGTTCTACAATGCTGTGTCACATCCTCCA 
5_R TACGGTAGCAGAGACTTGGTCTACTTGTTTGCTACCTCTACTCCT 
6_F ACACTGACGACATGGTTCTACATGACAGATGAGACCAACAGGA 
6_R TACGGTAGCAGAGACTTGGTCTCAGGCTGAGAGACGCTAGG 
7_F ACACTGACGACATGGTTCTACACTGCCTACAAACTCAGTCTCTG 
7_R TACGGTAGCAGAGACTTGGTCTCAGAAAAGGGTCCATTGGCC 
8_F ACACTGACGACATGGTTCTACATAACCGCACAAACCTGACCA 
8_R TACGGTAGCAGAGACTTGGTCTTCTCTCAAAGTGTATAAAACCCAGT 
9_F ACACTGACGACATGGTTCTACACGACCTCTCTCTTCCACTGG 
9_R TACGGTAGCAGAGACTTGGTCTAATGCCTTGTTGTCCACCTG 
10_F ACACTGACGACATGGTTCTACAGGCTGCTCTCAATCACCTCT 
10_R TACGGTAGCAGAGACTTGGTCTGCAGTGCTGTTAGGTGTCTC 
11_F ACACTGACGACATGGTTCTACAGAGACACCTAACAGCACTGC 
11_R TACGGTAGCAGAGACTTGGTCTTCCCATCAACAAGGCAGAGA 
12_F ACACTGACGACATGGTTCTACAGCCATTTCAACAGCAACACC 
12_R TACGGTAGCAGAGACTTGGTCTGGGGCTCTGAGATTCTTCCA 
13_F ACACTGACGACATGGTTCTACAGGAAGAATCTCAGAGCCCCA 
13_R TACGGTAGCAGAGACTTGGTCTCACACTAACCTGCATGCCTT 
14_F ACACTGACGACATGGTTCTACAATGGACTTGTGCAAATGCCTAGTAA 
14_R TACGGTAGCAGAGACTTGGTCTTGGAGGTGGACATTTATCCAACAA 
15_F ACACTGACGACATGGTTCTACATGTTTTCCTGAGATCTAACCACA 
15_R TACGGTAGCAGAGACTTGGTCTCAAGGCCACGTATTACTGTAACA 
16_F ACACTGACGACATGGTTCTACATGTAGAACACTAAACTAGACTGCT 
16_R TACGGTAGCAGAGACTTGGTCTACACAGTATTAGAAACATGCCTTTT 
17_F ACACTGACGACATGGTTCTACAGTTCTGGGAGGAGGAGGAAA 
17_R TACGGTAGCAGAGACTTGGTCTAGCACAGGATAACTCTTTGCA 
18_F ACACTGACGACATGGTTCTACAAAACTTCCACAGGTATTTGTAGC 
18_R TACGGTAGCAGAGACTTGGTCTCCAACATGGCTTAGAAGATTTCC 
19_F ACACTGACGACATGGTTCTACAGTGGAAGTTGCAGCTACATGA 
19_R TACGGTAGCAGAGACTTGGTCTTGCTCCCTGGAACTTTCATG 
20_F ACACTGACGACATGGTTCTACAACCGTGTGCTAACCAATTGC 
20_R TACGGTAGCAGAGACTTGGTCTACAAACCATTCACAGTCACCT 
21_F ACACTGACGACATGGTTCTACAGGAGCTTCTTAATGTAGTTGATCC 
21_R TACGGTAGCAGAGACTTGGTCTGCTGAATAAACCTATACACTGGAAC 
22_F ACACTGACGACATGGTTCTACACTAATGGGTTCTTGGTGGCC 
22_R TACGGTAGCAGAGACTTGGTCTTGAACCCAATGAACAGTGCC 
23_F ACACTGACGACATGGTTCTACAGCTGGTCACAAATAATTTCTCCC 
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23_R TACGGTAGCAGAGACTTGGTCTTGAGCTGGTTCTTCTTTTGTCC 
24_F ACACTGACGACATGGTTCTACAACTTGGAAAACTTTGTGGTGCT 
24_R TACGGTAGCAGAGACTTGGTCTCACTGCTGCTTCATAACCCA 
 
Table B.4 Primers used for amplification of area around KRAS codons 12 and 13 as well 
as the mimic gene PITPNM2.  
Number = amplicon number, F = forward primer, R = reverse primer. Sequence includes 
Fluidigm CS adapters. 
Primer Sequence (5' -> 3') 
KRAS_1_F ACACTGACGACATGGTTCTACATAAGGCCTGCTGAAAATGACT 
KRAS_1_R TACGGTAGCAGAGACTTGGTCTATGGTCCTGCACCAGTAATATG 
MIMIC_1_F ACACTGACGACATGGTTCTACATAGCACCCAGCCAGCTTG 
MIMIC_1_R TACGGTAGCAGAGACTTGGTCTATGACCACCCATGAAATATGAGCT 
KRAS_2_F ACACTGACGACATGGTTCTACAGGTGGAGTATTTGATAGTGTATTAACC 
KRAS_2_R TACGGTAGCAGAGACTTGGTCTTAGCTGTATCGTCAAGGCAC 
MIMIC_2_F ACACTGACGACATGGTTCTACACCTGCTGTTCCTACAAAGCTG 
MIMIC_2_R TACGGTAGCAGAGACTTGGTCTAGGCTTCTCCCGTCTAAGGA 
 
  
 
 Appendix C Mathematical modelling of clonal marks 
data 
Analysis of clone data was performed by Dr Edward Morrissey, who wrote the following 
sections about the mathematical methods used. They were also published as part of our recent 
publication (Nicholson et al., 2018). 
C.1 A general note on simulations and the mathematical model 
Generally, we make use of a mathematical model (described below) that models the acquisition 
of a mutation, the competition of the mutant stem cell with the other stem cells and, once fixed, 
the fission of the mutant crypt.  
Additionally, the model was challenged with a more complex scenario to study whether more 
complexity is warranted. This was done using simulations that encode the same assumptions as 
the mathematical model but with additional behaviours. Specifically, the effect of double hits 
on the clonal dynamics was modelled.  Double hit simulations require just one tracking the 
individual cells and how many mutations each one has. All the simulations were coded in 
python using the numba library for speed.  
C.2 Statistical inference 
All data fitting was done using the statistical models described in the fitting sections below and 
sampled from using Rstan (Carpenter et al., 2017). Rstan was run using 5 chains of 10,000 
iterations and a thinning of 5. The default parameters were used for the sampler, though where 
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necessary, the models were reparamertised and run parameters adapted. Convergence was 
checked using the scale reduction factor provided by Rstan.  
Within chapters 4 and 5 estimates are presented as credible intervals (CI) or alternatively as a 
margin of error (ME) expressed as a median and 1.96 times the standard deviation of the 
posterior. For cases where new parameters, are calculated that are functions of the inferred 
parameters we apply the function to all the posterior mcmc samples and present the median and 
1.96 times the standard deviation of the transformed samples.  
For some of the cases below, Gaussians were used to model the population variability of a 
parameter defined in the [0, 1] range, for these cases the range of the parameter was specified 
in Stan. 
C.3 Statistical model 
Patients were selected based on tissue block size that so as to be able to estimate a mutation rate 
per block. In some cases we had several such blocks for the same patient, which we used within 
the statistical model to estimate the within patient variability and experimental error. A 
hierarchical model was used as follows, assuming we measure  TA clones for patient  in 
block , the number of goblet cells measured is  and the mutation rate for patient  is  the 
counts are distributed as 
 
 
We calculate the distribution of the mutation rate in the patient population as  
 
The priors used were: 
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C.4 Continuous labelling of a neutral mutation 
Here we describe the continuous labelling model that can be found in Kozar et al., (2013). It 
has been shown that crypts are maintained by an equipotent population of stem cells at the crypt 
base that constantly replace each other in a stochastic fashion (Lopez-Garcia et al., 2010; 
Snippert, van der Flier, et al., 2010). The equations that govern the change in clone size with 
time assume we start tracking the progeny of a clone of size 1 stem cell at t=0. The probability 
of a crypt having clone of size n (for 0<n<N) at time t is: 
 
Here n is the number of stem cells that make up the clone, N is the total number of stem cells 
in the crypt base and  is the rate of stem cell replacement. For the probability of the clone 
being of maximum size, i.e. a monoclonal crypt: 
 
For our case if we are tracking mutationally tagged clones. If we take the mutation rate to be  
the rate at which a crypt will get a mutationally activated clone will be  
 
If we write down the stochastic master equation for this: 
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We can solve and get  
 
As the mutation rate is very low we can use a Taylor expansion to get 
 
New clones of size one stem cell are appearing continuously over time, assuming the mutation 
has no effect on the stem cell dynamics, the clone size will evolve according to the equations 
above. To model the probability of clone size over time we can use the integral  
 
Which assumes that the clones that disappear due to stem cell competition have a negligible 
effect on .  
Solving for the non-monoclonal clones and pooling them to get the partial clone prediction we 
get: 
 
For the monoclonal clones we get 
  
The effect of the exponential term is quickly lost, leading to a constant term for the partials and 
a linear function for the monoclonals.  
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C.5 Continuous labelling of a non-neutral mutation 
Vermeulen et al., (2013) showed that certain mutations can affect the clonal dynamics. 
Furthermore, they showed that these altered dynamics could be parameterized by introducing a 
replacement probability, . The equations for the non-monoclonal and monoclonal clones are 
as follows: 
 
 
 
 
Where the following shorthand has been used: 
 
 
 
 
 
While the drift dynamics are different to the neutral case, the dynamics of the appearance of the 
initial mutations are the same; therefore we can derive the continuous labelling equations in the 
same way: 
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Which leads to  
 
 
 
For the sake of brevity we do not expand the equations, however it is worth noting that much 
like the neutral mutations, after a short initial period the monoclonals follow a linear equation 
and the partials converge to a constant value. For both the neutral and non-neutral cases the 
equations are proportional to the mutation rate, meaning that the ratio of the slope of the 
monoclonal accumulation over the partials gives a value that is independent of the mutation 
rate. This can be used as a way of comparing the clonal dynamics for different mutations. 
C.6 Fitting the monoclonal clones and partial clones 
As the probability of a crypt containing a monoclonal clone at time t is a linear function we fit 
the following model to the monoclonal data: 
 
 
Where  is the number of monoclonal crypts found for patient i,  is the number of crypts 
in the tissue sample,  is the patient age,  is the slope of the monoclonal accumulation for 
patient i and  is the x-axis intercept. As we expect the mutation rate to have some variation 
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between individuals, as well as the drift parameters, we allow each patient to have its own slope, 
using a hierarchical model 
 
The priors on the parameters are as follows 
 
 
 
Note how we are allowing  to be negative. While the stem cell dynamics equations suggest 
that the y-intercept should be negative, and as such the x-intercept should be positive it is 
possible that clones might arise during development that would increment the y-intercept 
allowing for the x-intercept to become negative. We choose a value that encompasses ~ 20 
years to either side of the origin to allow a wide range of values, however restricting implausible 
values. 
We follow a similar analysis for the partial clones.  
 
 
With priors 
 
 
C.7 Sequential mutations 
The mutation of STAG2, a gene that when mutated is associated with chromosomal instability, 
was found to have a biased behaviour. The fact that STAG2 is associated to chromosomal 
instability raises the question of whether the biased behaviour is the consequence of further 
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unmeasured mutations enabled by the chromosomal instability or directly caused by STAG2. 
To find which might be the most likely scenario we run simulations where we assume that a 
first neutral mutation raises the mutation rate of a second mutation that biases drift.  
The simulation uses the Gillespie Algorithm to simulate a single crypt with N stem cells, each 
of which starts with no mutations and can acquire a first mutation which doesn’t change the 
drift dynamics, however the mutant cells now have an enhanced probability of a second 
mutation which does lead to a bias. The simulation produces two outputs, the monoclonal and 
partial crypts for the first mutation, regardless of whether or not they have the second mutation 
(this would be what we measure with STAG2) and also outputs the full and partial crypts with 
both mutations (as you can’t have mutation 2 without 1).  
If we can only measure mutation 1, as happens with STAG2, in order to see altered dynamics 
caused by mutation 2 the mutation has to occur while mutation 1 has not yet become 
monoclonal, otherwise we would measure no difference.  
 
C.8 Crypt fission and mutation burden 
We model crypt fission as a Yule-Furry pure birth process. The general solution to this process 
is: 
 
Where  is the patch size at time t = 0 and  is the rate of crypt fission. In order to calculate 
the patch size distribution over time given that the monoclonal crypts appear following a known 
function we can use a similar calculation as for the continuous labelling equations. We fix 
 and integrate: 
 
Ignoring the exponential term from  which has a negligible effect, we find  
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Here  is the slope of the monoclonal accumulation. This equation also holds for 
mutations that affect clonal drift. We use this equation to estimate the mutant burden per million 
crypts used in the main text:  
 
C.9 Statistical model for patch sizes 
The patch size equation depends on the slope of the monoclonals, which we can infer from the 
monoclonal data. However, in order to minimise the uncertainty in the crypt fission estimation, 
we calculate the equation for the relative distribution of patch sizes that does not depend on the 
slope of the monoclonals: 
 
This is the same equation used by Baker et al., (2014). We also apply a correction for the 
confounding effect of two unrelated clones randomly being found next to each other and 
counted as a patch. If a tissue sample has  clones,  crypts and each crypt has  neighbouring 
crypts the proportion of clones that form random doublets will be: 
 
We do not calculate the probability of patches larger than two appearing due to chance as the 
probability of these events will be negligible. When fitting the model to the data we add  to 
 and subtract  from .  
As a first step for the fitting we filter samples with no clones as we are fitting the relative patch 
size. Again, we use a hierarchical model to account for patient-to-patient variability. If  is a 
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vector of measured patch sizes,  is the age of the patient,  is the fission rate for that patient 
we have  
 
 
Where  is the vector of probabilities of each patch size calculated from the fission equation 
and corrected as specified above. The priors used for the population parameters are 
 
 
C.10 Effect of crypt fusion on patch size 
A recent study has shown that crypts not only undergo fission, where a crypt divides into two 
crypts, but they can also fuse with a neighbouring crypt thus combining the stem cell pools. 
The study found that fission and fusion are balanced, both occurring at the same rate.  
At the clonal level fusion can cause a mutant crypt to join with a non-mutant producing a 
partially mutant crypt or two mutant crypts can join forming a single mutant crypt. This 
introduces a spatial aspect to the model, which complicates an analytical approach. To assess 
the effect of fusion we implement a stochastic simulation algorithm which uses the gillespie 
algorithm. The simulation models a field of crypts and implements the mutation process, stem 
cell drift, fission and fusion, including the spatial aspects as well as the two types of fusion 
events described above.  
The simulations showed that relative patch size is dominated by fission, with fusion having a 
very modest effect (Figure C.1). 
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Figure C.1 Effects of fission and fusion on patch size. 
Figure by Dr Edward Morrissey, modified from Supplementary Figure 6 in (Nicholson et al., 
2018). 
(A) Output of mathematical model for effects in WT crypts. 
(B) Output of mathematical model for effects in STAG2-deficient crypts. 
  
 
 Appendix D Mathematical modelling of KRAS data 
and comparison to clonal marks 
Mathematical modelling to infer the behaviour of KRAS-mutant clones from targeted 
sequencing data was performed by Dr Edward Morrissey who wrote the following sections. 
These were also partly published in our most recent publication (Nicholson et al., 2018). 
D.1 Statistical model for KRAS patch size estimation 
To analyse the KRAS mutant allele frequency data we first convert it to mutation burden. To do 
so we note that if in a section of tissue we have m mutant crypts, C total crypts and n cells per 
crypt the ratio of mutant copies of a gene to total copies of the gene will be 
 
 
which means that the allele frequency is half of the mutation burden. 
In order to model this data we can use the equation for patch sizes derived earlier, namely 
 
Which gives us the probability of finding a patch of size  at age .  The model has two 
parameters the fission rate  and the monoclonal accumulation rate . These are the two 
parameters we wish to infer from the data.  
The statistical fitting must account for the fact that there is a detection limit below which there 
may be clones but we cannot detect them. We set up the statistical model so that if the 
mathematical model predicts that there should be a patch but we measure none, as long as it is 
below the specified detection threshold, it does not penalise the fit.  
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We first take the measured allele frequency and convert them to mutation burden, we then use 
the number of crypts from that sample to convert the burden into patch size. We know how 
many crypts we have in the sample from the image analysis.  
We cannot directly use the patch size equation as we need to accommodate the fact that we 
have a range of possible patch sizes of which each patient will only have one, also the 
probability of not detecting a patch will need to be calculated depending on the values of the 
parameters.  
We model each patient sample as a multinomial with three categories, probability that a crypt 
has no detectable clone , probability  that we see a patch of size n (where n is the observed 
patch size) and  the probability of all the remaining patch sizes, used to normalise the 
multinomial . We calculate , which incorporates the detection threshold 
as  
 
 
Here  is the largest patch size that would not be detected. We calculate the probability of 
no clone with 
 
 
 
The likelihood will be 
 
 
 
Where q is the vector described above and  is a vector of 3 counts for patient : total crypts, 
zero or one if there is a patch and 0 for the third category. 
The priors used for the two parameters are:  
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We also need to scale  by the number of mutations we look at, which are 12.  
D.2 Relative expansion coefficient 
In order to derive a metric for each mutation that allows comparison of the ability of the 
mutation to spread through the tissue we calculate the burden of a mutation averaged over the 
lifetime of the individual. We then calculate the ratio of average burden between a given 
mutation and the wild-type parameters. By fixing the mutation rate to the same value for both 
average burden estimates, the mutation rate disappears from the ratio. 
 
We refer to this value as a relative expansion coefficient (Cexp). The values used in the main 
text were calculated numerically using the burden equation described in section C.8. 
  
 
 Appendix E Mathematical modelling of crypt fusion 
This was performed by Dr Doran Khamis who wrote the following paragraphs about the 
mathematical methods used. 
E.1 Fusion/Fission events as Poisson processes 
For individual crypts, fusion/fission events occur at a rate ρ and have a duration Δτ. If we take a snapshot 
of a piece of tissue at a time t0 we see all fusion/fission events that occurred in the window [t0 − Δτ, t0]. 
Calculating the average number of events per crypt, X, in a time Δτ over many snapshots is the same as 
calculating the probability of an event for a single crypt in the window Δτ (as we can only have a single 
event in any time window equal to the event duration). The number of events for a single crypt follows 
a Poisson distribution, 
X1 ∼ Poi(ρ Δτ). 
We want to observe events on the edge of mutant patches such that we can differentiate fission events 
from fusion events. For a patch with edge length N (that is, N crypts define the patch perimeter, each 
with at least one wild-type crypt as a neighbour), the number of crypts undergoing fusion or fission is 
distributed as  
XN ∼ Poi(N ρ Δτ). 
For a given patch with edge length N, then, the probability of zero events in a window Δτ is  
p{XN = 0} = e
−NρΔτ  ∼  1 − N ρ Δτ + 𝒪(N2ρ2Δτ2), 
where Nρ is considered small compared with Δτ such that we may define a parameter ε = N ρ Δτ where 
ε ≪ 1. Correspondingly, the probability of seeing at least one event in a window Δτ is  
p{XN ≥ 1} = 1 − p0  ∼  N ρ Δτ + 𝒪(ε2).    (1) 
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This equation can be applied to either fusion events or fission events separately by changing the event 
rate ρ to ρfu or ρfi, the event rates of fusion and fission, respectively, assuming that the event duration Δτ 
is approximately equal for fission and fusion. 
E.2 Calculating the fusion rate 
Let the number of partially mutant (partial) and fully mutant (monoclonal) fufi events observed on the 
edge of mutant patches be np and nm respectively. These numbers are combined over many different 
mutant patches and tissue samples, with a total patch edge length of N. To calculate the fusion rate ρfu 
given the fission rate ρfi, we use the following observations and assumptions: 
1. All fission events are monoclonal (mut fufis). 
2. Not all monoclonal events are fissions. 
3. All partial events (WT-mut fufis) are fusions. 
4. Not all fusions are partials (WT-mut fufis). 
The first and third assumptions stem from the belief that the time scale over which monoclonal 
conversion occurs in a crypt is short compared to the time between fusion/fission events. The second 
and fourth observations are alternative statements of the fact that fusion at the patch edge can happen 
inwards: a mutant crypt on the patch edge can fuse with a mutant crypt within the patch, hence creating 
a monoclonal event. We define the parameter χ to be the proportion of fusion events that are “inwards” 
and hence monoclonal. Then the ratio np/nm may be written as  
np / nm = nfu (1 – χ) / (nfi + nfuχ),    (2) 
where nfu and nfi are the number of fusion and fission events, respectively. We do not know nfu and nfi a 
priori, however. 
We may recast the probability p{XN ≥ 1} from eq. (1) as the number of observed events over sample 
size, nevents/N, for fusion and fission, we get  
nfu / N ~ N ρfu Δτ      and      nfi / N ~ N ρfi  Δτ, 
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where we have assumed the duration of a fusion event is approximately equal to that of a fission event. 
Thus, we find the approximate equivalence  
nfi / nfu ~ ρfi / ρfu  
between the ratios of numbers and rates of events. Using this, we may rewrite eq. (2) as  
np / nm = (1 – χ) / (ρfi / ρfu + χ), 
and subsequently find an expression for the fusion rate:  
ρfu = ρfi / [(nm / np) (1 - χ) + χ]. 
The simplest model for the parameter χ is to assume unbiased (isotropic) fusion, such that the proportion 
of fusions that are monoclonal is simply  
χ = (Nt – Nw) / Nt , 
where Nt and Nw are the total number of neighbours and number of wild-type neighbours of a given 
fusion event, respectively. 
E.3 Calculating the event duration 
The duration of a fusion event is assumed to be the same as that of a fission event. To find this duration, 
we treat fusion and fission as two Poisson processes occurring simultaneously. Thus, 
p{X1 = 0} = exp{−(ρfi + ρfu)Δτ}, 
and p{XN ≥ 1} = 1 − p{X1 = 0}. We can recast the probability p{XN ≥ 1} as a proportion of fufi events 
over total crypts, nf /Nc and then rearrange for the duration:  
Δτ = -log(1 - nf / Nc) / (ρfi + ρfu). 
We observe the total number of crypts Nc and the number of events nf, but we do not know how many 
of the nf are fission or fusion. We choose to approach this problem by splitting the data into wild type 
and mutant to find two event durations. This leads to two expressions for the bulk population mean 
durations: 
ΔτWT = -log(1 - nf 
WT/ Nc
WT) / (ρfi WT + ρfuWT), 
for fusion/fission events in wild type crypts, where a superscript WT denotes wild type and  
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ΔτMut = -log(1 - nf 
Mut/ Nc
Mut) / (ρfiMut + ρfuMut), 
for fusion/fission events in mutant crypts. 
We can capture the variability in the system further by using a Bayesian hierarchical model for the fufi 
occurrence.  We model the fufi counts on a given slide, ñf, as a binomial distribution 
ñf ~ Binom(Ñ, pf), 
where Ñ is the crypt count of the slide and event probability pf is drawn from a Gaussian distribution: 
pf ~ Norm(μf, σf). 
Thus patient-to-patient variability in fufi occurrence, assumed to derive from differences in baseline 
fission and fusion rate, is captured as variation under a single normal distribution with mean μf and 
variance σf. We use Markov Chain Monte Carlo sampling to infer the hyper-parameters defining the 
distribution on the population fufi fraction pf, then use the sampling draws to calculate the mean and 
95% confidence intervals for the fufi duration. 
 
  
